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Abstract 
Effects of a low protein (LP) diet during gestation on the metabolism of rat offspring have 
been well characterized and leads to glucose intolerance in adulthood. It is unknown how LP 
impacts endocrine pancreas development in the mouse, or whether this affects future β-cell 
plasticity. Streptozotocin (STZ) – induced β-cell injury has been demonstrated to be followed by 
β-cell regeneration in young animals, but the mechanism(s) of regeneration are not clear. Our 
objective was to characterize a mouse model of maternal LP, in addition to identifying factors 
that contribute to the long term development of glucose intolerance and the mechanism of β-
cell regeneration.  
We hypothesized that protein restriction during gestation in mice will alter development, 
leading to long term glucose impairments and a failure to regenerate β-cell mass after STZ.  
Pregnant Balb/c mice were placed on a control (C; 20% protein) or an isocaloric LP (8% 
protein) diet throughout gestation and C thereafter. Offspring were injected with multiple low 
doses of STZ or vehicle at postnatal day 1 for each dietary treatment. The offspring were 
examined to assess β-cell mass, glucose homeostasis and potential sources of regenerated β-
cells. Additionally, differential gene expression was analyzed by cDNA microarray to identify 
candidate genes involved in β-cell regeneration.  
LP-fed offspring had a reduced birth weight, and females developed glucose intolerance at 
d130, confirming previous studies in rats. LP offspring had a reduced capacity for β-cell 
regeneration following STZ compared to C-fed offspring. LP+STZ mice were observed to have an 
increased presence of putative precursor β-cells within islets, assessed by the frequency of cells 
containing the transcription factor Pdx-1, but not insulin. This suggests that such cells may fail to 
differentiate and contribute to new β-cell formation following exposure to LP. Additionally, 
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female LP+STZ mice had a reduced presence of the trophic islet peptide, regenerating islet-
derived 1 (Reg1), when compared to the C+STZ animals. 
In conclusion, these studies have developed a mouse model of nutrition-induced fetal 
programming of metabolism, have shown that prior LP exposure compromised future β-cell 
plasticity, and have identified key genes relevant to β-cell regeneration whose expression is 
altered in LP-treated animals. 
 
Keywords 
low protein diet, development, pancreatic β-cell, streptozotocin induced regeneration, glucagon-
like peptide-1, regenerating islet-derived 1 
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CHAPTER 1:  
General Introduction 
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1.1. Diabetes 
Diabetes mellitus affects people of all ages and ethnic backgrounds, with serious 
health risks to the individual and a tremendous cost to the healthcare system. Diabetes 
is an epidemic with more than 285 million people worldwide affected by this disease (1). 
More specifically, in Canada over 9 million people have pre-diabetes or diabetes (1). The 
personal cost of diabetes is a reduced quality of life and the increased risk of 
complications such as blindness, kidney disease, and heart disease. The cost of diabetes 
and its complications to the Canadian Healthcare system is an estimated $13.2 billion a 
year (1). Therefore it is imperative that appropriate treatments are found to improve the 
quality and quantity of life of diabetic individuals and to also reduce the cost to the 
health care system. 
In general, diabetes mellitus is a disruption in glucose regulation. There are two 
main types of diabetes, with 10% affected by type 1 diabetes and 90% affected by type 2 
(2; 3). In individuals with type 1 diabetes, insulin deficiency is the result of substantial 
loss of pancreatic insulin – producing β-cells due to autoimmune destruction (4). 
Consequently, individuals are placed on insulin therapy to restore glucose homeostasis. 
Individuals with type 2 diabetes are characterized by having several metabolic defects 
including peripheral insulin resistance and β-cell deficiency in insulin secretion (5; 6). 
Obesity puts additional stress on the β-cells due to increased tissue requirements for 
insulin. High insulin demands and continuous imbalances in glucose homeostasis cause 
gluco- and lipo-toxicity, which contribute to a progressive decrease in β-cell mass (2; 7-
12) and increasing the likelihood of disease complications. This demonstrates the critical 
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importance of maintaining β-cell mass to compensate for increased insulin demands due 
to obesity and/or insulin resistance. Understanding the dynamics of β-cell growth, 
survival and dysfunction are crucial to manipulate the development or regeneration of 
β-cells for replacement therapy in diabetes.  
1.1.2. Current Therapies 
Individuals with type 1 diabetes require insulin daily to help maintain blood glucose 
values. Insulin supplementation is oral or by injection using either a syringe or an insulin-
administering pump. Whole pancreas transplantation has been accepted as an 
alternative therapy for individuals with type 1 diabetes who are undergoing 
simultaneous kidney transplant (13). Although there is still a significant cost and 
morbidity risk associated with this surgery, there is an 84-88% graft survival rate after 
one year (13; 14). Islet transplantation is a much less invasive procedure and may 
provide the best option for excellent glycemic control (13). Early attempts to transplant 
islets into type 1 individuals resulted in only 8% remaining insulin independent after 1 
year (15). With advancements in immunosuppressive agents, the Edmonton Protocol 
was developed in the late 1990’s with the aim to reduce toxicity and avoid the harmful 
effects of some immunosuppressants on the β-cells (16). The Edmonton Protocol 
consisted of a glucocorticoid – free immunosuppressive protocol that included sirolimus, 
low dose tacrolimus and a monoclonal antibody against the interleukin-2 receptor 
(daclizumab) (16). Insulin independence was achieved in ~30% and 10% of patients after 
2 and 5 years, respectively, demonstrating a marked improvement in the effectiveness 
of islet transplantation (17). However, there still remains a need to refine the islet 
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isolation technique and the immunosuppressive regime to better maximize graft survival 
and function while limiting toxicity. Additionally, 2-3 cadaveric donors are required per 
islet transplant with some individuals requiring multiple transplants over time. 
Lifestyle changes are recommended for individuals with type 2 diabetes, including 
diet and exercise, as well as weight loss for obese individuals. Additionally oral 
medications may be given, such as Metformin to reduce hepatic glucose production 
(18), Thiazolidinediones to improve peripheral tissue insulin sensitivity, or Sulfonylureas 
to stimulate insulin secretion (19). Glucagon-like peptide-1 (GLP-1) receptor agonists or 
inhibitors of the GLP-1 inactivating enzyme dipeptidyl peptidase-4 are used to enhance 
glucose-stimulated insulin secretion (GSIS) (19). Insulin therapy may be required in 
addition to one of the above agents with progression of the disease.  
1.2. Pancreas Anatomy and Development 
The pancreas is situated in the abdomen, attached at the initial curvature of the 
duodenum and also the stomach and extends to where the tail of the pancreas attaches 
to the spleen (Figure 1.1). There are two main compartments of the pancreas serving 
endocrine and exocrine functions. The endocrine pancreas plays a role in glucose 
metabolism and accounts for 1-2% of the total pancreas. The remaining portion is the 
exocrine pancreas, which is made up of acinar cells and ducts that produce and deliver 
digestive enzymes and bicarbonate to the small intestine. The Islets of Langerhans 
compose the endocrine pancreas and are made up primarily by β-cells (~80%) in the 
core and the remaining cells forming the mantle of the islet; α (~14%), δ (~6%) (20) and 
few epsilon and PP cells. In contrast, human islets do not display the core/mantle  
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Figure 1.1. Anatomical location of the pancreas.  
The head of the pancreas is attached at the initial curve of the duodenum and stretches 
across the abdomen where the tail attaches to the spleen. Inset, shows the organization 
of the five different cell types of the islet of Langerhans; the β (green), α (red), δ (blue), 
PP (yellow) and epsilon (purple) cells. Adapted from McKinley, M. and O’Loughlin V.D. 
Human Anatomy, 2nd Edition, 2003 (21).  
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architecture described in rodents, as all cell types are dispersed throughout the islet 
(22). Human islet composition varies widely, but contains approximately 54% β-cells, 
34% α-cells, and 10% δ-cells (22). Insulin secreting β-cells act to decrease blood glucose 
concentrations by stimulating glucose uptake in the liver, muscle and adipose tissues. 
Glucagon, which is secreted by the α-cells, is the counter regulatory hormone that acts 
to increase blood glucose levels in times of fasting. Glucagon stimulates liver and muscle 
cells to convert stored glycogen into glucose. Together, insulin and glucagon are the 
major pancreatic endocrine hormones that function in maintaining glucose homeostasis. 
The δ-cells produce somatostatin which acts to inhibit insulin and glucagon secretion 
and also controls gastric emptying. Epsilon cells produce ghrelin which stimulates 
appetite. The function of pancreatic polypeptide released by PP cells is unknown. 
At embryonic day (e) 8.5 in the mouse, the endodermal foregut expresses the 
transcription factor pancreatic duodenal homoebox-1 (PDX-1) defining the region for the 
pancreas, stomach, duodenum and common bile duct (23; 24). Pancreatic development 
begins with the appearance of the dorsal and ventral pancreatic buds at about e8.5 to 
e9.5 from the mid-gut endoderm (25). Each bud develops into highly branched 
structures, with endocrine cells visible in the early stages of bud development, while the 
acini and ducts are distinguishable by e14.5 (26). Endocrine cells develop from the 
pancreatic ductal epithelial cells and initially exist as individual cells or small clusters. 
Development of endocrine cells from the pancreatic ductal epithelium is initiated by 
expression of the basic helix-loop-helix transcription factor neurogenin 3 (NGN3) (27). 
Gradual expression of the transcription factors NGN3, ISL-1, NKX2.2, ΒETA2 and PAX6 in 
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immature endocrine cells is accompanied by a decrease in PDX-1 expression (28). 
Mature β-cell differentiation requires the return of PDX-1 expression, as well as 
expression of NKX6.1 and PAX4, with a loss of expression of NGN3 and ΒETA2 (26; 28; 
29). A few days before birth, mature islets form and there is a rapid 2-fold increase in β-
cell numbers due to β-cell replication and maturation of β-cell precursors (30-32). This 
rapid neogenesis of islets continues throughout neonatal life, but progressively declines 
at weaning (32). By adulthood the mitotic rate of β-cells is very low, about 0.5% of β-
cells (33). A remodelling of the pancreas occurs in the neonatal rat, which is marked by a 
decrease in insulin-like growth factor (IGF) -II expression, which acts as a survival factor 
for β-cells (34). This corresponds to a transient wave of β-cell apoptosis, peaking at 
postnatal day 14, however β-cell mass is maintained during the first few weeks in the 
neonatal rat, indicating the generation of new islets to replace β-cell loss (34-36). This 
transition period in the neonatal rodent may suggest a change in β-cell population, from 
cells with slow glucose responsiveness for insulin release, to cells with acute glucose-
stimulated insulin release that are better adapted to metabolic control in adult life (28). 
A similar wave of β-cell apoptosis has been described in the human fetal pancreas in the 
third trimester (34). Islet development complete and beta cell responsiveness acquired 
by birth in humans, while in rodents islet development is completed postnatally during 
lactation(34; 36). 
1.3. Pancreatic duodenal homeobox-1 in Development 
The most important transcription factor in pancreas development is PDX-1. It is the 
first molecular marker that temporally correlates with pancreatic commitment for 
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epithelial cells located in the primordial gut (23; 30; 37). PDX-1 is initially detected at 
e8.5 in the region of the gut epithelium that later develops into the pancreas, stomach, 
duodenum and common bile duct (23; 24). A high expression of PDX-1 is maintained in 
most epithelial cells of the pancreatic bud until e10.5 (37). Between e11.5 and e13.5 
PDX-1 is essential for the subsequent differentiation of endocrine and exocrine cells 
(38). By late gestation, PDX-1 is selectively maintained at high levels in β-cells, with low 
levels of expression in acinar cells (23; 39). In the adult, PDX-1 expression is largely 
limited to the β-cells and to a few δ-cells (37). In the mature β-cell, PDX-1 functions as an 
essential mediator of the glucose – induced effect on insulin gene transcription (40; 41). 
In addition to being the major regulator of the insulin gene, PDX-1 also regulates the 
expression of glucose transporter (GLUT) 2 (42), glucokinase (GCK) (43), and islet 
amyloid polypeptide (44) and represses glucagon expression (25). 
1.4. Islet Vasculature  
The dense capillary network that forms in pancreatic islets allows for nutrient and 
growth factor delivery, as well as accurate glucose sensing and dispersion of islet 
hormones into systemic circulation (45). Blood vessels also play an important role in 
pancreas development and differentiation. At e8.5-9.5 pancreatic growth is initiated 
where the endodermal epithelium contacts the endothelium of the dorsal aorta (46; 47). 
These sites of pancreatic growth are marked by expression of PDX-1 (48; 49) after which 
endocrine cell differentiation is detectable by the expression of insulin in the dorsal 
pancreatic endothelium adjacent to the portal vein (46). When isolated endoderm was 
cultured with dorsal aortae, PDX-1 and insulin expression were induced, suggesting a 
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strong signalling relationship between them during development (46; 47). It was further 
shown that development of islet vasculature and establishment of islet blood flow 
occurs concomitantly with islet formation by the observation that coalescing endocrine 
cells were adjacent to blood perfused lectin+ capillaries (50). The signalling mechanism 
between the vasculature and islet cells was shown to involve vascular endothelial 
growth factor-A (VEGF) (50). β-cell specific loss of VEGF expression caused an islet 
deficiency in vessel number, as well as reduced size/branching (50). Abnormal islet 
vasculature resulted in decreased insulin secretion and glucose intolerance (50).  While 
β-cells signal to endothelial cells through VEGF, the islet vasculature responds with the 
production of hepatocyte growth factor (HGF) which acts as a potent stimulator of β-cell 
growth (45; 51; 52). When HGF was overexpressed in the islet, β-cell proliferation 
significantly increased leading to an increase in β-cell mass and insulin production (52). 
1.5. β-Cell Function 
The glucose transporter, GLUT2, is responsible for the insulin-dependent uptake of 
glucose into the β-cell (53; 54). Following transport into the cell, glucose is 
phosphorylated by GCK in the rate limiting step for glucose metabolism (55; 56). The 
resulting change in the ATP : ADP ratio leads to closure of the ATP-sensitive K+ channels 
and depolarization of the cell membrane (56; 57). Depolarization triggers opening of the 
voltage gated Ca2+ channels and rapid influx of Ca2+ (56; 57). The readily releasable pool 
of insulin secretory granules are located close to the plasma membrane in the vicinity of 
the rise in intracellular Ca2+, which stimulates exocytosis of insulin (56; 57). This first 
phase response occurs within 5-10 min of stimulation and accounts for about 10% of 
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secretory granules (58; 59). The second phase of insulin secretion is independent of the 
KATP channel and mainly involves the recruitment of granules from the intracellular 
storage pool (58; 60). Second messengers such as protein kinase C, cyclic AMP, inositol 
triphosphate, and diacylglycerol may all contribute to further increasing intracellular 
Ca2+ levels, however the exact signalling mechanism and transport of the secretory 
vesicles to the membrane remains unknown (57; 58; 61). Insulin released into circulation 
can then act on peripheral tissues to stimulate glucose uptake.  
1.6. β-Cell Plasticity 
An adequate source of proper functioning β-cells is necessary to improve the health 
of diabetic individuals. β-cell mass is a dynamic balance between β-cell growth and β-cell 
loss. β-cell growth occurs through replication of pre-existing β-cells, neogenesis of β-
cells via stem/precursor cells and also through β-cell hypertrophy, while β-cell death 
occurs by apoptosis or necrosis (62-64). In rodents, there is an enhanced rate of 
replication and neogenesis that is interrupted by a brief episode of increased apoptosis 
during the neonatal period (34; 36). These changes early in life lead to an increase in β-
cell mass soon after weaning (36). However, the rates of β-cell growth and death are 
dramatically decreased as the young rodent matures into adulthood. In adult rodents 
there is very slow turnover of β-cells, with about 0.5% of β-cells self-replicating (33) and 
a corresponding rate of apoptosis of 0.5% of β-cells (65; 66). This would suggest a 
limited ability for β-cell growth in adult rodents under normal physiologic conditions.   
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1.6.1. Expansion of β-Cell Mass 
Despite low replication rates, pregnancy and obesity are two physiologic situations 
in which β-cell expansion in the adult is possible. During pregnancy, prolactin and 
placental lactogen drive β-cell hyperplasia and hypertrophy (67). This allows for 
compensation of the increasing metabolic demands of the developing fetus (35). Insulin 
resistance is a main feature of obesity, but two-thirds of obese individuals do not 
develop diabetes (68). A study showed that glucose homeostasis was maintained 
through endocrine tissue hyperplasia in non-diabetic obese subjects (2; 69). In animal 
models, there was a significant increase in β-cell mass in the obese non-diabetic Zucker 
fa/fa rat compared to the lean Fa rat due to hyperplasia, hypertrophy or by neogenesis 
(70). Therefore plasticity of β-cell mass can exist in the adult under particular physiologic 
conditions. However, in the pathological setting of diabetes, the plasticity of β-cells from 
type 2 diabetic individuals was reduced when examined in vitro compared to non-
diabetic β-cells (71). 
1.7. Alternative Sources of β-Cells 
Given the demand for β-cell replacement therapy in diabetes and the current 
limitations to pancreas and islet transplantation, alternative approaches to generate β-
cells are being pursued. Three areas of focus include differentiation of stem cells, 
expansion of primary β-cells ex vivo and transdifferentiation. The embryonic stem (ES) 
cells are pluripotent cells capable of differentiation into β-like cells. Several groups have 
demonstrated the ability to produce β-cells from mouse ES cells or human ES cell lines 
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(72-76). These studies provided evidence that the ES-derived cells expressed key 
markers of β-cells such as PDX-1, insulin, GLUT2, GCK, NKX2.2, NKX6.1; they released 
insulin in response to glucose and improved glycemia following transplants into diabetic 
mice (72-76). As techniques and culture conditions improve, ES-derived cells more 
closely resemble β-cells phenotypically, based on electron microscopy, and expressing 
genes characteristic of mature β-cells (75; 76). Additionally, following transplant into 
immune compromised mice, measurements of serum C-peptide levels, an indication of 
insulin production, were similar to that of 3,000-5,000 transplanted islets (75). While 
advancements are being made, ES-derived β-cells must express the full complement of 
mature β-cell markers and be capable of tightly regulating blood glucose levels to be 
useful clinically.  
Isolation of β-cells and their subsequent expansion and transplantation back into 
the individual is a promising approach. Isolated islets placed into culture will 
dedifferentiate into a mesenchymal-like phenotype, losing expression of islet hormones 
and key β-cell transcription factors (77; 78). These more primitive cells can be expanded 
and then directed to redifferentiate back to a β-cell phenotype, however, like efforts to 
differentiate stem cells, these newly formed β-cells have very low levels of insulin mRNA 
(77-79). 
There are many political and ethical issues associated with ES cell use and limited 
success with the expansion of β-cells ex vivo, have forced researchers to look at other 
cell types as possible sources for new β-cells. The process of converting one cell type 
into another cell type is called transdifferentiation. A study in mice showed that liver 
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cells transfected in vivo with an adenovirus expressing pdx-1 led to the expression of β-
cell markers and considerable amounts of serum insulin, as well as the reversal of 
chemically induced diabetes (80). Acinar cells can be converted into β-cells through 
adenoviral transfection of three key transcription factors: PDX-1, NGN3 and MAFA (81). 
Recently α-cells were also converted into β-cells through the ectopic expression of Pax4 
(82), while another group observed the spontaneous conversion of α-cells into β-cells 
following near-total β-cell ablation using a lineage tracing model (83). 
1.8. Mechanisms of β-Cell Regeneration 
Stimulation of endogenous tissue regeneration is another avenue that is being 
examined for β-cell replacement therapy. The capacity to repair tissue following an 
insult has been demonstrated in many tissues, including the skin (84), liver (85) and 
heart (86). This mechanistic tissue regeneration has also been demonstrated in many 
animal models of pancreas injury such as partial duct ligation and partial 
pancreatectomy or by β-cell specific injury with alloxan and streptozotocin. These 
studies have attempted to identify the source of new β-cells following regeneration as a 
means to generate an increased supply of β-cells. There are three main sources of new 
β-cells: replication, islet ductal neogenesis and stem/precursor cell differentiation. 
1.8.1. β-Cell Replication 
The first source to consider for increasing β-cell numbers is through cell replication. 
The cell cycle involves the initiation and completion of the DNA replication (S) phase, cell 
division or mitosis and a number of gaps (G) between these phases (87). Previous 
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literature has made it clear that the cell cycle checkpoint at the G1/S phase transition 
(Figure 1.2.) is central to the control of β-cell proliferation (88). Crossing this checkpoint 
and successful completion of the S phase requires that genes important for cell cycle 
progression be upregulated, while suppressors of cell cycle progression are repressed. 
This is accomplished via a family of transcriptional activators and repressors called the 
E2F proteins (88). The retinoblastoma protein (pRb) is regarded as the molecular brake 
on cell cycle progression, resulting in G1/S arrest (88). pRb binds preferentially to  
E2F1, -2, and -3 and serves to repress their transcriptional activity (88-91). As well, pRb 
enforces cell cycle arrest by recruiting histone deacetylases to the promoters of cell 
cycle progression genes, restricting chromatin remodeling and therefore repressing cell 
cycle progression (92; 93).  
Targeted phosphorylation of pRb by cyclin dependent kinase (CDK) -2, -4, -6 or PI3K 
serves to inactivate the protein (88; 94; 95). The actions of CDK4 and -6 occur through 
their association with cyclin D1 to phosphorylate and inactivate pRb (96). Adenoviral 
overexpression of CDK4 and cyclin D1 in rodent and human islets resulted in marked 
increased pRb phosphorylation and increased β-cell replication (97). Furthermore, CDK4 
knockout mice develop diabetes due to a reduction in β-cells (98). Phosphorylation of 
pRb interferes with its binding to E2F proteins, relieving inhibition of E2F responsive cell 
cycle genes (88; 99; 100), allowing for the progression of the cell cycle. The levels of 
control of activation and inhibition of cell cycle progression are quite extensive as 
suggested by Figure 1.2 and are described in greater detail in the review by Cozar- 
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Figure 1.2. The cell cycle check point at the G1/S phase transition.  
A schematic representing the proteins involved in regulation of the G1/S phase 
transition of the cell cycle. Cozar-Costellano et al. Endocrine Reviews, 27(4): 356-370, 
2006 (88).  
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Costellano (88). Understanding the mechanisms of control of the β-cell cycle are 
important for targeted stimulation of β-cell replication in order to increase β-cell mass. 
1.8.2. Ductal Islet Neogenesis 
During embryonic development, the formation of new islets, or islet neogenesis, is 
believed to originate from ductal epithelial cells. The growing epithelium forms 
proliferating ductules that branch and ultimately differentiate giving rise to mature 
ducts, acinar cells and islets (101). A recapitulation of this process has been observed 
during regeneration following 90% partial pancreatectomy (Px) in the rat (101). 
Increased proliferation of ductal epithelium is followed by expression of PDX-1 during 
the differentiation stage, leading to the formation of new islets and acinar cells (101; 
102). In less rigorous models of regeneration, evidence of islet neogenesis was observed 
by immunohistochemical analysis showing islet hormone positive cells within ducts or as 
small clusters budding from ducts (103-105). Further evidence for the ductal origin of 
neogenic islets has been shown recently through lineage tracing of the ductal marker 
carbonic anhydrase II (CA II) in the mouse Px model (106).  
1.8.3. Stem/Precursor Cell Differentiation 
Finally, new β-cells may also arise from the differentiation of stem or precursor cells 
within the postnatal pancreas, or from an extra-pancreatic source such as the liver.  A 
colony forming assay using adult mouse pancreatic cells identified multipotent precursor 
cells capable of producing pancreatic endocrine cells in vitro (107). In addition to mature 
duct cells, another study suggests that the ductal structures contain NGN3 expressing 
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endocrine precursor cells within the ductal lining and are responsible for giving rise to 
new β-cells (108). Other studies have provided evidence of an early endocrine precursor 
cell marked by PDX-1 expression in the absence of insulin expression (109; 110). Co-
hormone expression may represent differentiation of precursor cells. Expression of 
somatostatin and insulin or glucagon and insulin has been observed by 
immunohistochemistry during regeneration (111; 112). In contrast, strong evidence 
using lineage cell tracking has shown that adult β-cells arise from replication rather than 
stem cell differentiation (113), however, this does not exclude the contribution of stem 
cells to β-cell formation during the neonatal period and during regeneration (79). 
Hepatic oval stem cells have also been studied as a potential non-pancreatic source for 
the generation of new β-cells (114), but in addition to all of these cellular sources, it 
remains to be determined whether they can be a clinically useful supply of new β-cells.  
1.9. Models of β-cell Regeneration 
Several different experimental models have been developed to study β-cell 
regeneration. These models range from pancreas injury to β-cell specific insults and 
describe observations of β-cell replication, ductal islet neogenesis or stem/precursor cell 
differentiation during regeneration.  
1.9.1. Partial Duct Ligation 
The partial pancreatic duct obstruction model was developed by Rosenberg and 
colleagues by wrapping a narrow piece of cellophane tape around the head of the 
pancreas of the adult Syrian golden hamster (115). This led to the formation of new 
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islets through migration of cells out from the epithelium of small intralobular ductules 
reiterating normal fetal ontogeny (115; 116). There was a significant increase in ductal 
cell proliferation 2 weeks following surgery and at 8 weeks an increase in islet cell 
proliferation culminating in a 2.5 fold increase in islet mass (115; 116). This phenomenon 
of islet neogenesis from duct cells was also observed in the adult rat following 
pancreatic partial duct ligation (PDL) (117). These findings were supported by lineage 
tracing of the ductal marker CA II in the mouse (106). The results of this study showed 
that β-cells were marked by the tracer, β-galactosidase, following PDL suggesting they 
were derived from CA II expressing duct cells (106). However, a study by Solar et al. 
found contrasting results by cell lineage tracking of the duct cell marker HNF1β (118). No 
evidence that duct cells gave rise to new endocrine cells following PDL was observed 
(118). Previous work from this group suggests that NGN3+ endocrine precursor cells are 
responsible for giving rise to new β-cells following PDL (108). 
1.9.2. Partial Pancreatectomy 
Partial pancreatectomy (Px) is another method that has been used to study β-cell 
regeneration and is typically performed in adult animals. Following 90% resection of the 
rat pancreas there is substantial regeneration of the exocrine and endocrine pancreas 
(119; 120). In this model, two pathways of regeneration were observed: 1) replication of 
pre-existing, differentiated exocrine and endocrine cells, and 2) the proliferation and 
differentiation of ductal epithelium to form new pancreatic lobules (101; 119). More 
recently, lineage tracing was performed using RIP-CreER;Z/AP adult mice to label the β-
cells and look at regeneration after 70% Px (113). They determined that β-cell replication 
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was the major source of new β-cells and not stem cell differentiation as previously 
suggested (113).  
1.9.3. Alloxan 
In 1943, it was reported that alloxan could induce diabetes in the rat due to specific  
necrosis of the β-cells (121; 122). Alloxan is a very unstable compound that is 
structurally similar to glucose (Figure 1.3) allowing for its uptake into the β-cell through 
the GLUT2 transporter (123-125). Once in the β-cell, alloxan selectively inhibits GSIS 
through specific inhibition of the glucose sensor, GCK, and causes necrosis of β-cells 
through its ability to induce reactive oxygen species (ROS) formation (126). Regeneration 
of mouse β-cells was observed following selective perfusion of alloxan after clamping 
the superior mesenteric artery (127). β-cell destruction occurred in perfused regions of 
the pancreas, while non-perfused regions were spared (127). Histological evidence 
suggested islet neogenesis from differentiation of duct cells in the alloxan perfused 
region and a significantly increased islet area due to β-cell replication in the non-
perfused region (127). In rats, a single intraperitoneal (i.p.) injection of alloxan led to 
increased serum glucose levels followed by β-cell regeneration 12 days later (128).  β-
cell replication rates were increased and neogenesis was observed as 
transdifferentiation of acinar and duct cells to β-cells (128). 
1.10. Streptozotocin 
Streptozotocin (STZ) is an antimicrobial agent and has also been used as a 
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Figure 1.3. Comparison of the molecular structures of streptozotocin, glucose and 
alloxan.  
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chemotherapeutic alkylating agent (129-131). In 1963, Rakieten et al. (132) reported 
that STZ was diabetogenic. STZ has become the main choice for the chemical induction 
of diabetes in animal models and for the study of β-cell regeneration (126). STZ is a 
glucose analogue known as 2-dexoymethyl-nitrosurea-glycopyranose (Figure 1.3) (133). 
Similar to alloxan, GLUT2 on the β-cell plasma membrane selectively recognizes STZ due 
to its similar structure to glucose and transports it into the cell (134; 135). The toxic 
effects of STZ mainly arise from the transfer of the methyl group to a DNA molecule 
leading to DNA fragmentation (136). Overstimulation of poly(ADP-ribose) polymerase 
occurs in an attempt to repair DNA, which leads to depletion of cellular NAD+ and ATP 
stores (136-138). Accordingly, diabetes develops due to necrosis of β-cells (126) leading 
to hypoinsulinemia and hyperglycemia (139-143). 
1.10.1. Single Dose STZ Model 
STZ is conventionally administered as a single injection (132). It has a serum half life 
of 15 minutes (144). β-cell necrosis is apparent within 24 hours by ultrastructural 
examination (145). Blood glucose values peak 1-2 days after STZ and remain elevated 
depending on the dose given (146). In neonatal rats, there are a few different protocols 
used. First, the n0-STZ model is generated by injecting 100 mg/kg STZ i.p. or 
intravenously at birth. Rats exhibit insulin deficient acute diabetes 3-5 days after birth 
(139; 147). At 3-4 weeks of age, body weight and basal plasma glucose values cannot be 
distinguished from control values (139; 147). However, by 8 weeks of age, rats show a 
mild basal hyperglycemia, an abnormal response to an i.p. glucose tolerance test (IPGTT) 
and 50% decrease in pancreatic insulin stores (147). Other neonatal models involve the 
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injection of STZ on day 2, 4, or 5 (112; 139; 147; 148) and the severity of diabetes and 
the degree of recovery that follows depends on the timing of STZ, as rats injected on day 
5 lacked re-accumulation of insulin in the pancreas 2 weeks following STZ (133). In the 
n0-STZ model, the recovery of plasma glucose to normal values 1 week after birth was 
related to recovery of pancreatic insulin content and β-cell mass (139; 147). From day 4 
onward, signs of regeneration became apparent in the numerous insulin positive cells 
found throughout the acinar parenchyma and within the ductal epithelium (104). The 
appearance of islets budding from ducts was a common feature (149). Examining the 
mitotic rate suggested that most β-cells were formed by mitosis of undifferentiated cells 
(149). However, the long term impairment of the plasma glucose homeostasis (147) and 
persistence of a reduced β-cell mass in 4 month old animals (133; 147) are proof that the 
regeneration process was incomplete. It has also been suggested that there may be 
strain differences in the regeneration potential in rats (133). 
1.10.2. Multiple Low Dose STZ Model 
The multiple low dose model, first described by Like and Rossini (140), used five 
daily injections of a sub-diabetogenic dose of STZ in mice, as compared to one large 
diabetes-inducing dose of STZ as used in the rat model. CD-1 mice were injected with 40 
mg/kg STZ daily for 5 days (140). Plasma glucose levels were significantly elevated after 
the 4th injection and increased further in the following days (140). Large numbers of 
lymphocytes and moderate numbers of macrophages surrounded or permeated the 
islets (140). β-cell necrosis was observed and remaining β-cells showed degranulation 
(140). Five daily injections of STZ (40 mg/kg) in rats failed to produce similar islet 
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inflammatory lesions, despite the fact that an equivalent single large injection of STZ 
(160 mg/kg) produced marked hyperglycemia (140). With the one injection technique, 
necrosis occurs within 4 hours, hyperglycemia is achieved rapidly and all islets are free of 
inflammatory lesions (140). In contrast, multiple sub-diabetogenic injections induced 
gradual elevation of plasma glucose, with mononuclear inflammatory cells in and around 
the islets (140). Multiple low doses of alloxan similarly altered islet morphology and 
increased blood glucose levels, however, no inflammatory infiltration was observed 
(150). 
1.10.3. STZ-Induced Regeneration 
It has been shown that young rodents have a large capacity to regenerate β-cell 
mass after STZ-mediated destruction (112; 143). Subtotal destruction of β-cells with STZ 
is followed by regeneration of β-cells and remission of hyperglycemia in young rodents 
(112; 143). The capacity to regenerate decreases with age, as observed when STZ was 
administered to adult rats, showing incomplete regeneration leading to diabetes later in 
life (133; 151). However, it was found that transplantation of bone marrow-derived stem 
cells were able to improve regeneration and survival rates (152), suggesting that 
regeneration is possible even in the adult. The limitation of regeneration in the adult 
may be a paucity of inductive signals from endothelial progenitor cells or a lack of β-cell 
precursors.  
In the PDL and pancreatectomy models, there has been much debate about the 
source of regenerated β-cells. There is strong evidence to suggest that new β-cells 
mainly arise from replication of pre-existing β-cells (113; 153) while others contest that 
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differentiation of progenitor cells is the main source of β-cells during regeneration (106; 
108). However, there is less known about the source of new β-cells in STZ induced 
regeneration. A recent study using lineage tracing technology demonstrated an increase 
in Pdx-1+/MafB+/insulin— cells following STZ treatment suggesting an increase in 
differentiation of β-cell progenitors leading to regeneration of mature insulin expressing 
cells (109). While endogenous (154) or transplanted (152) bone marrow cells have been 
shown to home to the regenerating pancreas, they differentiate into supportive vascular 
endothelium. Moreover, vascular growth in parallel to that of β-cell replication appears 
to be important for regeneration and involves growth factor signalling and extracellular 
matrix interactions (155). Together these results suggest that the intra-islet niche may 
facilitate β-cell replication, in addition to the differentiation of precursor cells for 
regeneration of β-cells following STZ. From Table 1.1 there is evidence to support the 
generation of new β-cells from all three main sources (replication, neogenesis, and 
differentiation), depending on the model. A key question is which mechanism can best 
be utilized to generate a functional supply of new β-cells and how can we stimulate this 
process? 
1.11. Genes involved in β-cell Regeneration 
Understanding the mechanism of β-cell regeneration will also require the 
elucidation of the genes involved. Following β-cell loss, upregulation of some genes are   
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Table 1.1. Models of β-cell plasticity 
Model Regimen Species Mechanism Reference 
STZ multiple low dose 
(50 mg/kg) 
Mouse differentiation (109) 
 n0-STZ (100 mg/kg) Rat replication, 
neogenesis 
(104; 143; 
149) 
 n4-STZ (70 mg/kg) Rat replication, 
differentiation 
(112; 155) 
 multiple low dose 
(40 mg/kg) 
Rat ND (140) 
Alloxan perfusion; adult Mouse replication, 
differentiation, 
neogenesis 
(127) 
 multiple dose; adult Mouse ND (150) 
 single injection; 
adult 
Rat replication, 
neogenesis 
(128) 
Partial 
Pancreatectomy 
70, 90% resection; 
adult 
Rat replication, 
neogenesis 
(101; 113; 
119) 
Partial Duct 
Obstruction 
cellophane 
wrapping; adult 
Hamster neogenesis (115; 116) 
Partial Duct 
Ligation 
adult Mouse neogenesis, 
differentiation 
(106; 108; 
118) 
 adult Rat neogenesis (117) 
Glucose infusion adult Rat replication (156) 
Pregnancy  Human neogenesis (157) 
  Rat replication, 
hypertrophy 
(67) 
  Mouse proliferation (158) 
Obesity adult Human replication, 
neogenesis 
(2; 69) 
 adult Mouse replication, 
neogenesis 
(33) 
 adult Rat replication, 
neogenesis 
(70) 
Studies on β-cell plasticity following β-cell or pancreas insult and under physiologic 
conditions in humans, mice, rats or hamsters have been described in both neonatal and 
adult models. The method of β-cell regeneration is listed; β-cell replication, ductal islet 
neogenesis or differentiation of stem/precursor cells. n0-STZ = STZ injection on neonatal 
day 0 (day of birth); n4-STZ = STZ injection on neonatal day 4. ND = not determined.  
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expected to initiate the process of regeneration, while other genes may play a role in 
cell proliferation and/or precursor differentiation. 
1.11.1. The Regenerating gene family 
The regenerating islet-derived gene family (Reg) belongs to the calcium dependent 
C-type lectin gene superfamily (159). The Reg gene family encodes for group of small 
secreted proteins, which can function as acute phase reactants, lectins, anti-apoptotic 
factors or growth factors for β-cells, neural cells and epithelial cells in the digestive 
system (160). In 1984, administration of nicotinamide to 90% pancreatectomized rats 
accelerated the regeneration of pancreatic islets (161). A rat regenerating islet-derived 
cDNA library was then screened and a novel gene was isolated encoding a 165 amino 
acid protein, which was called Reg gene (161). It was later named Reg1 and is also 
known as pancreatic thread protein (PTP), pancreatic stone protein (PSP) or 
lithostathine (162). Since then, several Reg and Reg-related genes have been isolated 
from a number of species and they have been grouped into three subclasses (Table 1.2) 
based on the primary structures of the encoded proteins (163). Reg genes have 
previously been shown to be upregulated during β-cell regeneration (164-166). 
Specifically, REG1 and islet neogenesis associated peptide (INGAP; mouse Reg3δ) 
proteins are thought to be regeneration or growth factors for pancreatic β-cells (164; 
167-169). Reg genes have been shown to stimulate β-cell replication and this likely 
occurs through the upregulation of cell cycle genes such as cyclin D1 and Cdk4 (168; 170; 
171). Additionally, Reg genes have been shown to act on the ducts to stimulate β-cell 
neogenesis (116; 169; 172). 
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Table 1.2. The Reg gene family 
 
Species 
Type Human Rat Mouse Hamster Cow 
I Reg1α 
(PSP/Lithostathine/PTP) 
Reg1 Reg1   
 
Reg1β 
    II 
  
Reg2 
  III HIP/PAP Reg3/PAP2 Reg3α INGAP PTP 
  
PAP1/Peptide 23 Reg3β 
  
  
PAP3 Reg3γ 
  
   
Reg3δ 
  
Reg, Regenerating gene; PSP, gene for pancreatic stone protein; HIP, gene expressed in 
hepatocellular carcinoma, intestine, and pancreas; PAP, gene for pancreatitis-associated 
protein; PTP, gene for pancreatic thread protein; INGAP, gene for islet neogenesis-
associated protein. Adapted from Okamoto, J Hepatobiliary Pancreat Surg, 6: 254-262, 
1999 (163).  
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1.11.2. PDX-1 and β-cell Regeneration 
In addition to its role in development, PDX-1 has also been shown to play a role in β-
cell maturation and differentiation in the adult. A population of PDX-1+ cells expressing 
little or no insulin (insulinlow) were tracked in vitro and over time acquired insulin 
expression (insulin+) without cell division (110). This suggested the existence of a 
precursor pool of immature β-cells in the adult. These immature β-cells had increased 
expression of MAFB and NKX2.2, markers of early β-cell development, and also had 
higher replication rates than mature β-cells. Using a lineage tracing model in adult mice, 
Liu et al. (109) similarly found an insulin— precursor population within the islet that 
differentiated into insulin+ cells over time. Additionally, these precursor cells contributed 
to β-cell regeneration following five daily injections of STZ (50 mg/kg) (109). These 
precursor cells also had higher rates of replication and were marked by expression of 
PDX-1 and MAFB, demonstrating their immature state. Furthermore, after 90% Px in 
adult rats there was an increased proliferation of the pancreatic ducts followed by an 
increased expression of PDX-1 in the ducts (102). These findings suggested that β-cell 
regeneration following Px involved differentiation of ducts to β-cells through expression 
of PDX-1 (102). Collectively these studies suggest the existence of a PDX-1 expressing 
immature cell population, which could be a valuable source of new β-cells.  
1.12. Environmental effects on β-cell development and plasticity 
 As illustrated thus far, β-cell growth and regeneration are complicated processes 
involving multiple cell types, coordinated timing of gene expression and signalling 
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cascades. Therefore it is expected that external factors, such as the environment, may 
strongly influence β-cell development and plasticity. One important factor to consider is 
the intrauterine environment. Gestation is a critical developmental window and 
metabolic abnormalities at this time may permanently reset important homeostatic 
processes that could predispose an individual to disease later in life (173). Hales et al. 
(174) studied a cohort of adult men to determine if fetal and infant growth were 
associated with type 2 diabetes and impaired glucose tolerance. They found that 
individuals with lower birth weight and body weight at 1 year had a higher proportion of 
glucose intolerance (174). Of these low birth weight individuals, 17% were diagnosed 
with type 2 diabetes (174). The thrifty phenotype hypothesis was proposed to describe 
the etiology of type 2 diabetes. The hypothesis states that poor nutrition in fetal and 
early infant life is detrimental to the development and function of β-cells (175). These 
deficits, which may include more complex features such as the islet vasculature and 
innervation, predispose the individual to the later development of type 2 diabetes (175). 
There is also evidence to support an increased risk for low birth weight individuals for 
the development of hypertension and the metabolic syndrome (176). 
Animal models of intrauterine growth restriction (IUGR) have been developed as a 
method to understand the role of the intrauterine environment in the development of 
the fetus and the predisposition to adult disease. IUGR can be achieved through 
maternal dietary restriction of calories (177; 178) or nutrients (protein) (179; 180). 
Additionally, pharmacological (181; 182) or surgical intervention through uterine artery 
ligation (183) can be used to mimic IUGR. In all cases the fetus becomes growth  
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restricted due to inadequate nutrient delivery (173). 
1.12.1. Uterine Artery Ligation 
A rat model of uteroplacental insufficiency was produced by bilateral uterine artery 
ligation at 19 days of gestation, 3 days before term (183).  Uteroplacental insufficiency 
limits the supply of critical substrates, such as oxygen, glucose and amino acid to the 
fetus and results in poor growth (184). IUGR offspring had lower birth weights than 
controls until 7 weeks of age, when the growth rate was accelerated and by 26 weeks of 
age they became obese (183). At 14 days postnatally, IUGR pups exhibited a reduced β-
cell proliferation but a normal apoptotic rate (185). Pdx-1 expression was dramatically 
reduced at 14 days of age and the reduced expression persisted until 3 months (185). 
Despite reductions in Pdx-1 expression, β-cell mass was normal at 14 days of age, before 
dropping below control values by 15 weeks of age (183; 185). IUGR offspring are glucose 
intolerant and insulin resistant early on and by 7 weeks of age they develop mild fasting 
hyperglycemia and hyperinsulinemia and at 26 weeks they are markedly hyperglycemic 
(183). It was shown that Exendin-4 (Ex-4), a long acting glucagon-like peptide-1 analog, 
was able to reverse the adverse affects of uteroplacental insufficiency (185). Treatment 
of IUGR newborns for the first 6 days of life with Ex-4 restored Pdx-1 expression to 
normal levels, β-cell proliferation rates were normalized and the progressive loss of β-
cell mass was prevented (185). These effects of Ex-4 administration were attributed to 
the restoration of islet vascularity and VEGF expression (186). This indicates the 
plasticity of the neonatal pancreas, which with intervention has the ability to overcome 
adverse events in fetal life. 
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1.12.2. Pharmacological Induction of IUGR 
Injection of 30 mg/kg body weight of STZ to a pregnant rat will induce mild diabetes 
and macrosomic offspring (187; 188). These offspring become glucose intolerant in 
adulthood due to decreased insulin secretion (189). On the other hand, injection of a 
higher dose of STZ (50mg/kg) to a pregnant rat induces severe maternal hyperglycemia 
with fetal growth restriction (190; 191). Development of the fetal endocrine pancreas is 
enhanced by the elevated blood glucose concentrations with resulting hypertrophy and 
hyperplasia of the islets from day 20 of gestation until birth (term is 23 days) (192). Fetal 
pancreatic islets are overstimulated and consequently the fetal β-cells become 
degranulated, disorganized and incapable of responding to any stimulus (192; 193). 
Fetuses cannot benefit from the increased fuel supply from the maternal rat because of 
fetal hypoinsulinemia (188). Hypoinsulinemia, a reduced number of insulin receptors on 
target cells (191) and suppression of plasma membrane-associated GLUT1 in skeletal 
muscle (194) of fetuses leads to a reduction in fetal glucose uptake. After birth, the 
percentage of islet tissue decreased to values lower than normal during the suckling 
period (188). The β-cells can partly restore their secretory capacity because of 
normalization of β-cell granulation (188). Body weight in these offspring remains 
significantly lower during the entire postnatal life, the suckling period and after weaning 
(173). At adult age, there were an increased number of neogenic islets in the 
morphologically normal endocrine pancreas (187), with normal or elevated plasma 
insulin concentrations (195; 196). However, the adult offspring become insulin resistant 
(195; 196). 
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1.12.3. Calorie Restriction Model 
In maternal food restriction models, the decreased availability of nutrients for 
transplacental transport and decreased placental blood flow result in a decreased 
nutrient supply to the fetus (197), whose growth is restricted (198; 199). In one study, 
the food intake of pregnant rats was restricted by 50% on e15 for the last week of 
gestation (199). Insulin content was decreased in the IUGR offspring at postnatal day 1, 
along with a reduced β-cell mass which was attributed to a decreased islet number. 
Body weight and pancreatic weight recovered by day 21 after being nursed by control 
mothers from birth. However, β-cell mass and insulin content were still reduced at this 
time. β-cell proliferation rates were normal at both 1 and 21 day time points. The 
authors concluded from this study that in utero undernutrition impairs β-cell 
development but does not affect postnatal β-cell growth (199). Another study looked at 
maternal food restriction for the entire period of gestation until birth or until weaning 
(198). Offspring of both groups were growth restricted, exhibited decreased plasma 
insulin levels and similar to the first study, insulin resistance in adulthood. It was 
determined that insulin resistance resulted from decreased sensitivity of the liver, while 
insulin action in peripheral tissues remained normal (198; 200). Offspring of food 
restricted rats for the fetal period alone or both the fetal and neonatal periods, only 
showed slight differences in plasma glucose, but a more dramatic reduction in body 
weight with the extended food restriction (173; 198). Otherwise, there were no 
differences in plasma insulin levels or tissue insulin sensitivity (173; 198). However, β-
cell mass was not measured in this second study with a longer duration of caloric 
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restriction, but similar reductions in β-cell mass could be expected. (180). While reduced 
calorie intake may occur in times of famine, such as the Dutch Hunger Winter (201), a 
more common nutritional insult would be an imbalance of particular nutrients, such as 
reduced protein. 
1.13. The Low Protein Model 
Maternal protein restriction is a well established model that has been used to 
examine the impact of the fetal environment on endocrine pancreas development and 
long term glucose homeostasis. The model was initially established by Snoeck et al. 
(180) through the administration of an isocaloric 8% protein diet (LP group; versus 20% 
in the control diet (C)) to pregnant rats for the entire period of gestation. The 
composition of the diets can be found in Table 1.3. LP fed rats had an increased food 
intake with no change in weight gain during pregnancy. Placental weight was unchanged 
and litter size was similar to controls, however, birth weight was significantly reduced in 
the LP offspring (180). At birth, LP offspring had a decreased islet cell proliferation rate, 
which corresponded to fewer large islets and a decreased mean islet size. Additionally, 
islet vascularization was reduced by more than 50% in LP offspring due to a decrease in 
blood vessel number. Other studies have also observed similar reductions in birth 
weight, β-cell proliferation, mean islet size and islet vascularization in LP offspring (202-
204). Furthermore, isolated islets of LP offspring at birth secreted less insulin in response 
to glucose and amino acids than control islets (179; 205). 
Postnatally, when dams are maintained on a LP diet for the period of lactation, body 
weight is reduced at all time points until the day of weaning (day 21) (179; 202). 
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Table 1.3. Composition of the diets (g/100g of diet) 
 Control LP 
Cornstarch 40 40 
Casein (88% protein) 22.3 8.6 
Maltodextrin 13.2 13.2 
Sucrose 10.0 23.6 
Soybean oil 4.5 4.5 
Cellulose 5.0 5.0 
Mineral mix 3.5 3.5 
Vitamin mix 1.0 1.0 
L-Cystine 0.3 0.3 
Choline Bitartrate 0.25 0.25 
Tert-butyl hydroquinone 0.0014 0.0014 
Bio-Serv, Frenchtown, NJ, USA.  
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Offspring pancreatic weight was reduced between days 2 and 14 compared to control-
fed animals (202). β-cell mass and mean islet area were decreased in LP offspring 
throughout lactation (202; 204) with an observed decrease in proliferation due to a 
prolonged G1 phase of the cell cycle (202). In addition there was an increase in the 
incidence of apoptosis in LP offspring at this time. The increased apoptosis 
corresponded with a decreased mRNA expression and immunoreactive staining in the 
islets for the islet survival factor, IGF-II compared to control offspring. There was a 
decrease in nestin and CD34 expressing cells in the islets and pancreatic ducts in LP 
offspring from birth to day 14 (204). These cells are thought to represent either 
endocrine or endothelial cell precursors, which may be related to the limitation in 
endocrine cell development. Despite the changes in islet development, blood glucose 
values did not change between groups (202). 
In adulthood, the prominent observation in LP offspring is the development of 
glucose intolerance (179; 206; 207). Glucose intolerance in LP offspring was observed at 
70 days of age and this was associated with a reduced insulin secretory response to 
glucose (179; 208). There was no difference in blood glucose values from weaning to 
day 84 between control and LP offspring, despite lower blood insulin levels in the LP 
offspring (179; 208). As well, the islet volume density was reduced in the LP group at 
day 84 (179). In a related study, glucose intolerance was first observed in LP offspring at 
130 days of age, specifically in females (206; 207). In contrast to the previous study, no 
difference in plasma insulin levels was observed between female control and LP 
offspring, but the islet number and β-cell mass were decreased in LP offspring (207). 
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Moreover, male LP offspring did not exhibit reductions in β-cell mass, but were insulin 
resistant. Insulin levels were increased by 2 fold in male LP offspring but there was a 
reduction in Akt phosphorylation in adipose and skeletal muscle, an indication of 
decreased insulin signaling in these tissues. Both of these studies noted reductions in 
body weight after weaning in both male and female LP offspring throughout the time 
period studied (179; 207).  
Thus far the studies have examined the administration of a LP diet during gestation 
and lactation and while both periods are critical times for endocrine pancreas 
development, studies have tried to determine the specific window in which glucose 
homeostasis is programmed. If LP is administered only for the period of gestation, and 
dams are given control food at parturition, glucose intolerance in adulthood still occurs 
(179). However, glucose tolerance was slightly improved over the group that received LP 
until weaning and body weight was similar to controls if protein was returned to normal 
at birth. After weaning, blood insulin levels were no different from controls at all time 
points measured and at day 84, islet volume density was not significantly different. 
Furthermore, varying the timing of LP administration within gestation demonstrated 
that the impact of LP was most pronounced in females when LP was given for the 2nd 
week of gestation only and in males when LP was given during the 3rd week of gestation 
only (207).  
1.13.1. The Low Protein Mouse Model 
While the LP rat model is well established and has been extensively studied, the LP 
mouse model would allow for the use of genetic tools such as transgenic mice. 
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Additionally, the effects of LP in a mouse model on pancreas development have only 
recently been investigated. In one study, LP was administered to pregnant C57BL/6 
mice for the entire period of gestation until day 3 postnatally when pups were cross 
fostered to control fed dams (209). Body weight in LP offspring was reduced at day 3, 
but following cross fostering to control fed dams, there was rapid catch up growth at 
day 7 and overgrowth by day 21 compared to offspring receiving the control diet 
throughout. Pancreas weight was reduced in LP offspring at day 21 when normalized to 
body weight. There was no difference in fasting blood glucose or insulin levels at day 21 
in male LP offspring. However, protein expression of key insulin signaling molecules in 
muscle tissue were decreased compared to controls at day 21. In a second study, 
pregnant C57BL/6J mice were given an isocaloric 9% LP diet (versus 19% in control) for 
the period of gestation only and the offspring were cross fostered to control fed dams 
at birth (210). Birth weights were significantly reduced in LP offspring. Male offspring 
showed catch up growth by 8 weeks of age and surpassed the weight of the controls by 
week 32. In contrast, female LP offspring showed growth restriction from birth until 32 
weeks of age. Male LP offspring were glucose intolerant with a higher adiposity at 32 
weeks of age, while female LP offspring were not significantly different from controls. 
Studies on the LP mouse offspring have yet to address the impact on endocrine cell 
development, which is of interest to understand the development of glucose 
intolerance in adulthood. The main findings of the LP mouse model are contrasted with 
other species and models of IUGR in Table 1.4. 
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Table 1.4. Models of Intrauterine Growth Restriction 
Insult Species Sex 
Birth 
Weight 
Glucose 
Tolerance Islet histology Reference 
Low Protein 
gestation only 
Mouse male 
female 
↓ 
↓ 
↓ 
NS 
ND (209; 210) 
 Rat mixed NS ↓ NS (179) 
 Rat mixed ↓ ND ↓replication 
↓islet size 
↓vasculature 
(180) 
Low Protein 
gestation & 
lactation 
Rat male 
female 
↓ 
↓ 
NS  
↓ 
↓replication 
↓beta cell 
mass 
↓vasculature 
(202; 204; 
206; 207) 
Low Protein 
all of life 
Rat mixed NS ↓ ↓islet 
volume 
(179) 
Calorie 
Restriction  
last 2 weeks 
gestation 
Rat female ↓ ND ND (177; 178) 
last week 
gestation 
Rat mixed ↓ ND ↓islet 
number 
(199) 
gestation and/or 
lactation 
Rat female ↓ NS ND (198) 
Uterine Artery 
Ligation       (e19) 
Rat mixed ↓ ↓ ↓beta cell 
mass - 15 wks 
(183) 
Pharmacological Rat female ↓ ND ND (177) 
 Rat mixed ↓ ↓ ↑fetal islet 
mass 
↓postnatal 
islet mass 
(173; 189; 
191; 192) 
Hertfordshire 
cohort 
Human male ↓ ↓ ND (174) 
Different models and timing of insults inducing fetal growth restriction in humans, mice 
and rats comparing birth weight, glucose tolerance and changes to the islet mass or 
structure based on histology. ND = not determined. NS = no significant change.  
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1.13.2. Relevance of the Low Protein Model 
The calorie restriction rat model provides an adequate representation of the effects 
of famine on fetal development. In humans, these effects were well documented in 
studies on the Dutch famine (201). In North America famine is of lesser concern and 
placental insufficiency is a major cause of IUGR, thus the uterine artery ligation model 
may be most appropriate. However, given that placental insufficiency in humans can 
produce a protein deficiency in the fetus (211), the LP model shares features in common 
with the human placental insufficiency IUGR condition. Furthermore, the LP model will 
be useful to differentiate the specific effects of amino acid deficiency from placental 
insufficiency which results in both decreased oxygen and nutrient delivery. 
1.13.3. Reversal Strategies 
While the consequences of development in a poor intrauterine environment have 
been well documented, it is important to determine whether or not intervention can 
reverse these effects. The LP diet was shown to alter the plasma amino acid profile of 
dams and fetuses and specifically the amino acid taurine (212). Taurine is a sulfur 
containing amino acid that is involved in coordination of nerve function, stabilization of 
the cell membrane, detoxification, antioxidant reactions and modulation of osmotic 
pressure (213). In the pancreas, taurine is found in the islets and stimulates insulin 
release by fetal β-cells in vitro (214; 215). Taurine (25 g/L) was added to the drinking 
water of LP dams to see if supplementation could reverse the negative impact of the LP 
diet on the offspring (203; 216). Taurine supplementation to LP fed dams had no effect 
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on body weight and pancreas weight, however, β-cell mass returned to control levels at 
day 30 (216). This corresponded with a recovery of proliferation rates and a reduction in 
apoptosis. As well, the islet blood vessel volume and numerical density returned to 
control values and VEGF immunoreactivity in the islet was recovered in LP offspring 
with taurine supplementation (203). In a related study, IUGR rats were injected with Ex-
4 for 6 consecutive days from birth (185; 217). Ex-4 normalized blood glucose levels and 
glucose tolerance in IUGR offspring (185). Additionally, neonatal Ex-4 treatment 
restored Pdx-1 expression, β-cell proliferation rates and β-cell mass. Increased islet 
vascularity and restoration of VEGF expression prior to reversal of diabetes suggested 
the requirement for islet vascular growth before recovery of β-cell mass and glucose 
homeostasis (217). These studies suggest a degree of plasticity remains despite the 
influence of fetal nutrient deficiency and allows for the possibility of intervention. 
1.14. Maternal Malnutrition and Tissue Plasticity  
Based on intervention studies, a degree of tissue plasticity is evident in growth 
restricted offspring, but whether this plasticity is capable of tissue regeneration 
following damage or loss is currently being investigated. A study by Elmes et al. (218) 
looked at cardiac dysfunction and myocardial damage following ischemia-reperfusion 
(IR) in offspring exposed to low protein in utero. They found that a LP diet during 
gestation significantly impairs recovery of male adult rats after IR. When considering 
tissue regeneration in the pancreas, β-cell neogenesis was activated and β-cell 
proliferation was unaffected following Px in undernourished adult rats (219). Pregnant 
rats were 65% calorie restricted (R) for the last week of gestation through lactation and 
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the offspring maintained on the restricted diet until day 70 at which point male 
offspring were subjected to a 90% Px (219). Two days following surgery, RPx rats 
showed a significant increase in neogenesis which was greater than in control fed 
offspring receiving Px. Additionally, β-cell proliferation was observed in RPx rats, but 
was not different than in CPx rats. This study suggests that undernourished rats 
maintain a capacity for β-cell regeneration in adulthood. In contrast, when dams were 
50% calorie restricted from day 15 of gestation until weaning and the offspring injected 
with a single dose of STZ (100 mg/kg) at birth, β-cell regeneration was impaired (220). β-
cell mass regenerated rapidly by day 7 in STZ treated rats of C-fed dams, however, 
despite an initial increase to 40% of non-injected rats, the R+STZ rats show poor 
regeneration to day 21. The observed impairment in β-cell regeneration was attributed 
to reduced neogenesis, while β-cell proliferation was preserved. Tissue plasticity is 
important for adaptations to physiologic and pathological conditions, as well as for 
tissue repair after damage or loss. Therefore there are serious implications for 
reductions in tissue plasticity due to fetal programming by environmental insults. 
1.15. Rationale 
Type 1 diabetic and advanced stage type 2 diabetic individuals have reductions in β-
cell mass which contributes to uncontrolled glucose homeostasis. Stimulation of 
endogenous β-cell regeneration could prove to be a very beneficial therapeutic 
approach for these individuals. Rodent models of β-cell regeneration following STZ 
induced β-cell loss have been extensively studied, but the mechanism of regeneration 
and the signalling pathways involved remain widely debated. We will use multiple low 
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doses of STZ to partially reduce β-cell mass to determine whether newly regenerated β-
cells were the result of increased β-cell replication, duct associated islet neogenesis, 
and/or precursor cell differentiation.  
Models of IUGR have been used to understand the role of the intrauterine 
environment in fetal programming and susceptibility to adult diseases such as obesity, 
cardiovascular disease and diabetes. Protein restriction in pregnant rats during the 
period of gestation is a reproducible model of glucose intolerance, insulin resistance 
and type 2 diabetes. However, the administration of a LP diet to a pregnant mouse has 
not been extensively characterized, especially regarding pancreas development. 
Additionally, replication of the LP rat findings in a mouse model would open up an 
avenue for the use of genetic tools to further study the mechanism behind fetal 
programming of adult diseases. Furthermore, alterations in pancreas development due 
to LP exposure in utero may limit the capacity for β-cell regeneration. Specifically, fetal 
programming may reduce the precursor population or the replicative capacity of the β-
cells following LP, as has been observed in the rat model (202; 204). Moreover, the 
effects of prior LP-feeding may cause altered expression of critical genes involved in β-
cell regeneration.  
Microarray technology can be a powerful tool to examine gene expression profiles 
between groups, as well as to identify altered expression of novel genes. Performing 
microarray experiments in the current study could allow for identification of signalling 
pathways and genes involved in: 1) β-cell regeneration and 2) the development of adult 
disease following LP exposure. 
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1.16. Hypothesis 
We hypothesize that protein restriction during development in mice leads to IUGR 
and impairment of long term glucose homeostasis. In C-fed offspring, β-cells will 
regenerate following STZ treatment due to an increased expression of effector genes 
leading to β-cell proliferation and/or precursor cell differentiation. However, LP 
offspring treated with STZ will have a failure in β-cell regeneration with a lack of β-cell 
proliferation and/or precursor cell differentiation and a corresponding decrease in 
effector gene expression. 
1.17. Objectives 
1. To characterize a LP mouse model, in which a LP diet will be administered for the 
period of gestation only, and the histology of the endocrine pancreas examined for 
short and long term changes in β-cell mass, in addition to functional measurements of 
glucose homeostasis. 
2. Using a multiple low dose regimen of STZ administration, we will determine if newly 
regenerated β-cells originate from ductal or intra-islet precursor cell differentiation, 
and/or from self-replication of β-cells. 
3. We will determine the capacity for β-cell regeneration in LP offspring, and if this 
process is compromised, identify whether the precursor cell population or the ability to 
self replicate was altered in LP offspring.  
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4. Using microarray technology and real-time PCR experiments, we will elucidate genes  
and signalling pathways that are critical for β-cell regeneration and might be altered 
following LP diet.  
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The Effects of Low Protein during Gestation on Mouse Pancreatic Development and 
Beta Cell Regeneration. 
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2.1. Introduction 
Poor fetal growth and low birth weight are associated with increased risk of 
impaired glucose tolerance (1), type 2 diabetes (2), the metabolic syndrome (3) and 
cardiovascular disease (4) in adult life. Animal models that have been developed to 
understand the role of the intrauterine environment in susceptibility to postnatal 
disease have included maternal dietary calorie restriction (5), nutritional imbalance (6), 
and pharmacological (7) or surgical intervention (8). Administration of a low protein (LP) 
diet to rats during pregnancy results in reduced birth weight (6), impaired islet cell 
development, deficient insulin release (9), an increased islet apoptotic rate (10; 11) and 
decreased β-cell mass in the offspring (9-11). Offspring of LP-fed dams were glucose 
intolerant at 130 days of age (12). Our first objective was to characterize an LP model in 
mice, to facilitate future exploration into the mechanisms whereby nutritional insult can 
predispose to adult disease by using genetically manipulated transgenic mice. 
Pancreatic β-cells have a significant capacity to regenerate after injury in early life. 
Subtotal deletion of β-cells with streptozotocin (STZ) is followed by their partial 
regeneration and remission of hyperglycemia in young rodents (13; 14). However, this 
regenerative ability decreases with age (15). New β-cells have been postulated to be 
generated through 3 possible mechanisms: 1) β-cell replication (16), 2) ductal islet 
neogenesis (17) and 3) stem/precursor cell differentiation (18). It remains to be 
determined which mechanism is most important for β-cell regeneration, and could be 
exploited for β-cell therapy. It is not known if administration of a LP diet to a pregnant 
mouse will alter β-cell plasticity in the offspring following an STZ insult, or by which 
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mechanism regeneration occurs, which constitutes our second objective in this study. 
Understanding how the intrauterine environment alters plasticity of β-cell mass in the 
offspring could lead to strategies to intervene before the onset of type 2 diabetes. 
To investigate these objectives, the Balb/c mouse will be used over the more 
common C57BL/6 mouse strains. Previous studies demonstrated that adult C57BL/6 
mice were less glucose tolerant than other mouse strains, including Balb/c (19; 20). 
Development of glucose intolerance in adult mice could potentially confound the results 
obtained with the LP model. Furthermore, C57BL/6 mouse strains develop significant 
insulitis following multiple low doses of STZ, while the Balb/c strain is resistant to 
immune cell infiltration (21). Thus, the Balb/c mouse will provide an ideal model to 
examine the current objectives without confounding factors such as glucose intolerance 
and insulitis. 
2.2. Materials and Methods 
2.2.1. Animals 
Balb/c mice (Charles River Ltd, Montreal, QC, Canada) were housed in a 
temperature controlled room with 12 h light : dark cycle. Water and food (Bio-Serv, 
Frenchtown, NJ, USA) were given ad libitum. The low protein (LP) diet (similar to Snoeck 
et al. (6)) was isocaloric with 8% protein versus 20% in the control (C) diet. Pregnancy 
was confirmed by a vaginal plug and mothers were randomly assigned to C or LP diet for 
the duration of gestation. A total of 61 C litters and 52 LP litters were used, with 15 
litters/diet followed for maternal weight and food intake measurements every 5th day 
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until weaning. All dams were maintained on the C diet after parturition. On days 1 
through 5 the offspring received injections of either 35 mg/kg dose of STZ (Sigma 
Chemical, St.Louis, MO, USA) in sodium citrate buffer (0.1 mol/L, pH 4.5), or equal 
volume of the vehicle (sham). The offspring were divided into four groups: C = control 
diet, sham injected; C+STZ = control diet, STZ injected; LP = low protein diet, sham 
injected; LP+STZ = low protein diet, STZ injected. On day (d) 1, 7, 14, 30 and 130 the 
weights of the offspring were recorded and blood glucose levels were measured after a 
24 h fast using an Ascencia Breeze glucometer (Bayer Inc., Toronto, ON, Canada). Mice 
were then killed and the pancreata were removed and fixed in 10% formalin for 
morphological analysis. Three mice from independent litters were included per group 
for each gender. On d42 and 130 an intraperitoneal glucose tolerance test (IPGTT) was 
performed for 90 min after a 4 h fast as described previously (22). At d130 the total 
abdominal adipose tissue was removed and weighed. All animal procedures were 
approved by the Animal Care Committee of the University of Western Ontario in 
accordance with the guidelines of the Canadian Council for Animal Care (Appendix 1).  
2.2.2. Immunohistochemistry  
Simultaneous immunohistochemistry was performed on sections for glucagon and 
insulin as described previously (23). Briefly, tissue sections were incubated with a mouse 
anti-glucagon antibody (1:2000; Sigma) and a horse anti-mouse secondary antibody 
(1:50 Vector Laboratories, Burlingame, CA, USA) and localized using ExtrAvidin-
Peroxidase (Sigma) and a liquid DAB substrate kit (BioGenex, Fremont, CA, USA). 
Subsequently, sections were incubated with a rabbit anti-insulin antibody (1:200; Santa 
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Cruz, Biotechnology, Santa Cruz, CA, USA) and a goat anti-rabbit secondary antibody 
(Vector) and localized using the Vectastain ABC-AP kit (Vector) with the Vector Red 
Alkaline Phosphatase substrate kit I (Vector). Sections were mounted under glass 
coverslips with Permount (Fisher Scientific, Toronto, ON, Canada). A triple stain was 
performed to determine co-localization of proliferating cell nuclear antigen (PCNA) with 
insulin and glucagon. Glucagon was localized as above, using a rabbit anti-glucagon 
antibody (1:300; Santa Cruz) with a goat anti-rabbit secondary antibody (1:50; Vector). 
PCNA was localized using a mouse anti-PCNA antibody (1:50; Dako Cytomation, 
Mississauga, ON, Canada) with a horse anti-mouse secondary antibody (1:50; Vector) 
followed by Vectastain ABC-AP kit (Vector) and visualized using Vector Blue Alkaline 
Phosphatase substrate kit III (Vector). Tween-20 1X Tris buffered saline was used as a 
wash, with phosphate buffered saline (PBS) used for the insulin staining portion. Insulin 
was localized as above with a guinea pig anti-insulin antibody (1:300; Abcam, 
Cambridge, MA, USA) with a goat anti-guinea pig secondary antibody (1:50; Vector). 
Apoptag Plus Peroxidase In Situ Apoptosis Dectection Kit (Millipore, Etobicoke, ON, 
Canada) was used to visualize apoptotic cells. This was followed by staining for glucagon 
(1:200) and insulin (1:200), as described in the above triple stain, and visualized with 
Vector Red and Blue Alkaline Phosphatase substrate kits I and III (Vector), respectively. 
Pancreatic duodenal homeobox-1 (PDX-1) and insulin dual immunofluorescent 
staining was performed using a rabbit anti-PDX-1 primary antibody (1:200; generous gift 
from Dr. Chris Wright, Vanderbilt University, Nashville, TN, USA) with donkey Cy3 anti-
rabbit secondary antibody (1:50; Jackson ImmunoResearch Laboratories Inc., West 
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Grove, PA, USA), mouse anti-insulin primary antibody (1:200; Sigma) and Alexafluor 488 
goat anti-mouse secondary antibody (1:50; Invitrogen Canada Inc., Burlington, ON, 
Canada) with 4’,6-diamidino-2-phenlindole (DAPI) nuclear counterstain (Invitrogen). 
Sections were mounted under glass coverslips with Fluorescent mounting medium 
(Dako). PDX-1+ cells were counted for every islet/section and the PDX1+/insulin— cell 
population was expressed as percentage of total PDX1+ cells. 
Appropriate controls were performed for all antibodies used as described in 
Appendix 2. 
2.2.3. Morphometric analysis  
Three representative pancreatic sections (sections were 20 μm (d1) up to 60 μm 
(d130) apart; coefficient of variation = 10.45%) from each of 3 animals/group were 
imaged and analyzed using Northern Eclipse software (version 7.0; Empix Imaging, 
Mississauga, ON, Canada). Total pancreas area for each section and the area of insulin 
and glucagon immunoreactivity for each islet were measured. Islets with an area <300 
µm2 (≤3 cells) were excluded from analysis to distinguish islets from scattered single cells 
in the parenchyma and to avoid the bias of sampling of islets that were sectioned at the 
tops. β- (and α-) cell mass was calculated as previously described (11) by determining 
the β-cell fractional area of the total tissue section area multiplied by the pancreas 
weight. Individual β- and α-cell size were determined by averaging the individual cell 
area measured from 10-15 random islets for each of 3 sections per pancreas and 3 
pancreata per group. Islet neogenesis from pancreatic ducts was identified by endocrine 
cell clusters associated with a pancreatic duct as previously described (24-26). 
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Neogenesis was quantified by the number of small clusters (between 3-10 cells) per 
mm2 pancreas area. 
2.2.4. Serum and Pancreatic Insulin  
On d7, 14 and 30 at least 20 µL of serum was collected and stored at -80°C. Insulin 
was measured using an Ultra Sensitive Mouse Insulin ELISA Kit (Crystal Chem Inc., 
Downers Grove, IL, USA) according to the manufacturer’s instructions with sensitivity 0.1 
ng/mL (intra- and inter-assay coefficient of variance ≤ 8% and ≤ 10% respectively). 
Insulin was extracted from d14 whole pancreata (~50 mg) by mechanical 
homogenization in 500 µL acid ethanol (165mM HCl in 75% ethanol). After overnight 
incubation at 4°C, samples were centrifuged (2000g) for 5 min at 4°C. Insulin was 
quantified in the supernatant by rat insulin radioimmunoassay (Linco Research Inc, St. 
Charles, MO, USA; 100% reactivity to mouse insulin) and normalized to pancreatic DNA 
content. Assay sensitivity was 0.1 ng/mL, with an intra- and inter-assay coefficient of 
variance of 4.6% and 9.4%, respectively. Representative standard curves are shown in 
Appendix 3. 
2.2.5. Statistical Analysis  
Three-way ANOVA was performed using SPSS revealing significant differences with 
respect to gender. The genders were separated to examine the effects of diet and 
treatment using a two-way ANOVA with a Bonferroni post-test to look at main effects 
and group differences. An unpaired t-test was used for d1 comparisons. GraphPad Prism 
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v5 software (GraphPad Software, La Jolla, CA, USA) was used. All values are means ± 
SEM and with a significance level of p < 0.05.  
2.3. Results 
2.3.1. Body, Organ Weights and Diabetes Onset 
No difference in weight gain or food intake (g consumed/d) was observed between 
the C and LP fed dams at any time during pregnancy or lactation (n = 15 dams per 
group). The mean litter size for the C (5.1 ± 0.3 pups; n = 61) and the LP (5.8 ± 0.3 pups; 
n = 52) groups was not significantly different. On d1, male and female LP offspring had 
significantly reduced (p < 0.05) weights and at d7 the LP diet significantly reduced (p < 
0.01) body weight in both genders, although all mice recovered weight by d14 (Table 
2.1). Pancreas weight (% body weight) was significantly decreased (p < 0.05) in both 
male C+STZ and LP mice on d7 compared to controls, while the effect of LP treatment 
continued to significantly reduce (p < 0.05) pancreas weight (%) in male offspring at d 14 
(Table 2.1). 
All female mice survived to d130 and showed no difference in weight between 
groups (Table 2.1). Male C+STZ and LP+STZ mice became overtly diabetic between d60-
80 as defined by a qualitative observation of increased urination, water consumption 
and blood glucose measurements of ≥25 mmol/L on consecutive days, at which point 
they were killed. The survival rates at 130 days for male C+STZ and LP+STZ mice were 
67% and 33%, respectively (n = 6). Therefore only male C and LP mice were examined at 
d130, where no difference in weight was observed (Table 2.1). At d130, previous STZ   
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Table 2.1. Body weight, relative pancreas weight and blood glucose measurements. 
 Body Weight (g) 
Pancreas Weight/ 
Body Weight (%) 
Blood Glucose 
(mmol/L) 
 Male Female Male Female Male Female 
Day 1       
Control 1.67 ± 0.08 1.55 ± 0.04 0.35 ± 0.07 0.32 ± 0.06 3.8 ± 0.4 4.4 ± 0.3 
LP 1.40 ± 0.04* 1.42 ± 0.03* 0.30 ± 0.04 0.42 ± 0.05 4.4 ± 0.2 3.8 ± 0.3 
Day 7       
Control 5.58 ± 0.54 4.71 ± 0.22 0.23 ± 0.04 0.15 ± 0.04 5.7 ± 0.4 6.0 ± 0.4 
C+STZ 6.24 ± 0.68 4.89 ± 0.21 0.10 ± 0.03* 0.17 ± 0.01 6.6 ± 0.4** 5.9 ± 0.5 
LP 4.73 ± 0.22† 4.22 ± 0.13† 0.09 ± 0.01* 0.14 ± 0.06 5.2 ± 0.3 5.7 ± 0.3 
LP+STZ 4.30 ± 0.17† 4.25 ± 0.13† 0.09 ± 0.01* 0.16 ± 0.05 6.0 ± 0.3** 6.3 ± 0.5 
Day 14       
Control 8.34 ± 0.49 8.81 ± 0.46 0.39 ± 0.01 0.21 ± 0.08 8.2 ± 0.6 8.6 ± 0.7 
C+STZ 8.57 ± 0.63 8.36 ± 0.57 0.40 ± 0.03 0.24 ± 0.07 11.8 ± 1.3** 9.6 ± 0.6 
LP 8.95 ± 0.27 8.82 ± 0.31 0.29 ± 0.03‡ 0.45 ± 0.15 8.4 ± 0.8 8.5 ± 0.9 
LP+STZ 8.81 ± 0.28 8.38 ± 0.27 0.25 ± 0.06‡ 0.18 ± 0.07 13.3 ± 2.7** 9.4 ± 1.2 
Day 30       
Control 15.8 ± 0.9 15.0 ± 0.6 0.76 ± 0.02 0.86 ± 0.06 8.1 ± 0.5 8.1 ± 0.8 
C+STZ 16.2 ± 1.0 13.9 ± 0.3 0.78 ± 0.11 0.79 ± 0.01 10.7 ± 1.1§ 9.6 ± 1.6 
LP 15.2 ± 0.6 13.6 ± 0.7 0.76 ± 0.09 1.04 ± 0.20 8.4 ± 0.8 8.0 ± 1.4 
LP+STZ 15.0 ± 0.7 13.7 ± 0.4 0.87 ± 0.02 1.07 ± 0.37 15.2 ± 2.8§ 9.9 ± 1.0 
Day 130       
Control 28.4 ± 0.9 22.8 ± 0.5 0.81 ± 0.04 0.99 ± 0.16 6.9 ± 0.3 6.9 ± 0.4 
C+STZ N/A 22.6 ± 0.7 N/A 1.00 ± 0.03 N/A 8.4 ± 0.7** 
LP 27.3 ± 0.7 22.9 ± 0.3 0.92 ± 0.02 0.94 ± 0.08 6.3 ± 0.5 7.3 ± 0.5 
LP+STZ N/A 22.5 ± 0.4 N/A 1.07 ± 0.08 N/A 8.2 ± 0.4** 
The body weight (g ± SEM; n = 7-17 per group), pancreas weight relative to body weight 
(% ± SEM; n = 3 per group) and blood glucose values (mmol/L ± SEM; n = 6-13) are given 
for male and female mouse offspring receiving C or LP with or without subsequent STZ 
administration over the time points studied. Data was analyzed using an unpaired t-test 
for d1 comparisons and a 2-way ANOVA with Bonferroni’s post-test for all other time 
points. * p < 0.05 vs Control; † p < 0.01 effect of LP diet; ‡ p < 0.05 effect of LP diet;  
** p < 0.05 effect of STZ; § p < 0.01 effect of STZ.  
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treatment caused a decrease in mean abdominal adipose weight (% body weight), but 
the LP diet had no effect in either gender (Female: C = 2.5 ± 0.3, C+STZ = 1.8 ± 0.4, LP = 
2.9 ± 0.4, LP+STZ = 1.6 ± 0.4; Male: C = 2.0 ± 0.4, LP = 1.9 ± 0.3; n = 4-5). 
2.3.2. β-Cell Mass  
β-cell mass was significantly decreased (p < 0.05) in male LP offspring at d7 and was 
unchanged throughout the remaining period studied. Female LP mice similarly had a 
significantly decreased (p < 0.01) β-cell mass at d7, however, by d14 showed a significant 
increase (p < 0.001) compared to C animals (Figure 2.1b). At d30 and 130, the β-cell 
mass in LP females was comparable to C values (Figure 2.1b). Therefore, LP exposure 
alone had no long term effects on β-cell mass of either gender. 
β-cell loss occurred following STZ treatment for both control and LP-treated mice as 
shown on d7, two days after the final STZ injection (Figure 2.1 & 2.2a,b; p < 0.05). No 
histological evidence of insulitis was observed in animals receiving STZ. STZ 
administration decreased β-cell mass by 51% and 45% in female C+STZ and LP+STZ mice 
compared to the respective sham-treated groups on d7. In the male C+STZ and LP+STZ 
groups there was a 64% and 52% decrease respectively. On d14 in males given STZ, with 
or without LP exposure, there was a partial recovery of β-cell mass (Figure 2.1a). By d30, 
male C+STZ mice fully recovered β-cell mass versus controls. In contrast LP+STZ mice 
showed a significant deficit (p < 0.05) compared to LP sham treated mice (Figure 2.1a). 
This indicates that the initial increase in β-cell mass in male LP+STZ mice was not   
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Figure 2.1. Changes in β-cell mass with diet and STZ treatment.  
β-cell mass (mg) for C (white bars), C+STZ (grey bars), LP (black bars) and LP+STZ 
(hatched bars) offspring over time for male (a) and female (b) mice. Mean ± SEM; n = 3 
animals per group, and 3 sections per pancreas. Data was analyzed using a 2-way 
ANOVA with Bonferroni’s post-test. (a) ** p < 0.05 vs sham; § p < 0.001 vs sham; ││ p < 
0.05 vs C+sham; (b) ** p < 0.05 vs sham; § p < 0.001 vs sham; # p < 0.001 vs C+sham; * p 
< 0.01 effect of LP diet; † p < 0.01 effect of STZ; ‡ p < 0.001 effect of STZ. 
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Figure 2.2. Representative immunohistochemical and -fluorescent images.  
Localization of insulin (red) and glucagon (brown) in an islet from a female (a) C and (b) 
C+STZ mouse showing a decrease in insulin immunoreactive positive β-cells on d7. No 
histological evidence of lymphocyte infiltration was observed, or any gender differences 
in islet architecture. (c-f) Identification of Pdx-1+/insulin— progenitor cells (arrows) from 
a female LP+STZ islet. (c) Insulin; (d) Pdx-1; (e) insulin and Pdx-1; (f) merged image with 
nuclear DAPI stain (blue). Magnification bars represent 100 µm.  
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sustained. Due to poor survival rates in the STZ treated male mice, the data set for β-cell 
mass at d130 was incomplete (C+STZ = 0.60 ± 0.07 mg, n = 3; LP+STZ = 0.54  ± 0.15 mg, n 
= 2) but suggests a decreased β-cell mass without development of overt diabetes. In 
female mice, LP+STZ animals had a significantly lower (p < 0.01) β-cell mass compared to 
LP sham injected mice on d 7 (Figure 2.1b). Subsequently, female LP mice showed a 
significant increase (p < 0.001) in β-cell mass by d14 compared to C animals which was 
not seen following STZ treatment (Figure 2.1b). β-cell mass was completely recovered by 
d30 in C+STZ but not LP+STZ mice. However, β-cell mass was not maintained over the 
long term as measured at d130 in the C+STZ group, which was significantly lower (p < 
0.001) than in C mice, while LP+STZ mice continued to show a reduced (p < 0.001) β-cell 
mass compared to LP animals (Figure 2.1b). 
2.3.3. α-Cell Mass  
To determine if the effects of the LP diet were specific to β-cells, the α-cell mass was 
also examined by histology (Figure 2.3). α-cell mass in male LP mice was significantly 
reduced (p < 0.01) at d7, but was comparable to C mice for the remaining period of 
study (Figure 2.3a). In female mice, initially there was a significant effect (p < 0.05) of the 
LP diet in reducing α-cell mass at d7, however, LP mice significantly increased (p < 0.01) 
α-cell mass at d14 and 30 when compared to C mice (Figure 2.3b). In male C+STZ mice 
there was a transient decrease (p < 0.001) in α-cell mass on d7 compared to C (Figure 
2.3a). In female mice, STZ treatment under LP conditions significantly reduced α-cell 
mass at d14 and 30 (p < 0.05; Figure 2.3b).  
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Figure 2.3. Changes in α-cell mass with diet and STZ treatment.  
α-cell mass (mg) for C (black bars), C+STZ (white bars), LP (grey bars) and LP+STZ 
(hatched bars) offspring over time for male (a) and female (b) mice. Mean ± SEM; n = 3 
animals per group, and 3 sections per pancreas. Data was analyzed using a 2-way 
ANOVA with Bonferroni’s post-test. (a) § p < 0.001 vs sham; ││ p < 0.05 vs C+sham; (b) 
** p < 0.05 vs sham; § p < 0.001 vs sham; † p < 0.01 vs C+sham; ‡ p < 0.001 vs C+sham; * 
p < 0.05 effect of LP diet.  
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2.3.4. Islet Size Distribution 
Islets were grouped into large (>10,000 µm2), medium (5,000-10,000 µm2) and small 
(300-5,000 µm2) sizes by measuring mean islet area and normalized to total pancreas 
area (mm2). The LP diet did not alter the islet distribution (Table 2.2), and therefore the 
change in β-cell mass in LP female mice was not attributed to an increase in new small 
islets or small islets becoming large. Additionally, STZ treatment did not alter the 
distribution of islet sizes on d7, demonstrating that the reduced β-cell mass associated 
with STZ affected all sizes of islets equally (Table 2.2). By d14 C+STZ male, but not female 
mice, showed a significant reduction in the number of large islets compared to sham 
controls. By d30 there were no longer any differences in islet size distribution for 
control-fed animals receiving STZ, but LP female mice showed reduced numbers of islets 
of all sizes following STZ (Table 2.2). This shows that the relative deficit in β-cell mass in 
these animals shown in Figure 2.1 was due to an overall reduction in the number of 
islets, rather than a failure of smaller islets to become large. 
2.3.5. Islet Cell Proliferation  
The percentage of PCNA positive β- and α-cells was measured to determine the 
contribution of replication to the observed changes in islet mass. No significant 
differences in β- or α-cell proliferation were observed at d7 between the groups for 
either gender (data not shown). On d14 there was a significant increase (p < 0.01) in β- 
and α-cell replication in male C+STZ mice compared to C mice (Figure 2.4a,b). This may 
contribute to the 4.5-fold increase in β-cell mass from d7 to 14 and continued expansion  
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Table 2.2. The number of small, medium and large sized islets per mm2 of 
pancreas.  
 Small Medium Large 
 Male Female Male Female Male Female 
Day 7       
Control 5.6 ± 0.7 4.5 ± 0.4 1.07 ± 0.23 1.00 ± 0.16 0.63 ± 0.15 0.87 ± 0.09 
C+STZ 3.3 ± 0.4 5.6 ± 0.7 0.77 ± 0.16 0.86 ± 0.13 0.47 ± 0.11 0.43 ± 0.08 
LP 5.5 ± 0.6 4.7 ± 0.5 1.11 ± 0.15 0.84 ± 0.23 0.46 ± 0.10 0.54 ± 0.15 
LP+STZ 4.4 ± 0.4 4.4 ± 0.4 0.63 ± 0.13 0.91 ± 0.36 0.26 ± 0.08 0.27 ± 0.07 
Day 14       
Control 2.0 ± 0.3 3.6 ± 0.4 0.29 ± 0.06 0.34 ± 0.06 0.53 ± 0.11 0.33 ± 0.10 
C+STZ 1.6 ± 0.3 2.6 ± 0.3 0.30 ± 0.06 0.49 ± 0.11 0.17 ± 0.04** 0.22 ± 0.08 
LP 2.1 ± 0.3 3.3 ± 0.4 0.40 ± 0.08 0.49 ± 0.07 0.44 ± 0.05 0.69 ± 0.12 
LP+STZ 2.0 ± 0.2 2.9 ± 0.4 0.46 ± 0.09 0.42 ± 0.09 0.36 ± 0.09 0.46 ± 0.09 
Day 30       
Control 0.63 ± 0.05 0.75 ± 0.11 0.11 ± 0.02 0.13 ± 0.03 0.12 ± 0.03 0.12 ± 0.03 
C+STZ 0.51 ± 0.07 0.83 ± 0.10 0.10 ± 0.03 0.17 ± 0.03 0.12 ± 0.02 0.17 ± 0.03 
LP 0.59 ± 0.05 0.93 ± 0.09 0.10 ± 0.02 0.20 ± 0.03 0.16 ± 0.03 0.22 ± 0.03 
LP+STZ 0.42 ± 0.04 0.48 ± 0.05‡ 0.07 ± 0.02 0.10 ± 0.02* 0.08 ± 0.02 0.06 ± 0.01‡ 
The number of islets per mm2 of pancreas (± SEM) with a mean area between 300 and 
5,000 µm2 (small), between 5,000 and 10,000 µm2 (medium), or >10,000 µm2 (large) in 
animals receiving C or LP diet, with or without subsequent administration of STZ at 
various ages. Data was analyzed using a 2-way ANOVA with Bonferroni’s post-test (n = 3; 
3 sections per pancreas). * p < 0.05 vs LP+sham; ** p < 0.01 vs C+sham; ‡ p < 0.01 vs 
LP+sham.  
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Figure 2.4. β- and α-cell proliferation.  
Percentage of PCNA +ve proliferating β (a,c) and α (b,d) cells at d14 for male (a,b) and 
female (c,d) in offspring of control or LP fed mice. White bars = sham, black bars = STZ. 
Mean ± SEM; n = 3 animals per group, and 3 sections per pancreas. Data was analyzed 
using a 2-way ANOVA with Bonferroni’s post-test. ** p < 0.01 vs C+sham. 
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to d30, as well as the increased α-cell mass. However, in female mice there were no 
significant changes in β- or α-cell proliferation (Figure 2.4c,d). 
2.3.6. Apoptosis for d14 Female Mice 
Apoptosis was measured by Tunel assay to determine if reduced rates of apoptosis 
in female LP offspring contributed to the observed increased β- and α-cell mass at d14. 
However, no significant differences were found for the percentage of apoptotic β- and 
α-cells between any groups at d14. (β-cell: C = 0.19 ± 0.09%; C+STZ = 0.32 ± 0.10%; LP = 
0.16 ± 0.04%; LP+STZ = 0.24 ± 0.08%; α-cell: C = 0.25 ± 0.09%; C+STZ = 0.32  ± 0.11%; LP 
= 0.15 ± 0.06%; LP+STZ = 0.21 ± 0.08%; n = 3; 3 sections per pancreas). 
2.3.7. Individual Cell Size for d14 Female Mice 
Since cell proliferation rates were unchanged (Figure 2.4c,d) and no change in 
apoptosis was found, cell size was examined to determine the relative contribution of 
cell hypertrophy to the increased β-cell mass and α-cell mass in d14 female LP mice. 
Individual β-cell area was significantly increased (p < 0.01) in the LP group (71.77 ± 3.18 
µm2) compared to the C group (61.01 ± 1.41 µm2). This change in the LP group is 
associated with an approximate 5.8 fold increase in β-cell mass compared to the C 
group. No difference was found for individual α-cell area between C and LP groups at 
d14. 
2.3.8. PDX-1+/insulin— Islet cells 
The offspring were further analyzed by histology to identify a possible precursor cell  
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population that might contribute to regeneration of β-cell mass. In C animals between 
4% and 8% of islet cells were found to be PDX-1+/insulin— and this did not change with 
STZ treatment (Table 2.3; Figure 2.2c-f). However, the abundance of these cells was 
significantly increased (p < 0.01) in female LP mice after STZ at d7 and 14. Examining 
male mice showed a significant increase (p < 0.05) in PDX-1+/insulin— in LP-fed offspring 
at d7, however this difference did not persist to d14 (Table 2.3).  
2.3.9. Duct Associated Islet Neogenesis 
Small clusters (3-10 cells) associated with ductal structures have been considered an 
indication of neogenesis as previously described (24-26)and are depicted in Figure 2.5. 
Duct associated clusters were counted and normalized to pancreas area (mm2). On d7, 
female C+STZ offspring had a significant increase (p < 0.05) in duct associated islet 
clusters compared to the C group. However there was a minor but significant reduction 
(p < 0.05) of these neogenic clusters in C+STZ mice at d14, which may suggest an 
increase in replication within the small clusters and were therefore outside of the 10 cell 
consideration for neogenesis. No changes were observed between the male groups at 
either time point studied. 
2.3.10. Glucose Homeostasis 
Both male STZ-treated groups were relatively hyperglycemic compared with sham 
injected mice at days 7, 14 and 30 (Table 2.1), while female STZ treated mice were able 
to maintain euglycemia despite changes in β-cell mass. At d42, STZ treatment in male 
and female mice led to fasting hyperglycemia (data not shown). At this age an IPGTT was  
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Table 2.3. Percentage of PDX-1+/insulin— progenitor cells. 
 Day 7 Day 14 
 Male Female Male Female 
Control 3.8 ± 0.6  4.1 ± 0.4 3.6 ± 0.9  5.9 ± 1.3 
C+STZ 4.4 ± 0.4  5.2 ± 0.3 5.3 ± 1.7  7.8 ± 1.2 
LP 5.6 ± 0.9#  4.5 ± 0.8 2.0 ± 0.6  4.0 ± 1.1 
LP+STZ 5.9 ± 0.8# 12.2 ± 1.6§ 2.9 ± 0.2 10.9 ± 1.6** 
The number of PDX-1+/insulin— cells as a percentage of the total PDX-1+ cells (% ± SEM; 
n = 3, 3 sections per pancreas) on d7 and 14 for male and female mice receiving C or LP 
diet, with or without subsequent administration of STZ. Data was analyzed using a 2-way 
ANOVA with Bonferroni’s post-test. # p < 0.05 effect of LP; ** p < 0.01 vs LP+sham; § p < 
0.001 vs LP+sham. 
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Figure 2.5. Duct associated islet neogenesis. 
Micrographs depicting small islets associated with ducts, with insulin stained in red and 
glucagon stained in brown (a,b). Magnification bars represent 100 µm. The number of 
duct associated islets per mm2 pancreas area at d7 (c,e) and d14 (d,f) for male (c,d) and 
female (e,f) in offspring of control or LP fed mice. White bars = sham, black bars = STZ. 
Mean ± SEM; n = 3 animals per group, and 3 sections per pancreas. Data was analyzed 
using a 2-way ANOVA with Bonferroni’s post-test. * p < 0.05 vs C+sham.  
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performed. Blood glucose levels in the C+STZ and LP+STZ groups were elevated over the 
time course compared to non-STZ treatment, and did not reach baseline within 90 min. 
The area under the curve (AUC) for STZ treated groups was significantly increased (p < 
0.05; Figure 2.6a,b insets), indicating a relative impairment of glucose tolerance. 
Exposure to LP diet did not impair glucose tolerance at this age.  
At d130 fasting hyperglycemia was observed in female STZ treated mice, while no 
difference was found between C and LP groups for either gender (Table 2.1). Following 
an IPGTT at d130, female STZ, LP and LP+STZ mice displayed glucose intolerance 
determined by an elevated AUC (p < 0.05; Figure 2.6d inset). However, the LP male mice 
had a comparable glucose response to the C mice during the IPGTT (Figure 2.6c).   
2.3.10. Serum and pancreatic insulin 
Measurements of serum insulin concentration were made on days 7, 14 and 30. 
Despite changes in β-cell mass, serum insulin concentrations were similar between 
groups and genders, with d14 mean values listed in Table 2.4. On d14, pancreatic insulin 
content was significantly reduced (p < 0.05) in male mice exposed to LP, but not in 
females (Table 2.4). STZ-treatment significantly reduced (p < 0.05) insulin content in 
females, but the extent of the reduction was greater in animals receiving LP diet. No 
change in pancreatic insulin content was observed in males treated with STZ, however, 
this may have been more evident after the initial β-cell loss on d7. 
2.4. Discussion 
The pancreas has the ability to regenerate new β-cells after injury (13; 24; 26),  
 
 
88 
 
0
5
10
15
20
25
30
35
Time (min)
0 15 30 60 90
B
lo
od
 G
lu
co
se
 (m
m
ol
/L
)
Control LP
0
250
500
750
1000
1250
*
*
Diet
A
U
C
 (m
in
 · 
m
m
ol
/L
)
0
5
10
15
20
25
30
35
0 15 30 60 90
Time (min)
B
lo
od
 G
lu
co
se
 (m
m
ol
/L
)
Control LP
0
250
500
750
1000
1250
*
*
Diet
A
U
C
(m
in
· m
m
ol
/L
)
0
10
20
30
0 15 30 60 90
Time (min)
B
lo
od
 G
lu
co
se
 (m
m
ol
/L
)
Control LP
0
250
500
750
1000
1250
A
U
C
 (m
in
 · 
m
m
ol
/L
)
0
10
20
30
0 15 30 60 90
Time (min)
B
lo
od
 G
lu
co
se
 (m
m
ol
/L
)
Control LP
0
250
500
750
1000
1250 *
*§
§
Diet
A
U
C
 (m
in
 · 
m
m
ol
/L
)
a b
c d
Male - d42 Female - d42
C+Sham
C+STZ
LP+Sham
LP+STZ
Male - d130 Female - d130
Figure 2.6. Intraperitoneal glucose tolerance test. 
IPGTTs were performed at d42 (a,b) and 130 (c,d) on male (a,c) and female (b,d) 
offspring of C (solid lines) or LP dams (dashed lines), with (open squares) or without 
(closed squares) subsequent STZ treatment. Insets represent the corresponding AUC, 
where white bars = sham, black bars = STZ. Mean ± SEM; n = 10-13 (a,b); n = 3-5 (c,d). 
Data was analyzed using a 2-way ANOVA with Bonferroni’s post-test. * p < 0.05 effect of 
STZ treatment (a,b,d insets); § p < 0.05 effect of LP (d, inset). 
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Table 2.4. Serum insulin and pancreatic content at day 14. 
 
Serum Insulin 
Concentration (ng/mL) 
Pancreatic Insulin Content 
(ng Insulin/µg DNA) 
 Male Female Male Female 
Control 1.2 ± 0.3 0.9 ± 0.5 17.3 ± 4.7 12.1 ± 2.1 
C+STZ 1.4 ± 0.3 0.9 ± 0.3 11.7 ± 3.4 9.2 ± 0.4 § 
LP 1.2 ± 0.5 0.7 ± 0.3 9.9 ± 2.0* 13.2 ± 2.0 
LP+STZ 0.9 ± 0.3 1.0 ± 0.3 4.6 ± 0.5* 6.0 ± 3.0 § 
Serum insulin concentration (ng/mL ± SEM; n = 3-5) and pancreatic insulin content (ng 
insulin/µg DNA ± SEM; n = 3 ) were measured on d14 for male and female mice receiving 
C or LP diet, with or without subsequent administration of STZ. Data was analyzed using 
a 2-way ANOVA with Bonferroni’s post-test. * p < 0.05 effect of LP; § p < 0.05 effect of 
STZ. 
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however, regeneration after sub-total deletion with a single, high dose of STZ may be 
incomplete (13) and this ability decreases with age (15). We used multiple low doses of 
STZ to create partial β-cell deletion in young mice that was not accompanied by 
lymphocyte infiltration, with the expectation that β-cell mass would largely regenerate. 
No significant change in blood glucose levels, or circulating insulin was observed in 
female mice following STZ, although there was a decrease in pancreatic insulin content 
consistent with β-cell mass loss. Male STZ-treated mice showed elevated blood glucose 
levels throughout the study which may have been due initially to a marginally greater 
loss of β-cell mass following STZ in males than in females.  
Glucose tolerance was impaired in C+STZ females on d42 and β-cell mass was 
reduced by d130. This suggests that while β-cell replacement is possible, it is functionally 
incomplete, consistent with previous findings in rat (13). Based on sampling at d7 and 
14, recovery of β-cell mass by d30 was not due to significant increases in β-cell 
proliferation or β-cell hypertrophy, but may be the result of stem/precursor cell 
differentiation. A PDX-1+/insulinlow islet cell population was described (27) which were 
capable of maturing into insulin expressing cells. Our findings show that 4-8% of islet 
cells in C neonatal mice were PDX-1+/insulin—. Additionally, precursor cells within the 
ductal tissue may be stimulated to differentiate into new islets as evidenced by the 
increased number of small islet clusters associated with the ducts within the female 
C+STZ group. Previous studies have observed single insulin+ cells within the ducts or 
small clusters of cells budding from the ducts (23-25). These observations are more 
qualitative but recently, definitive evidence using lineage tracing of the ductal marker 
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carbonic anhydrase II (CA II) demonstrated that ductal cells gave rise to new islets during 
regeneration (28). 
As in females, β-cell mass was fully replaced by d30 but in males this was attributed 
to an increase in β-cell proliferation when sampled at d14. Male C+STZ mice remained 
hyperglycemic, which led to overt diabetes in 33% of mice. The gender difference in 
blood glucose levels following STZ treatment is consistent with previous findings (29), 
which suggest a protective effect of estrogen and an negative impact of testosterone on 
blood glucose. Moreover, previous studies in the STZ treated rat, where long term 
diabetes develops even with an initial regeneration of β-cells, males develop diabetes 
earlier than females (15; 30). However, here we report a novel finding that male and 
female mice appear to regenerate β-cell mass by different mechanisms.  
This is the first study to describe the effects of LP during gestation on the 
development of the endocrine pancreas in the mouse offspring. Protein restriction did 
not affect maternal weight gain or food intake, contrary to the findings in rats where 
maternal weight gain decreased, even with increased food intake (6; 9). Birth weight 
was decreased, as observed previously (6; 31; 32), however a relative overgrowth 
compared to C was reported in mice by 3 weeks (31) or 8 months (32), which was not 
observed here. β-cell mass was significantly increased in the female offspring on d14, 
unlike the findings in rat (6; 9; 11), indicating important species and gender differences. 
This could represent a compensatory response to meet the demands of increased 
nutrient availability, leading to β-cell hypertrophy, but no increase in pancreatic insulin 
content was found. On d14 the β-cell mass in female LP mice was approximately three-
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fold greater than in C. Hypertrophy of individual β-cells could account for this, whereas 
proliferation and apoptosis were unchanged. Male LP offspring did not show increased 
β-cell mass on d14, and had comparable values to control-fed animals on d30. These 
gender differences could be related to changes in endocrine hormones. Studies have 
shown in the LP-fed rat that maternal plasma levels of prolactin, leptin, estradiol and 
progesterone are all altered during gestation (33). These changes may differentially 
affect fetal trajectory of β-cell growth and glucose homeostasis later in life. 
A study in C57BL/6J mice found that male, but not female mice, showed glucose 
intolerance at 8 months of age following exposure to LP in early life (32). In contrast 
glucose tolerance at d130 was impaired predominantly in female LP mice in the present 
study, although the mouse strains and time course used differed. Our results agree with 
the corresponding rat model where LP-fed female rats became glucose intolerant at 130 
days of age (12). Research has also shown a strong link between poor human fetal 
development during times of famine and glucose intolerance later in life (34). Despite 
the compensatory β-cell response shown in LP mice early in life, the long term effects 
are consistent with rat and human studies.  
The effects of malnutrition during fetal development are transmitted to the F2 
generation (35; 36). This may occur as a direct result of a hyperglycemic intrauterine 
environment, or potentially through epigenetic mechanisms (37-39). Therefore 
understanding the mechanism of fetal programming of glucose homeostasis is critical to 
future generations as well. 
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We found that LP exposure affected pancreatic endocrine plasticity after STZ. 
LP+STZ mice failed to reach an equivalent β-cell mass to that of LP mice, unlike control-
fed animals, indicating a reduced capacity for β-cell regeneration. In female animals at 
d30 this was associated with a reduced number of islets relative to STZ treatment alone, 
but this was not seen in males. Consistent with our observations, other studies have 
shown that nutrient deficiency early in life effects tissue plasticity. LP diet during 
gestation significantly impaired recovery of male adult rats following ischemia-
reperfusion (40), while maternal calorie restriction during gestation and lactation 
impaired β-cell replacement after STZ (41). Changes in islet morphometry resulting from 
prior exposure to LP were not specific to β-cells, as the α-cell mass was also increased at 
days 14 and 30 in females. Thus the increased β-cell mass in LP-fed females at d14 is 
likely to represent a more general increase in islet mass. In the LP+STZ group, α-cell 
mass was significantly reduced versus LP alone by d30. This suggests that the inability of 
LP-fed animals to recover β-cell mass following STZ also resulted in a delayed ability to 
increase α-cell mass as would normally occur with age, implying that the mechanisms 
involved might be common to multiple endocrine cell types.  
PDX-1+/insulinlow cells secrete less insulin then PDX-1+/insulin+ cells and over time, 
this population has the ability to become PDX-1+/insulin+ without cell replication (27), 
perhaps functioning as a strategic reserve. In our model, the proportion of the PDX-
1+/insulin— islet cells was not altered by LP diet, but was increased following STZ. 
Previous studies identified a population of PDX-1+/MAFB+/insulin— cells that contributed 
to β-cell regeneration following STZ treatment (18). More recently, pancreas derived 
 
 
94 
 
multipotent precursor cells were identified in the mouse and found to express insulin, 
high levels of Ngn3, and Glut2 was expressed at near-absent levels (42). Further 
characterization of PDX-1+/insulin— precursor cells will be necessary in future 
experiments. Expansion and differentiation of β-cell precursors ex vivo would provide an 
excellent source of β-cells for replacement therapy. 
These findings may indicate that normal maturational pathways that allow such 
cells to differentiate into functional β-cells are impaired by LP exposure, resulting in a 
reduced β-cell mass. In addition to a risk for later diabetes, the loss of plasticity may 
compromise the female offspring during pregnancy, where a substantial expansion of 
maternal β-cell mass normally occurs.  
In conclusion, we describe a mouse model in which exposure to a LP diet during 
gestation has critical effects on the development of the endocrine pancreas and β-cell 
recovery after STZ. We have shown that mouse pancreatic development in a protein-
deficient environment was altered to produce morphological changes in islet mass in 
early life, and glucose intolerance in females later in life. Additionally, recovery from 
STZ-induced injury was impaired by prior LP exposure, whereas C-fed STZ treated 
offspring regenerated β-cell mass through replication or precursor differentiation. Our 
results therefore suggest that the prior dietary environment is a determinant of 
subsequent β-cell plasticity in a mouse model.  
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CHAPTER 3: 
The Mechanism Underlying the Development of Glucose Intolerance and the Failure of 
β-cell Regeneration in Fetal Protein Restricted Mice. 
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3.1. Introduction 
Maintenance of β-cell mass is important to provide adequate blood glucose 
regulation. In individuals with type 1 diabetes the β-cell mass is reduced by greater than 
90%, while in individuals with type 2 diabetes the β-cell mass is reduced with 
progression of disease (1; 2). Stimulation of endogenous regenerative mechanisms to 
restore β-cell mass is one strategy that is being actively pursued for β-cell replacement 
therapies in diabetes. Promising research in rodent models of β-cell injury has 
demonstrated the capacity for β-cell regeneration. For example, administration of the β-
cell specific toxin, streptozotocin (STZ), in single or multiple doses to neonatal rodents 
has been followed by rapid and significant regeneration (3-5). However, in adult animals, 
the response is less robust leading to diabetes later in life (6; 7). Collectively, there is 
evidence to support both β-cell replication and precursor cell differentiation in the 
mechanism of β-cell regeneration (8-11). However, it is imperative to determine which 
mechanism will be most beneficial as a therapeutic approach to diabetes.  
It is important to consider how environmental factors, such as diet, affect β-cell 
development and plasticity. Poor fetal growth and low birth weight are associated with 
increased risk of impaired glucose tolerance (12), type 2 diabetes (13) and the metabolic 
syndrome (14) in adult life. Previous work has examined the impact of maternal protein 
restriction (LP) during fetal life in mice on islet development and long term glucose 
homeostasis (Chapter 2). Specifically, offspring of LP fed mice were characterized by a 
decreased birth weight and in females, an altered islet mass and an impaired glucose 
tolerance in adulthood. Additionally, it was observed that neonatal offspring of LP dams 
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subsequently treated with multiple low doses of STZ were unable to regenerate their β-
cell mass to control levels by d30. In contrast, offspring of control (C) fed dams receiving 
STZ regenerated β-cell mass within 30 days. There was a significant increase in islet 
neogenesis in female C+STZ mice at d7, while the female LP+STZ mice had an increased 
presence of PDX-1+/insulin— precursor cells. A lack of differentiation of this PDX-
1+/insulin— population into mature β-cells may account for the failure of regeneration. 
In addition to identifying the source of new β-cells and the supportive cells 
contributing to β-cell regeneration, it is also essential to determine the signalling 
mechanism involved. Studies have identified various mitogenic and differentiation 
factors associated with β-cell regeneration such as insulin-like growth factor (IGF) -I (15), 
glucagon-like peptide-1 (GLP-1) (3), activin A and betacellulin (16) and gastrin and 
epidermal growth factor (17). The regenerating-islet derived (Reg) gene family members 
are upregulated during β-cell regeneration (18-22). Additionally, Reg genes stimulate β-
cell replication, likely through the upregulation of cell cycle genes such as cyclin D1 
(Ccnd1) and cyclin dependent kinase (Cdk) 4 (19; 23; 24). Furthermore, the Wnt pathway 
signals through dishevelled (DVL) and β-catenin (CTNNB1) to upregulate gene expression 
of Cdk4 and Ccnd1, leading to an increased proliferation of β-cells (25; 26).  
Our first objective is to look at the expression profiles of C and LP fed offspring 
following STZ to determine if these or other novel genes may be altered under LP 
conditions leading to a failure in β-cell regeneration. Identification of novel factors 
capable of stimulating β-cell expansion could provide new therapies for β-cell 
replacement. Furthermore, understanding how the intrauterine environment affects β-
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cell development could lead to intervention strategies to prevent glucose dysregulation 
and type 2 diabetes. Therefore our second objective was to identify signalling pathways 
and cellular functions that may be altered by LP exposure in utero based on altered gene 
expression profiles. 
3.2. Materials and Methods 
3.2.1. Animals 
Balb/c mice (Charles River Ltd, Montreal, QC, Canada) were housed in a temperature 
controlled room with 12 h light:dark cycle. Water and food (Bio-Serv, Frenchtown, NJ, 
USA) were given ad libitum. An isocaloric LP diet (8% protein) or control (C; 20% protein) 
diet was administered to pregnant mice during gestation as described previously 
(Chapter 2). On d 1 through 5, female offspring received injections of either 35 mg/kg 
body weight of STZ (Sigma Chemical, St.Louis, MO, USA) in sodium citrate buffer (0.1 
mol/L, pH 4.5) or equal volume of the vehicle (sham). Female offspring were divided into 
four groups: C = control diet, sham injected; C + STZ = control diet, STZ injected; LP = low 
protein diet, sham injected; LP + STZ = low protein diet, STZ injected. On day 7, 14 and 
30 female offspring were killed and the pancreas was removed and stored in RNAlater 
(Applied Biosystems Canada, Streetsville, ON, Canada) at -80°C.  
3.2.2. Islet Isolation 
Female offspring were killed on day 7 and islets were isolated by a modified protocol 
previously described (27). Briefly, the pancreas was removed and perfused in a petri dish 
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with 1 mL of Collagenase type V (1 mg/mL; Sigma) in Hank’s Buffered Salt Solution 
(HBSS; Invitrogen Canada Inc., Burlington, ON, Canada). Pancreata from 2-4 female mice 
for each litter were perfused and collected in 4-8 mL of HBSS + Collagenase type V and 
placed in a 37°C shaking water bath for 30 min. Digested tissue was passed through a 14 
gauge needle and washed in HBSS + 5% bovine serum (Invitrogen) by centrifugation. 
Islets were separated from acinar and duct cells using a Dextran (MP Biomedicals, Solon, 
OH, USA) gradient consisting of 27, 23 and 11% Dextran which was centrifuged for 25 
min at 1250 rpm. Islets were collected from the 23-11% boundary and washed in HBSS + 
5% serum. Islets were placed in a petri dish with HBSS + 5% serum and picked using an 
inverted microscope. Islets for RNA use were stored in RNAprotect (Qiagen, Mississauga, 
ON, Canada) at -80°C and islets for protein use were sonicated in lysis buffer and stored 
at -80°C.  
3.2.3. Microarray Experiments 
Total RNA was extracted and purified from whole pancreas of 30 day old female 
offspring using the Qiagen column method with the RNeasy Plus Mini kit (Qiagen). 
Separate RNA samples were extracted from 3 pancreata per group (C, C+STZ, LP, LP+STZ) 
with each sample hybridized to a separate GeneChip (n=3). All GeneChips were 
processed at the London Regional Genomics Centre (Robarts Research Institute, London, 
Ontario, Canada; http://www.lrgc.ca). RNA quality was assessed using the Agilent 2100 
Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA, USA) and the RNA 6000 Nano kit 
(Caliper Life Sciences, Mountain View, CA, USA) (Appendix 4). 
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Biotinylated complimentary RNA (cRNA) was prepared from 10 μg of total RNA as 
per the Affymetrix GeneChip Technical Analysis Manual (Affymetrix, Santa Clara, CA, 
USA). Double-stranded cDNA was synthesized using SuperScript II (Invitrogen) and 
oligo(dT)24 primers.  Biotin-labeled cRNA was prepared by cDNA in vitro transcription 
using the BioArray High-Yield RNA Transcript Labeling kit (Enzo Biochem, New York, NY, 
USA) incorporating biotinylated UTP and CTP. Ten μg of labeled cRNA was hybridized to 
Affymetrix Mouse 430 2.0 arrays for 16 h at 45°C as described in the Affymetrix 
Technical Analysis Manual (Affymetrix).  GeneChips were stained with Streptavidin-
Phycoerythrin, followed by an antibody solution and a second Streptavidin-
Phycoerythrin solution, with all liquid handling performed by a GeneChip Fluidics Station 
450 (Affymetrix).  GeneChips were scanned with the Affymetrix GeneChip Scanner 3000 
(Affymetrix). 
Probe level data from the .CEL files were analyzed using Partek Genomics Suite v6.5 
(Partek, St.Louis, MO, USA).  Probes were imported and summarized using RMA and 
ANOVA was used to determine fold changes and p-values.  Differentially expressed 
genes between the four groups were selected based on fold change (≥ 1.5) differences 
and a p-value cut-off of 0.05.  Gene Ontology (GO) enrichment was performed within 
Partek to determine enriched GO terms (molecular functions, biological processes or 
cellular components) within a specific list of genes.  A Fisher’s exact test was used to 
determine significantly enriched GO terms.  
3.2.4. Reverse Transcription and Real–Time PCR  
Total RNA was extracted from whole pancreas from 7, 14 and 30 day old female 
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offspring and from isolated islets of d7 mice with the RNeasy Plus Mini kit (Qiagen). RNA 
quality was assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies Inc.) and 
the RNA 6000 Nano kit (Caliper Life Sciences) (Appendix 4). RNA from whole pancreas 
was treated with DNase (Invitrogen) to remove contaminating DNA and 4 μg were 
reverse transcribed (RT) using Superscript III Reverse Transcriptase (Invitrogen) and 
random hexamers (Invitrogen). Eight μL of RNA from isolated islets was treated with 
DNase (Invitrogen) and then RT using the Superscript Vilo kit (Invitrogen). Primer sets 
directed against insulin I, insulin II, glucagon, Reg1, Reg3δ, Ctnnb1, Cdk4, Ccnd1 and the 
housekeeping genes 18s and cyclophilin A were designed using NCBI Primer Blast 
(http://www.ncbi.nlm.nih.gov/; National Center for Biotechnology Information, 
Bethesda, MD, USA) (Table 3.1). Primers were designed to have a melting temperature 
~60°C, a product size between 80 and 150 bases, 4-5 base mismatches with similar non-
target sequences, at least 1 near the 3’ end and spanning an exon-exon junction when 
possible. Cyclophilin A primer set was designed as previously described (28). 
The relative abundance of each RNA transcript was determined by quantitative real-
time RT-PCR (qPCR) using the Bio-Rad CFX384 real-time PCR machine (Bio-Rad, 
Mississauga, ON, Canada) with SYBR Green (Bio-Rad) for detection of PCR products. Over 
a wide range of known cDNA concentrations, all primer sets were demonstrated to have 
good linear correlation (slope = −3.32) and equal priming efficiency for an input cDNA 
dilution series compared with their cycle threshold (Ct) values (Appendix 5). The relative 
abundance of each target compared with the calibrator was determined by comparative 
Ct method using 2-ΔΔCt; ΔΔCt is the calibrated Ct value (primer − internal control).  
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Table 3.1. Real-time PCR primers utilized 
Target Primer (5’-3’) Reference no. 
Insulin I Forward: AGCCCCGGGGACCTTCAGAC NM_008386 
 
Reverse: GCGGGTCGAGGTGGGCCTTA  
Insulin II Forward: ACCATCAGCAAGCAGGAAGCCT NM_008387 
 
Reverse: GAAGAGCAGGGCCAGCAGGG  
Glucagon Forward: AGCTTGGGCCCAGGACACACT NM_008100 
 
Reverse: CCAGCTGCCTTGCACCAGCA  
Beta catenin Forward: ACGCACCGTCCTTCGTGCTG NM 007614 
 
Reverse: AGGCGAACGGCATTCTGGGC  
Cyclin D1 Forward: GCACCAGCCACACAGCGGTA NM_007631 
 
Reverse: GATGTGGGCAGGCTGCAGGG  
Cdk4 Forward: CCTCTCTAGCTCGCGGCCTGT NM_009870 
 
Reverse: TTCCTGCGGCGCCATACACC  
Reg1 Forward: TCCTGGGCAACTGGGTCTCCT NM_009042 
 
Reverse: GGGCATCACAGTTGTCATCCTTCCA  
Reg3δ Forward: TCCACGCATCAGCTGTCCCCA NM_013893 
 
Reverse: AGCCCAGGTCTGTGGTTCCAG  
Cyclophilin A Forward: ATGGTCAACCCCACCGTGT NM_008907 
 
Reverse: TTCTGCTGTCTTTGGAACTTTGTC  
18s Forward: ACGATGCCGACTGGCGATGC NR_003278 
 
Reverse: CCCACTCCTGGTGGTGCCCT  
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3.2.5. Western Blot Analysis 
At least 200 islets isolated from 7 day old female mice were sonicated in lysis buffer 
containing 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM phenylmethanesulfonylfuoride, 
0.1% Igepal (MP Biomedicals, Solo, OH, USA), 0.1% Aprotinin (Sigma), 14% mini 
complete 7x solution (Roche, Mississauga, ON, Canada) in deionized water. Protein 
quantification was performed using a micro BCA protein assay kit (Peirce Protein 
Researcher, Rockford, IL, USA) according to manufacturer’s instructions. A 
representative standard curve is shown in Appendix 3.3. Acetone precipitation was 
performed to concentrate the protein samples and was then dissolved in 50 μL of 1x 
sample buffer. Protein (≤5 µg) was resolved on a 12% SDS-PAGE gel and transferred to a 
nitrocellulose membrane using the iBlot Dry Blotting System (Invitrogen). Membranes 
were probed with a sheep anti-REG1 antibody (1:200; R&D Systems, Minneapolis, MN, 
USA) with a donkey anti-sheep secondary (1:1000; R&D Systems) and then stripped and 
probed with a rabbit anti-β-actin antibody (1:5000, Abcam, Cambridge, MA, USA) used 
as a loading control with a goat anti-rabbit secondary antibody (1:10,000; Santa Cruz 
Biotechnology, Santa Cruz, CA, USA). Antibody specificity is demonstrated in Appendix 6. 
Relative abundance of REG1 was determined by densitometry using GeneSnap v7.09 and 
GeneTools v 3.06 software (SynGene, Cambridge, England) and normalized to β-actin. 
3.2.6. Pancreatic Insulin, Glucagon and GLP-1 Content 
Whole pancreas tissue was collected at d7 from female offspring and snap frozen in 
liquid nitrogen and stored at -80°C. Tissue samples (~20 mg) were mechanically 
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homogenized in 200 µL of lysis buffer with 2% DPPIV inhibitor (Millipore, Etobicoke, ON, 
Canada). Insulin extraction was performed, adding 50 µL of tissue lysates to 150 µL acid 
ethanol (165 mM HCL in 75% ethanol). After overnight incubation at 4°C, samples were 
centrifuged (2000g) for 5 minutes at 4°C. Insulin was quantified in the supernatant with 
a sensitive rat insulin radioimmunoassay (RIA) (Millipore; 100% reactivity to mouse 
insulin) and normalized to pancreatic DNA content from the pellet. Assay sensitivity was 
0.2 ng/mL. Glucagon content was also measured from tissue lysates using the glucagon 
RIA kit (Millipore). Assay sensitivity for glucagon was 20 pg/mL. Pancreas tissue lysates 
(100-200 μL) were purified by Sep-Pak C18 (Waters, Milford, MA, USA) as previously 
described (29). Ten μL of each sample was dried down using a Savant and then 
reconstituted in hydrating buffer included with the RIA kit. Total GLP-1 content was 
measured using the GLP-1 (total) RIA kit (Millipore) according to the manufacturer’s 
instructions. Assay sensitivity for GLP-1 was 3 pM. A representative standard curve is 
shown in Appendix 3.3. 
3.2.7. Statistical Analysis 
The effects of diet and STZ treatment were analyzed using a two-way ANOVA with a 
Bonferroni post-test using GraphPad Prism v5 software (GraphPad Software, La Jolla, Ca, 
USA). Statistical analysis of microarray data was performed as detailed above (Methods 
3.2.1). All values are means ± SEM and significance level p < 0.05. 
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3.3. Results 
3.3.1. Microarray Experiments 
DNA microarray experiments were performed to identify pancreatic genes involved 
in β-cell regeneration following STZ treatment, and in the metabolic deficiencies seen in 
female LP offspring. Over 45,000 transcripts were examined on the Mouse 430 2.0 gene 
chip. Comparisons were made between groups (ie. C+STZ vs C; LP vs C; LP+STZ vs LP; 
LP+STZ vs C+STZ) to create gene lists containing all genes with a significant (p < 0.05) 
change in expression of ≥ 1.5 fold (Appendix 7). In the LP offspring 369 transcripts were 
significantly reduced (p < 0.05) by ≥ 1.5 fold compared to control-fed animals and 35 
transcripts were significantly increased (p < 0.05). The C+STZ group, which were capable 
of regeneration of β-cells by day 30 (Chapter 2), had a significantly decreased (p < 0.05) 
expression of 60 transcripts, while 18 transcripts were significantly increased (p < 0.05) 
by ≥ 1.5 fold compared to the sham injected controls. Only 9 transcripts were 
significantly decreased (p < 0.05) in the LP+STZ group compared to LP alone by ≥ 1.5 
fold. This suggests that STZ treatment does not have a large additive affect on gene 
expression in LP offspring. However, comparing LP+STZ to C+STZ mice, 411 transcripts 
were significantly decreased (p < 0.05) and 15 transcripts were significantly increased (p 
< 0.05). These represent candidate genes that might be linked to the failure of β-cell 
plasticity seen in LP-fed animals following STZ treatment. 
3.3.2. GO Enrichment – Islet Function 
Gene Ontology (GO) is a bioinformatics initiative to annotate genes based on their  
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biological process, molecular function or cellular component. A GO enrichment analysis 
can determine significantly shared GO terms within a set of genes (30). The algorithm 
attempts to determine whether an observed level of annotation for a group of genes is 
significant (p < 0.05) within the context of annotation for all genes within the genome 
(30). Using the gene lists created from the microarray data based on a ≥ 1.5 fold change 
and a p-value cut off of 0.05, GO enrichment analysis was performed as an indication of 
which biological processes, molecular functions or cellular components may be affected 
by prior LP exposure and regeneration following STZ. From this analysis specific genes 
with the significantly enriched GO term were identified within the data set. 
Our first observation was the significant enrichment (p < 0.05) of GO terms such as 
glucose transport, protein processing, protein maturation, secretory granule and 
hormone activity. Therefore genes encoding for the islet hormones, enzymes for 
hormone processing and glucose transporters were identified within the microarray 
data (Table 3.2). Both insulin genes and islet amyloid polypeptide were significantly 
decreased (p < 0.05) in expression in both the C+STZ and LP groups compared to control, 
with a further decrease (p < 0.05) in insulin expression in the LP+STZ group (Table 3.2). 
Glucagon and somatostatin were significantly decreased (p < 0.05) in the LP group 
compared to control (Table 3.2). Genes involved in glucose transport (Glut2), 
gluconeogenesis (G6pc2), and hormone processing (Pc2, Cpe, Scg2) were significantly 
decreased (p < 0.05) in the C+STZ and LP groups (Table 3.2). An additive effect of LP and 
STZ was not observed, except for insulin I and II genes, which corresponds with the 
reduced β-cell mass at this time (Chapter 2). 
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Table 3.2. Islet hormones, processing and secretion 
Probeset ID 
Gene 
Symbol Gene Name C+STZ LP LP+STZ 
1422447_at Ins1 insulin I -4.959* -2.434* -4.063# 
1422446_x_at Ins2 insulin II -3.285* -2.124* -3.570# 
1425952_a_at Gcg glucagon -1.764 -2.968* -2.092 
1417954_at Sst somatostatin -1.447 -1.812* -1.54 
1423510_at Iapp Islet amyloid polypeptide -5.323* -3.439* -4.385 
1449067_at Slc2a2/Glut2 glucose transporter 2 -1.912* -1.702* 1.894 
1448312_at Pcsk2/Pc2 proprotein convertase 2 -1.678* -1.648* -1.52 
1423529_at G6pc2 glucose-6-phosphatase, 
catalytic, 2 
-5.254* -3.687* -3.996 
1415949_at Cpe carboxypeptidase E -1.692* -1.756* -2.055 
1450708_at Scg2 secretogranin II -2.024* -1.795* -1.795 
1423150_at Scg5 secretogranin V -1.801 -1.704 -1.760 
1418149_at Chga chromogranin A -1.702* -1.445 -1.698 
Represents fold change in expression versus the C group for microarray analysis 
performed using total RNA samples from d30 pancreata of female offspring from C- and 
LP-fed dams, with or without subsequent STZ treatment. Data was analyzed using a two-
way ANOVA (n = 3). * p < 0.05 vs C+sham; # p < 0.05 vs LP+sham. 
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3.3.3. GO Enrichment – β-Cell Regeneration 
Regarding β-cell regeneration, GO enrichment analysis of the gene lists comparing 
C+STZ to C and LP+STZ to C+STZ revealed that GO terms including regulation of cell 
proliferation, G1/S transition checkpoint, tissue regeneration and cell differentiation 
were significantly enriched (p < 0.05). Genes encoding known regulators of the cell cycle, 
mitogenic factors and transcription factors were investigated in the microarray data 
(Table 3.3). Transcripts for cell cycle proteins that may be altered by LP and therefore 
affect cell proliferation were examined. Ccnd1 expression was significantly reduced (p < 
0.05) in the LP group compared to control, while other genes (Cdk4, Pcna, Ki67) were 
not significantly altered (Table 3.3). The proto-oncogene c-Myc was found to be 
significantly increased (p < 0.05) in the C+STZ group versus control and also when 
compared to the LP+STZ group (Table 3.3). Members of the Wnt signalling pathway 
(Ctnnb1, Dvl1) were examined since the pathway was recently shown to stimulate Ccnd1 
and c-Myc expression associated with β-cell proliferation (31). However, no significant 
expression changes in Ctnnb1 or Dvl1 mRNAs were observed. The regenerating islet-
derived gene, Reg1, was significantly decreased (p < 0.05) with prior LP exposure, while 
Reg3δ was unchanged (Table 3.3). Tmem27, which encodes for a protein that stimulates 
β-cell proliferation (32), and was found to be significantly decreased (p < 0.05) in both 
C+STZ and LP groups compared to control (Table 3.3). Igf-I was significantly 
downregulated (p < 0.05) in the LP and LP+STZ groups compared to the control and STZ 
groups, respectively (Table 3.3). However, the expression of insulin receptor substrate 2 
(Irs2), the downstream signalling target in the IGF-I and insulin signalling pathways, was   
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Table 3.3. Cell cycle genes, mitogenic and transcription factors 
Probeset ID 
Gene 
Symbol Gene Name C+STZ LP LP+STZ 
1448698_at Ccnd1 cyclin D1 -1.080  -1.099* -1.12 
1422441_x_at Cdk4 cyclin-dependent kinase 4 -1.100 -1.060 -1.180 
1417947_at PCNA proliferating cell nuclear antigen -1.236 -1.287 -1.610 
1426817_at Mki67 
antigen identified by monoclonal 
antibody Ki 67 -1.679 -1.236 -1.624 
1424942_a_at c-Myc myelocytomatosis oncogene    1.594*  1.175  -1.033† 
1420811_a_at Ctnnb1 β-catenin -1.231 -1.438 -1.564 
1450978_at Dvl1 Dishevelled, dsh homolog 1 -1.043 -1.087 -1.097 
1415905_at Reg1 regenerating islet-derived 1 -1.159  -1.441* -1.559 
1448290_at Reg3β regenerating islet-derived 3 beta  1.121 -1.551 -1.36 
1424009_at Reg3δ regenerating islet-derived 3 delta -1.080 -1.299 -1.524 
1435064_a_at Tmem27 transmembrane protein 27  -1.997*  -2.495* -2.078 
1452014_a_at Igf-1 insulin-like growth factor 1 -1.010  -1.253*  -1.511† 
1443969_at Irs2 insulin receptor substrate 2  1.111   1.181*  1.149 
1422174_at Pdx1 
pancreatic and duodenal 
homeobox 1  -1.237*  -1.183* -1.212 
1421112_at Nkx2.2 
NK2 transcription factor related, 
locus 2 -1.072  1.031  -1.076# 
1419424_at Ptf1a Ptf1a -1.184 -1.677 -1.813 
1416072_at Cd34 CD34 -1.413 -1.606* -1.547 
Represents fold change in expression versus the control group for microarray analysis 
performed using total RNA samples from d30 pancreata of female offspring from C- and 
LP-fed dams, with or without subsequent STZ treatment. Data was analyzed using a two-
way ANOVA (n = 3). * p < 0.05 vs C+sham; † p < 0.05 vs C+STZ; # p < 0.05 vs LP+sham. 
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significantly increased (p < 0.05) in LP offspring (Table 3.3). Important β-cell transcription 
factors were also significantly altered (p < 0.05); Pdx-1 was decreased in C+STZ and LP 
groups, while Nkx2.2 was decreased in the LP+STZ group compared to LP alone (Table 
3.3). Also of note was a significant decrease (p < 0.05) in the expression of the 
hematopoietic and endothelial progenitor cell marker, Cd34 in LP offspring (Table 3.3). 
3.3.4. GO Enrichment – Translation and Cellular Respiration 
The GO enrichment data was also analyzed to identify cellular systems affected by  
LP exposure that may predispose for the development of altered islet metabolism and 
protein synthesis. The gene list comparing the C and LP groups consisted of many GO 
terms relating to protein biosynthesis, such as ribosome binding and translation 
initiation (Table 3.4). These GO terms were significantly enriched as indicated by the 
respective p-value. Furthermore, GO terms relating to cellular respiration, such as the 
electron transport chain (ETC) and ATP synthesis coupled proton transport, were 
significantly enriched in the gene list comparing the C and LP groups (Table 3.5). This 
suggests that LP offspring have significant alterations to transcripts that may have an 
important impact on translation and cellular respiration. The gene list comparing fold 
change between C+STZ and LP+STZ was also significantly enriched for GO terms relating 
to translation and cellular respiration (Table 3.4 and 3.5). A greater percentage of genes 
from the C+STZ versus LP+STZ gene list were present within each GO term compared to 
the C versus LP list (Table 3.4 and 3.5). 
The mitochondria are the site of cellular respiration and the ETC, so transcripts 
encoding ETC enzymes were identified as an indication of potential mitochondrial  
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Table 3.4. Enrichment of GO terms relating to protein biosynthesis 
    LP vs Control gene list LP+STZ vs C+STZ gene list 
Function Type p-value 
% genes 
in group 
# genes 
in group p-value 
% genes 
in group 
# genes 
in group 
translation biological process 1.00E+00 24.08 59 1.92E-260 32.38 79 
ribosomal subunit cellular component 1.10E-12 47.62 10 3.38E-62 52.38 11 
rRNA binding molecular function 1.14E-06 30.00 6 4.12E-46 47.37 9 
translational elongation biological process 6.69E-04 30.00 3 7.54E-28 50.00 5 
translation factor activity, 
nucleic acid binding 
molecular 
function 1.94E-03 7.29 7 1.27E-07 9.47 9 
eukaryotic translation 
elongation factor 1 complex 
cellular 
component 1.97E-03 50.00 2 4.62E-12 50.00 2 
translation regulator activity molecular function 3.05E-03 6.73 7 6.94E-07 8.74 9 
translational initiation biological process 1.29E-02 11.11 3 2.26E-10 19.23 5 
ribosome binding molecular function 1.97E-02 16.67 2 9.13E-09 25.00 3 
translation elongation factor 
activity 
molecular 
function 2.05E-02 9.38 3 0.002531 9.38 3 
translation initiation factor 
activity 
molecular 
function 2.43E-02 6.67 4 5.52E-06 10.17 6 
Using the microarray data, gene lists were created for significantly altered (p<0.05) 
genes in the LP group compared to the C group with ≥ 1.5 fold change and also for the 
comparison LP+STZ versus C+STZ. These gene lists were analyzed for GO terms that were 
significantly enriched based on a Fisher’s exact test with p < 0.05. The percentage and 
number of genes from the gene list out of the total genes for that GO term are listed. 
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Table 3.5. Enrichment of GO terms relating to cellular respiration 
    LP vs Control gene list LP+STZ vs C+STZ gene list 
Function Type p-value 
% genes 
in group 
# genes 
in group p-value 
% genes 
in group 
# genes 
in group 
cytochrome-c oxidase 
activity 
molecular 
function 2.50E-07 37.50 6 2.24E-33 43.75 7 
proton-transporting ATP 
synthase complex, coupling 
factor F(o) 
cellular 
component 4.72E-07 50.00 5 2.10E-89 90.00 9 
electron transport chain biological process 1.46E-06 11.46 11 3.76E-61 25.53 24 
proton transport biological process 2.34E-04 12.50 6 4.75E-42 29.17 14 
ATP synthesis coupled 
proton transport 
biological 
process 3.14E-04 15.15 5 3.76E-54 39.39 13 
NADH dehydrogenase 
(ubiquinone) activity 
molecular 
function 3.44E-03 17.65 3 3.62E-16 29.41 5 
NADH dehydrogenase 
(quinone) activity 
molecular 
function 3.44E-03 17.65 3 3.62E-16 29.41 5 
ATP biosynthetic process biological process 2.00E-01 4.44 2 4.98E-11 15.56 7 
mitochondrial part cellular component 1.00E+00 7.08 24 3.71E-47 12.76 43 
oxidation reduction biological process 1.00E+00 2.85 17 1.26E-10 5.56 33 
Using the microarray data, gene lists were created for significantly altered genes in the 
LP group compared to the C group with ≥ 1.5 fold change and also for the LP+STZ versus 
the C+STZ groups. These gene lists were analyzed for GO terms that were significantly 
enriched based on a Fisher’s exact test with p < 0.05. The percentage and number of 
genes from the gene list out of the total genes for that GO term are listed. 
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dysfunction (Table 3.6). Most notably, 23 transcripts related to Complex I of the ETC 
were significantly altered (p < 0.05), the majority of which were downregulated in the LP 
and/or LP+STZ groups (Table 3.6). ATP synthase (Complex V) is the final step in the ETC 
leading to the production of ATP. Twelve transcripts encoding for ATP synthase subunits 
were also significantly downregulated in the LP and/or LP+STZ groups (Table 3.6). Similar 
observations were also found for transcripts encoding subunits of Complex II, III and IV 
(Table 3.6). Decreased expression of ETC enzyme encoding transcripts may result in 
mitochondrial dysfunction in LP offspring. 
3.3.5. Antioxidant Expression 
The mitochondrial respiratory chain is a major site of reactive oxygen species (ROS) 
production which can be detrimental to cell function and survival (33; 34). Since the LP 
diet had a significant effect on the expression of genes relating to cellular respiration, 
genes responsible for ROS scavenging were identified in the microarray (Table 3.7). 
Expression of transcripts encoding for the antioxidants glutathione peroxidase (Gpx1, 
Gpx3, Gpx4), peroxiredoxin (Prdx1, Prdx2, Prdx4) and glutathione S-transferase (Gstp1, 
Mgst1) were significantly decreased (p < 0.05) in the LP group compared to control 
(Table 3.7). Similarly, in the LP+STZ group there was a significant decrease (p < 0.05) in 
expression of transcripts for antioxidants (Gpx1, Gpx4, Prdx4, Prdx5, Gstk1, Gstm6, 
Gstt1) compared to the C+STZ group, while expression of the glutathione S-transferase 
members (Gstk1, Gstm6, Gstt1) were further downregulated (p < 0.05) compared to the 
LP group (Table 3.7). Interestingly, the expression of the enzyme involved in glutathione 
synthesis, glutathione synthetase (Gss), was significantly upregulated (p < 0.05) in the LP  
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Table 3.6 Mitochondrial electron transport chain components 
Probeset ID 
Gene 
Symbol Gene Name C+STZ LP LP+STZ 
Complex I 
1422241_a_at Ndufa1 NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, 1 
-1.158 -1.568* -1.94† 
1417368_s_at Ndufa2 NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, 2 
-1.069 -1.459* -1.62† 
1452790_x_at Ndufa3 NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, 3 
1.004 -1.340* -1.64† 
1417286_at Ndufa5 NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, 5 
-1.024 -1.266* -1.41† 
1448427_at Ndufa6 NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, 6 (B14) 
1.544* 1.096 -1.17† 
1428360_x_at Ndufa7 NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, 7 (B14.5a) 
1.125 -1.123 -1.39† 
1423692_at Ndufa8 NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, 8 
-1.137 -1.266* -1.36 
1418068_at Ndufa10 NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex 10 
1.131* 1.152* 1.15 
1429708_at Ndufa11 NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex 11 
1.103 -1.220 -1.47† 
1430713_s_at Ndufa13 NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, 13 
-1.116 -1.509* -1.83† 
1448483_a_at Ndufb2 NADH dehydrogenase (ubiquinone) 1 beta 
subcomplex, 2 
1.009 -1.383* -1.80† 
1416547_at Ndufb3 NADH dehydrogenase (ubiquinone) 1 beta 
subcomplex 3 
-1.091 -1.276* -1.51†# 
1434056_a_at Ndufb6 NADH dehydrogenase (ubiquinone) 1 beta 
subcomplex, 6 
-1.224 -1.753* -1.95† 
1416417_a_at Ndufb7 NADH dehydrogenase (ubiquinone) 1 beta 
subcomplex, 7 
-1.006 -1.314* -1.49† 
1448198_a_at Ndufb8 NADH dehydrogenase (ubiquinone) 1 beta 
subcomplex 8 
-1.215 -1.540* -1.78† 
1452184_at Ndufb9 NADH dehydrogenase (ubiquinone) 1 beta 
subcomplex, 9 
-1.190 -1.639* -1.86† 
1416056_a_at Ndufb11 NADH dehydrogenase (ubiquinone) 1 beta 
subcomplex, 11 
-1.098 -1.611* -1.850† 
1448284_a_at Ndufc1 NADH dehydrogenase (ubiquinone) 1, 
subcomplex unknown, 1 
1.554 1.110 -1.19† 
1423737_at Ndufs3 NADH dehydrogenase (ubiquinone) Fe-S 
protein 3 
1.101 -1.138 -1.33† 
1433603_at Ndufs6 NADH dehydrogenase (ubiquinone) Fe-S 
protein 6 
-1.060 -1.354* -1.575† 
1424313_a_at Ndufs7 NADH dehydrogenase (ubiquinone) Fe-S 
protein 7 
1.044 -1.258 -1.434† 
1428179_at Ndufv2 NADH dehydrogenase (ubiquinone) 
flavoprotein 2 
1.095 -1.225 -1.52† 
1424628_a_at Ndufv3 NADH dehydrogenase (ubiquinone) 
flavoprotein 3 
-1.156 -1.499* -1.83† 
Complex II 
1418005_at Sdhb succinate dehydrogenase complex, subunit B, 
iron sulfur (Ip) 
-1.079 -1.292 -1.52† 
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Complex III 
1453229_s_at Uqcrh ubiquinol-cytochrome c reductase hinge protein 1.101 -1.322* -1.582† 
1448292_at Uqcr ubiquinol-cytochrome c reductase (6.4kD) 
subunit 
1.259 -1.157 -1.43† 
Complex IV 
1448322_a_at Cox4i1 cytochrome c oxidase subunit IV isoform 1 -1.088 -1.538* -1.758† 
1415933_a_at Cox5a cytochrome c oxidase, subunit Va -1.164 -1.636* -1.73† 
1416902_a_at Cox5b cytochrome c oxidase, subunit Vb -1.042 -1.396* -1.612† 
1417417_a_at Cox6a1 cytochrome c oxidase, subunit VIa, polypeptide 
1 
-1.214 -1.697* -1.83 
1416565_at Cox6b1 cytochrome c oxidase, subunit VIb polypeptide 1 -1.082 -1.432* -1.69† 
1434491_a_at Cox6c cytochrome c oxidase, subunit VIc -1.217 -1.586* -2.06†# 
1416970_a_at Cox7a2 cytochrome c oxidase, subunit VIIa 2 -1.076 -1.573* -1.98† 
1429188_at Cox11 COX11 homolog, cytochrome c oxidase 
assembly protein (yeast) 
-1.137 -1.360* -1.497 
Complex V 
1416058_s_at Atp5c1 ATP synthase, H+ transporting, mitochondrial F1 
complex, gamma polypeptide 1 
-1.087 -1.336 -1.56† 
1423716_s_at Atp5d ATP synthase, H+ transporting, mitochondrial F1 
complex, delta subunit 
1.374* 1.020 -1.137† 
1416567_s_at Atp5e ATP synthase, H+ transporting, mitochondrial F1 
complex, epsilon subunit 
-1.037 -1.467* -1.791† 
1415980_at Atp5g2 ATP synthase, H+ transporting, mitochondrial F0 
complex, subunit c2 (subunit 9)  
1.160 -1.110 -1.34† 
1454661_at Atp5g3 ATP synthase, H+ transporting, mitochondrial F0 
complex, subunit c3 (subunit 9) 
-1.004 -1.459* -1.57† 
1423676_at Atp5h ATP synthase, H+ transporting, mitochondrial F0 
complex, subunit d 
-1.163 -1.536* -1.77† 
1416143_at Atp5j ATP synthase, H+ transporting, mitochondrial F0 
complex, subunit f 
-1.055 -1.503* -1.87† 
1416269_at Atp5j2 ATP synthase, H+ transporting, mitochondrial F0 
complex, subunit f, isoform 2 
1.122 -1.310 -1.675† 
1450640_x_at Atp5k ATP synthase, H+ transporting, mitochondrial 
F1F0 complex, subunit e 
-1.112 -1.487* -1.89† 
 
1448203_at 
 
Atp5l 
ATP synthase, H+ transporting, mitochondrial F0 
complex, subunit g 
 
1.115 
 
-1.257 
 
-1.60† 
1417970_at Atp5s ATP synthase, H+ transporting, mitochondrial F0 
complex, subunit s 
-1.120 -1.249* -1.244 
1416278_a_at Atp5o ATP synthase, H+ transporting, mitochondrial F1 
complex, O subunit 
1.107 -1.283 -1.52† 
Represents fold change in expression versus the control group for microarray analysis 
performed using total RNA samples from d30 pancreata of female offspring from C- and 
LP-fed dams, with or without subsequent STZ treatment. Data was analyzed using a two-
way ANOVA (n = 3). * p < 0.05 vs C+sham; † p < 0.05 vs C+STZ; # p < 0.05 vs LP+sham. 
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Table 3.7. Genes encoding antioxidants and related proteins 
Probeset ID 
Gene 
Symbol Gene Name C+STZ LP LP+STZ 
1460671_at Gpx1 glutathione peroxidase 1 1.048 -1.365* -1.594† 
1449106_at Gpx3 glutathione peroxidase 3 -1.191 -1.359* -1.34 
1451695_a_at Gpx4 glutathione peroxidase 4 -1.160 -1.468* -1.72† 
1441931_x_at Gss glutathione synthetase 1.145 1.750* 1.864† 
1451124_at Sod1 superoxide dismutase 1, soluble 1.028 -1.258* -1.446† 
1417634_at Sod3 superoxide dismutase 3, 
extracellular 
1.249* 1.219* 1.174 
1416000_a_at Prdx1 peroxiredoxin 1 -1.110 -1.541* -1.526 
1418506_a_at Prdx2 peroxiredoxin 2 -1.150 -1.322* -1.43 
1416167_at Prdx4 peroxiredoxin 4 -1.281 -1.696* -2.022† 
1416381_a_at Prdx5 peroxiredoxin 5 1.050 -1.102 -1.301† 
1452823_at Gstk1 glutathione S-transferase kappa 1 1.024 -1.052 -1.280†
# 
1422072_a_at Gstm6 glutathione S-transferase, mu 6 1.014 -1.043 -1.133†
# 
1449575_a_at Gstp1 glutathione S-transferase, pi 1 -1.189 -1.550* -1.682 
1418186_at Gstt1 glutathione S-transferase, theta 1 -1.092 -1.123 -1.35†
# 
1415897_a_at Mgst1 microsomal glutathione S-
transferase 1 
-1.348 -1.559* -1.91 
Represents fold change in expression versus the control group for microarray analysis 
performed using total RNA samples from d30 pancreata of female offspring from C- and 
LP-fed dams, with or without subsequent STZ treatment. Data was analyzed using a two-
way ANOVA (n = 3). * p < 0.05 vs C+sham; † p < 0.05 vs C+STZ; # p < 0.05 vs LP+sham. 
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and LP+STZ groups compared to the C and C+STZ groups, respectively (Table. 3.7). 
Transcripts encoding for superoxide dismutase (SOD), which converts superoxide into 
hydrogen peroxide and water, were differentially expressed; Sod1 was significantly 
downregulated (p < 0.05) in the LP and LP+STZ groups while Sod3 was significantly 
upregulated (p < 0.05) in the C+STZ and LP groups (Table 3.7).  
3.3.6. Real-Time PCR from Whole Pancreas 
Microarray experiments were used to identify candidate genes but this was 
followed up with quantitative real-time RT-PCR (qPCR) on d30 pancreatic RNA samples 
for more precise measurements of gene expression changes. Day 7 and 14 samples were 
also analyzed to look at a time course of changes in expression during β-cell 
regeneration. Eight candidate genes were identified for validation. Insulin I, insulin II, 
and glucagon were selected on the basis that altered islet mass may impact their gene 
expression. Ccnd1 and Cdk4 were also selected as prime regulators of the cell cycle. 
Potential regulators of these cell cycle genes, Ctnnb1, Reg1 and Reg3δ, were also 
selected as candidates. Gene expression for insulin I and II was significantly increased (p 
< 0.05) in C+STZ and LP offspring compared to control at d7, while in LP+STZ mice, 
insulin II was significantly greater (p < 0.05) than C+STZ mice (Figure 3.1a,b). By d14, 
insulin I gene expression was unaltered between groups, however, insulin II expression 
was significantly reduced (p < 0.05) by STZ and LP treatment (Figure 3.1a,b). At d30 both 
insulin genes were significantly upregulated (p < 0.05) in the LP offspring compared to 
controls, while the LP+STZ group had a significant reduction (p < 0.01) compared to the 
untreated LP offspring (Figure 3.1a,b). Glucagon gene expression was significantly   
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Figure 3.1. Gene expression changes in whole pancreas following LP diet or STZ 
treatment. 
Fold change in gene expression compared to d7 C determined by qPCR for the C (white 
bars), C+STZ (grey bars), LP (black bars) and LP+STZ (hatched bars) groups at d7, 14 and 
30 were calculated using the ΔΔCt method with cyclophilin A used as a reference gene. 
(a) insulin I, (b) insulin II, (c) glucagon, (d) Ctnnb1, (e) Ccnd1, (f) Cdk4, (g) Reg1, (h) 
Reg3delta (δ). Fold change ± SEM; n = 6/group. Data was analyzed using a 2-way ANOVA 
with Bonferroni’s post-test within each time point. * p < 0.05 vs sham; ** p < 0.01 vs 
sham; *** p < 0.001 vs sham; # p < 0.05 vs C+sham; ## p < 0.01 vs C+sham, † p < 0.001 
vs C+sham; ‡ p < 0.05 vs C+STZ; § p < 0.05 effect of STZ; a p < 0.05 effect of LP; b p < 0.01 
effect of LP; c p < 0.001 effect of LP.  
  
 
 
125 
 
increased (p < 0.01) at d7 in the LP offspring versus the control but no other changes 
were observed during the time of study (Figure 3.1c). The expression of Ctnnb1, Ccnd1, 
and Cdk4 were all similar at d7, with a significant reduction (p < 0.05) observed for the 
C+STZ and LP groups versus control (Figure 3.1d-f). Prior LP exposure had a significant 
effect (p < 0.05) increasing expression of Ctnnb1 and Cdk4 at d30, with a similar 
significant (p < 0.05) observation for ccnd1 at d14 (Figure 3.1d-f). The regenerating islet 
derived gene family members Reg1 and Reg3δ were also measured. Initially Reg1 was 
significantly upregulated (p < 0.05) with STZ treatment at d7, while LP exposure had an 
effect of significantly lowering (p < 0.05) expression at d14 (Figure 3.1g). For Reg3δ no 
changes were observed until d30 at which time prior LP exposure resulted in a 
significant increase (p < 0.001) in expression (Figure 3.1h). 
3.3.7. Real-Time PCR from Isolated Islets 
Aside from the islet hormones, the candidates may be widely expressed throughout 
the pancreas, therefore we examined islet specific expression. Reg1 is upregulated in 
regenerating islets (18) and in the current study Reg1 expression was increased in whole 
pancreas at d7 in STZ treated offspring. Therefore, to determine which candidate genes 
may be expressed early on as a driving force for β-cell regeneration, d7 was selected for 
analysis of the islet specific changes in expression. Insulin I gene expression was not 
significantly altered between groups, however, exposure to the LP diet significantly 
reduced (p < 0.01) expression of insulin II (Figure 3.2a,b). Glucagon gene expression was 
significantly increased (p < 0.01) in STZ treated groups, regardless of diet (Figure 3.2c). 
Similar to our observations in the whole pancreas, Reg1 gene expression  
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Figure 3.2. Gene expression changes in isolated islets at d7. 
Fold change in gene expression compared to the C group by qPCR in islets isolated at d7 
from female offspring of C and LP fed mice with or without subsequent STZ 
administration. Expression values were calculated using the ΔΔCt method with 18s used 
as a reference gene. (a) insulin I, (b) insulin II, (c) glucagon and (d) Reg1. White bars = 
sham, black bars = STZ. Means ± SEM; n = 3-5/group. Data were analyzed using a two-
way ANOVA with Bonferroni’s post test. b p < 0.01 effect of LP; * p < 0.05 effect of STZ; 
** p < 0.01 effect of STZ. 
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was significantly increased (p < 0.01) with STZ treatment and specifically a 5 fold 
increase in LP+STZ islets when compared to the LP sham group (Figure 3.2d). The 
expression of the other candidate genes, Ctnnb1, Ccnd1, Cdk4 and Reg3δ, were 
expressed at low or undetectable levels within the islets (data not shown). These genes 
are common to many cell types and therefore the changes observed from whole 
pancreatic RNA samples likely represent extra-islet changes in expression.  
3.3.8. Western Blot Analysis 
Protein lysates were collected from isolated islets at d7 and analyzed to correlate 
the observed changes in REG1 gene expression with protein expression. Western blot 
analysis demonstrated a reduced presence of REG1 protein expression following STZ in 
LP offspring, which significantly differed from the C+STZ (p < 0.01) and LP sham (p < 
0.05) groups (Figure 3.3). 
3.3.9. Pancreatic Insulin, Glucagon and GLP-1 Content 
Analysis by qPCR on isolated islets at d7 indicated significantly decreased expression 
of the insulin II gene in LP offspring, while glucagon expression was significantly 
increased with STZ treatment. To determine any corresponding changes in protein 
expression, pancreatic insulin and glucagon content were determined by RIA. Pancreatic 
insulin content was significantly reduced (p < 0.05) with STZ treatment, which is 
consistent with a loss of β-cell mass at this time (Figure 3.4a). Despite an upregulation of 
the proglucagon gene, no significant differences in glucagon protein content were 
observed (Figure 3.4b). This may suggest an increase in other products of the  
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Figure 3.3. Western blot analysis of Reg1. 
REG1 protein expression levels were determined by western blot analysis (a) from 
lysates of d7 isolated islets from female mice receiving C or LP diet, with or without 
subsequent administration of STZ. The top panel shows REG1 protein levels at 14 kDa 
and the lower panel shows β-actin at 42 kDa. (b) Densitometry was performed for 
quantification of REG1 and normalized to β-actin levels. White bars = sham; black bars = 
STZ. Means ± SEM; n = 3-6. Data were analyzed using a two-way ANOVA with 
Bonferroni’s post test. * p < 0.05 vs LP+sham; ** p < 0.01 vs LP+STZ. 
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 Figure 3.4. Pancreatic insulin, glucagon and GLP-1 content. 
Pancreatic (a) insulin, (b) glucagon and (c) total GLP-1 content were measured by 
radioimmunoassay on d7 from whole pancreas tissue from female mice receiving C or LP 
diet, with or without subsequent administration of STZ. White bars = sham; black bars = 
STZ. Means ± SEM; n = 3-6. Data was analyzed using a two-way ANOVA with Bonferroni’s 
post test. a p < 0.05 effect of STZ; b p < 0.01 effect of STZ. 
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proglucagon gene such as GLP-1. Measurements of pancreatic GLP-1 content indicated a 
significant increase (p < 0.05) in animals subsequent to STZ treatment (Figure 3.4c). A 
change in the post-translational processing of proglucagon was also supported by a 
significantly altered ratio of GLP-1 to glucagon pancreatic content (Figure 3.4d). 
3.4. Discussion 
Offspring exposed to protein restriction during fetal life have been associated with 
low birth weight and long term impairments in glucose tolerance and type 2 diabetes (5; 
12; 13; 35). Previously, we have shown that female LP mouse offspring have reduced 
body weights at d1, altered islet cell mass at d14 and develop glucose intolerance at 
d130 (Chapter 2). Here we used global expression arrays at d30 to identify genes that 
may be altered in the pancreas by LP exposure leading to impaired glucose metabolism 
in adulthood. Prior LP exposure significantly decreased all islet hormones, as well as the 
key transcription factor Pdx-1. Additionally, genes involved in glucose transport, insulin 
processing and secretion (Glut2, Pc2, Cpe, Scg2, Chga) were downregulated in LP 
offspring. However, the β-cell mass in the LP offspring was similar to the control group 
at d30 (Chapter 2). It is possible that altered expression of islet hormones and β-cell 
functional genes begins as early as d30, contributing to the later development of glucose 
intolerance. 
The gene lists comparing LP and C fed offspring demonstrated many significantly 
enriched GO terms relating to protein biosynthesis. Loss of expression of genes encoding 
translational machinery could limit protein biosynthesis and greatly influence cell 
function. The acute demand for insulin secretion during post-prandial states, or in the 
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case of hyperinsulinemia, in the presence of insulin resistance, can lead to an imbalance 
in protein homeostasis and ER stress (36). However, no changes in expression of genes 
relating to ER stress or the unfolded protein response were observed in the microarray. 
Furthermore previous observations in LP mice showed no changes in fasting blood 
glucose levels, serum insulin concentration or apoptosis (Chapter 2), therefore it is 
unclear how these changes impact protein production and cell function.  
The LP diet also significantly affected cellular respiration based on GO enrichment 
analysis. Cellular respiration is important for converting nutrient substrates into energy 
in the form of ATP, but more importantly in the β-cell, ATP generation increases the 
ratio of ATP/ADP initiating a cascade of events leading to insulin secretion. β-cells have 
an aerobic metabolism at least threefold higher than in most other cell types and may 
therefore be more susceptible to nutritional environment (37). Previous microarray 
studies from d21.5 fetuses of LP fed rat dams revealed observations that the cellular 
respiration pathway was one of the most affected by LP exposure in utero. At this time 
they found genes associated with cellular respiration were upregulated. However, at 3 
months of age they found that expression of respiratory genes encoding for malate 
dehydrogenase, citrate synthase, ATP6 and ND4L were downregulated in LP offspring 
(38). This is consistent with the current observations in LP mice, where cellular 
respiratory gene expression was largely downregulated at d30. Programming of the fetal 
mitochondria has been suggested as a key adaptation for survival in a suboptimal 
intrauterine environment (39-42). However, introduction into an optimal environment 
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postnatally may ultimately lead to mitochondrial dysfunction underlying the 
development of glucose intolerance in adult life. 
β-cell gene expression of antioxidants is relatively low and therefore the β-cell is 
vulnerable to ROS (43; 44). Mitochondrial function is particularly susceptible to oxidative 
damage, leading to decreased mitochondrial ATP synthesis, cellular calcium 
dyshomeostasis and induction of mitochondrial permeability transition (45). Specifically 
in mouse islets increased ROS production and mitochondrial damage resulted in 
decreased glucose stimulated ATP synthesis and deficiencies in insulin secretion (46). 
Moreover, mitochondrial dysfunction and ROS production have been shown to play a 
role in the development and progression of type 2 diabetes (33; 34; 47). In female LP 
offspring reduced expression of many antioxidants was observed in the whole pancreas, 
increasing susceptibility to ROS. If these changes are pertinent to the β-cell, along with 
the loss of expression of important ETC genes (potential for mitochondrial dysfunction), 
may contribute to the development of glucose intolerance at d130 in LP mouse 
offspring. While increased rates of apoptosis were not previously observed in LP mice 
(Chapter 2), the primary effect of these changes may be a reduced ATP production 
leading to decreased insulin secretion in adult life. Further experimentation is required 
to determine if gene expression changes related to the microarray analysis relate 
specifically to the β-cell and how the changes may produce defects in β-cell function. 
While application of the microarray findings to β-cells is intriguing, the effects of LP 
on gene expression must account for the whole pancreas. Acinar and duct cells are 
important for the production and dispersion of digestive enzymes and the bicarbonate 
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ion. The microarray data suggests a decreased expression of genes relating to protein 
synthesis, mitochondrial function and ROS scavenging. Reduced function of these 
processes may contribute to cell stress, decreased metabolism, and reduced enzyme 
production and secretion. Together this may impact digestion and therefore absorption 
of fats and proteins, which may cause downstream metabolic changes. 
Additionally, LP programming of the pancreas during fetal life reduces β-cell 
plasticity. Previously we demonstrated that LP offspring treated with multiple low doses 
of STZ were unable to regenerate and restore β-cell mass to the level of sham injected 
mice (Chapter 2). The microarray analysis also examined genes that may be altered by LP 
exposure resulting in an inability to regenerate β-cell mass. The insulin genes, as well as 
genes involved in glucose transport, insulin processing and secretion (Glut2, Pc2, Cpe, 
Scg2, Chga) were downregulated in C+STZ groups. In the C+STZ group β-cell 
regeneration was complete by d30 (Chapter 2), therefore decreased expression of these 
genes suggests either transcript levels were not restored to control values at this time or 
these changes mark an early decline in function preceding glucose intolerance 
previously observed at d42 (Chapter 2). Treatment of LP offspring with STZ further 
decreased expression of the insulin genes, which is consistent with the reduced β-cell 
mass at this time (Chapter 2).  
Neonatal growth and β-cell regeneration have been demonstrated to involve the 
Wnt/β-catenin pathway (48). The Wnt/β-catenin pathway acts to upregulate the cell 
cycle genes Ccnd1 and Cdk4 (25; 31). Through microarray analysis we found that Ccnd1 
had a significantly decreased gene expression in LP offspring, while Cdk4 was 
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unchanged, and neither gene was altered with STZ treatment. Despite observing 
changes in expression for Ctnnb1, Ccnd1 and Cdk4 in whole pancreas by qPCR, 
expression within isolated islets was low at d7 and therefore the cell cycle genes are 
unlikely to play a role early on during β-cell regeneration. 
Members of the Reg gene family have also been shown to play a role in β-cell 
regeneration. Reg1 gene expression was increased in regenerating β-cells and is 
mitogenic to both ductal and β-cells (18; 19; 49-51). Adjuvant therapy in diabetic NOD 
mice and STZ treated C57BL/6 mice induced an increased expression of Reg2, mediating 
β-cell regeneration (52). INGAP (mouse REG3δ) stimulates β-cell neogenesis from ductal 
cells, increasing β-cell mass and reversing diabetes in STZ treated C57BL/6J mice (20; 
53). Further support for the Reg genes as facilitators of β-cell regeneration was observed 
from a microarray analysis of 3 month old mice treated with multiple doses of STZ (80 
mg/kg) (21). Fifteen days after STZ treatment, gene expression for Reg2, Reg3α, Reg3β, 
Reg3δ, and Reg3γ were all increased (21). Additionally, Reg1 expression was significantly 
upregulated when quantified by northern blot hybridization (21). In the current study, 
our microarray analysis did not suggest any significant differences among the Reg genes 
in the C+STZ group. The disparity between these studies could be related to the age of 
the mice (3 months vs. 30 days) and the dose of STZ used (80 mg/kg vs. 35 mg/kg). 
However, we did observe a significant increase in gene expression with qPCR for Reg1 in 
STZ treated mice at d7 in whole pancreas and isolated islets. While other Reg genes 
were not measured by qPCR, Reg1 may be the primary target for induction of β-cell 
regeneration in neonates. 
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Despite a significant increase in Reg1 mRNA in the LP+STZ group, examination of 
protein presence suggested a reduction compared to the C+STZ group. A few 
possibilities may explain this discrepancy. First, increased protein ubiquitination may 
target REG1 for proteasomal degradation or other post-translational modification may 
lead to protein instability. Some proteins, such as β-catenin and cyclins, are normally 
regulated via the ubiquitin-proteasomal pathway (54; 55), however, it is not known if 
REG1 is post-translationally modified under normal circumstances. These changes could 
be a general effect of LP exposure, effecting many proteins and therefore cellular 
function. Secondly, an increased rate of secretion in an effort to stimulate β-cell 
regeneration could impact the measurement of REG1 islet content. Third, gene 
expression profiles in LP offspring suggest a potential deficit in protein biosynthesis and 
therefore may limit the production of key regulators of β-cell regeneration such as REG1.  
An increase in pancreatic GLP-1 content was observed in STZ-treated offspring, 
consistent with an increase in proglucagon gene expression and without a significant 
change in glucagon content. This suggests an altered processing of the prohormone. To 
support this theory, measurements of expression of the PC enzymes should be made at 
d7. A decreased expression of Pc2 was observed with the microarray at d30, but Pc1 was 
unchanged (data not shown). Similarly, a single injection of STZ to neonatal Wistar rats 
led to an increase in GLP-1 content (3). This was associated with α-cell hyperplasia and 
regeneration of β-cells (3). Previous research has also shown that in neonatal rats 
treated with STZ, administration of exogenous GLP-1 significantly improved β-cell 
regeneration, predominantly due to neogenesis of islets (56). However, in 7 day old 
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LP+STZ mice, the α-cell mass is reduced and β-cell regeneration fails. This may be 
attributed to possible alterations at the level of the GLP-1R or in the downstream 
signalling pathway. Although notably GLP-1R expression was unchanged by microarray 
analysis at d30 (data not shown). In contrast, STZ treatment of C-fed offspring did result 
in β-cell regeneration, while demonstrating a similar increase in GLP-1 content, 
suggesting that GLP-1 is an important stimulus for regeneration in the current model. 
 In conclusion, these results support the role of REG1 and GLP-1 in β-cell 
regeneration in C-fed offspring and suggest that reduced REG1 production and/or GLP-1 
signalling limits β-cell plasticity in LP-fed offspring. Further investigation is required to 
determine the defect in GLP-1 signalling and whether exogenous REG1 can rescue β-cell 
regeneration in LP mice. Additionally, the effects of fetal protein restriction appear to 
alter gene expression necessary for many cell functions, such as cellular respiration, free 
radical scavenging and protein biosynthesis. These alterations may critically impact β-
cell function leading to the development of glucose intolerance in adulthood.  
  
 
 
137 
 
3.5. References 
 
 1.  Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA and Butler PC. Beta-cell 
deficit and increased beta-cell apoptosis in humans with type 2 diabetes. 
Diabetes 52: 102-110, 2003. 
 2.  Butler PC, Meier JJ, Butler AE and Bhushan A. The replication of beta cells in 
normal physiology, in disease and for therapy. Nat Clin Pract Endocrinol Metab 3: 
758-768, 2007. 
 3.  Thyssen S, Arany E and Hill DJ. Ontogeny of regeneration of β-cells in the 
neonatal rat after treatment with streptozotocin. Endocrinology 147: 2346-2356, 
2006. 
 4.  Wang RN, Bouwens L and Kloppel G. Beta-cell proliferation in normal and 
streptozotocin-treated newborn rats: site, dynamics and capacity. Diabetologia 
37: 1088-1096, 1994. 
 5.  Cox AR, Gottheil SK, Arany EJ and Hill DJ. The effects of low protein during 
gestation on mouse pancreatic development and beta cell regeneration. Pediatr 
Res 68: 16-22, 2010. 
 6.  Wang RN, Bouwens L and Kloppel G. Beta-cell growth in adolescent and adult 
rats treated with streptozotocin during the neonatal period. Diabetologia 39: 
548-557, 1996. 
 7.  Portha B, Blondel O, Serradas P, McEvoy R, Giroix MH, Kergoat M and Bailbe D. 
The rat models of non-insulin dependent diabetes induced by neonatal 
streptozotocin. Diabete Metab 15: 61-75, 1989. 
 8.  Dor Y, Brown J, Martinez OI and Melton DA. Adult pancreatic beta-cells are 
formed by self-duplication rather than stem-cell differentiation. Nature 429: 41-
46, 2004. 
 9.  Teta M, Rankin MM, Long SY, Stein GM and Kushner JA. Growth and 
regeneration of adult beta cells does not involve specialized progenitors. Dev Cell 
12: 817-826, 2007. 
 10.  Xu X, D'Hoker J, Stange G, Bonne S, De LN, Xiao X, Van de CM, Mellitzer G, Ling 
Z, Pipeleers D, Bouwens L, Scharfmann R, Gradwohl G and Heimberg H. Beta 
 
 
138 
 
cells can be generated from endogenous progenitors in injured adult mouse 
pancreas. Cell 132: 197-207, 2008. 
 11.  Inada A, Nienaber C, Katsuta H, Fujitani Y, Levine J, Morita R, Sharma A and 
Bonner-Weir S. Carbonic anhydrase II-positive pancreatic cells are progenitors 
for both endocrine and exocrine pancreas after birth. Proc Natl Acad Sci U S A 
105: 19915-19919, 2008. 
 12.  Hales CN, Barker DJ, Clark PM, Cox LJ, Fall C, Osmond C and Winter PD. Fetal 
and infant growth and impaired glucose tolerance at age 64. BMJ 303: 1019-
1022, 1991. 
 13.  Hales CN and Barker DJ. Type 2 (non-insulin-dependent) diabetes mellitus: the 
thrifty phenotype hypothesis. Diabetologia 35: 595-601, 1992. 
 14.  Barker DJ, Hales CN, Fall CH, Osmond C, Phipps K and Clark PM. Type 2 (non-
insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia 
(syndrome X): relation to reduced fetal growth. Diabetologia 36: 62-67, 1993. 
 15.  George M, Ayuso E, Casellas A, Costa C, Devedjian JC and Bosch F. Beta cell 
expression of IGF-I leads to recovery from type 1 diabetes. J Clin Invest 109: 
1153-1163, 2002. 
 16.  Li L, Yi Z, Seno M and Kojima I. Activin A and betacellulin: effect on regeneration 
of pancreatic beta-cells in neonatal streptozotocin-treated rats. Diabetes 53: 608-
615, 2004. 
 17.  Suarez-Pinzon WL, Yan Y, Power R, Brand SJ and Rabinovitch A. Combination 
therapy with epidermal growth factor and gastrin increases beta-cell mass and 
reverses hyperglycemia in diabetic NOD mice. Diabetes 54: 2596-2601, 2005. 
 18.  Terazono K, Yamamoto H, Takasawa S, Shiga K, Yonemura Y, Tochino Y and 
Okamoto H. A novel gene activated in regenerating islets. J Biol Chem 263: 2111-
2114, 1988. 
 19.  Unno M, Nata K, Noguchi N, Narushima Y, Akiyama T, Ikeda T, Nakagawa K, 
Takasawa S and Okamoto H. Production and characterization of Reg knockout 
mice: reduced proliferation of pancreatic beta-cells in Reg knockout mice. 
Diabetes 51 Suppl 3: S478-S483, 2002. 
 20.  Rosenberg L, Lipsett M, Yoon JW, Prentki M, Wang R, Jun HS, Pittenger GL, 
Taylor-Fishwick D and Vinik AI. A pentadecapeptide fragment of islet 
 
 
139 
 
neogenesis-associated protein increases beta-cell mass and reverses diabetes in 
C57BL/6J mice. Ann Surg 240: 875-884, 2004. 
 21.  Lu Y, Ponton A, Okamoto H, Takasawa S, Herrera PL and Liu JL. Activation of the 
Reg family genes by pancreatic-specific IGF-I gene deficiency and after 
streptozotocin-induced diabetes in mouse pancreas. Am J Physiol Endocrinol 
Metab 291: E50-E58, 2006. 
 22.  Terazono K, Uchiyama Y, Ide M, Watanabe T, Yonekura H, Yamamoto H and 
Okamoto H. Expression of reg protein in rat regenerating islets and its co-
localization with insulin in the beta cell secretory granules. Diabetologia 33: 250-
252, 1990. 
 23.  Takasawa S, Ikeda T, Akiyama T, Nata K, Nakagawa K, Shervani NJ, Noguchi N, 
Murakami-Kawaguchi S, Yamauchi A, Takahashi I, Tomioka-Kumagai T and 
Okamoto H. Cyclin D1 activation through ATF-2 in Reg-induced pancreatic beta-
cell regeneration. FEBS Lett 580: 585-591, 2006. 
 24.  Cui W, De JK, Zhao H, Takasawa S, Shi B, Srikant CB and Liu JL. Overexpression 
of Reg3alpha increases cell growth and the levels of cyclin D1 and CDK4 in 
insulinoma cells. Growth Factors 27: 195-202, 2009. 
 25.  Rulifson IC, Karnik SK, Heiser PW, ten BD, Chen H, Gu X, Taketo MM, Nusse R, 
Hebrok M and Kim SK. Wnt signaling regulates pancreatic beta cell proliferation. 
Proc Natl Acad Sci U S A 104: 6247-6252, 2007. 
 26.  Rohrs S, Kutzner N, Vlad A, Grunwald T, Ziegler S and Muller O. Chronological 
expression of Wnt target genes Ccnd1, Myc, Cdkn1a, Tfrc, Plf1 and Ramp3. Cell 
Biol Int 33: 501-508, 2009. 
 27.  Jain K, Zucker PF, Chan AM and Archer MC. Monolayer culture of pancreatic 
islets from the Syrian hamster. In Vitro Cell Dev Biol 21: 1-5, 1985. 
 28.  Algul H, Wagner M, Lesina M and Schmid RM. Overexpression of ErbB2 in the 
exocrine pancreas induces an inflammatory response but not increased 
proliferation. Int J Cancer 121: 1410-1416, 2007. 
 29.  Friis-Hansen L, Lacourse KA, Samuelson LC and Holst JJ. Attenuated processing 
of proglucagon and glucagon-like peptide-1 in carboxypeptidase E-deficient mice. 
J Endocrinol 169: 595-602, 2001. 
 
 
140 
 
 30.  AmiGO Manual. 
http://wiki.geneontology.org/index.php/AmiGO_Manual:_Term_Enrichment.  
2011.  
Ref Type: Internet Communication 
 31.  Liu Z and Habener JF. Glucagon-like peptide-1 activation of TCF7L2-dependent 
Wnt signaling enhances pancreatic beta cell proliferation. J Biol Chem 283: 8723-
8735, 2008. 
 32.  Akpinar P, Kuwajima S, Krutzfeldt J and Stoffel M. Tmem27: a cleaved and shed 
plasma membrane protein that stimulates pancreatic beta cell proliferation. Cell 
Metab 2: 385-397, 2005. 
 33.  Green K, Brand MD and Murphy MP. Prevention of mitochondrial oxidative 
damage as a therapeutic strategy in diabetes. Diabetes 53 Suppl 1: S110-S118, 
2004. 
 34.  Sivitz WI and Yorek MA. Mitochondrial dysfunction in diabetes: from molecular 
mechanisms to functional significance and therapeutic opportunities. Antioxid 
Redox Signal 12: 537-577, 2010. 
 35.  Chamson-Reig A, Thyssen SM, Arany E and Hill DJ. Altered pancreatic 
morphology in the offspring of pregnant rats given reduced dietary protein is 
time and gender specific. J Endocrinol 191: 83-92, 2006. 
 36.  Fonseca SG, Urano F, Burcin M and Gromada J. Stress hypERactivation in the 
beta-cell. Islets 2: 1-9, 2010. 
 37.  Reusens B, Sparre T, Kalbe L, Bouckenooghe T, Theys N, Kruhoffer M, Orntoft 
TF, Nerup J and Remacle C. The intrauterine metabolic environment modulates 
the gene expression pattern in fetal rat islets: prevention by maternal taurine 
supplementation. Diabetologia 51: 836-845, 2008. 
 38.  Theys N, Bouckenooghe T, Ahn MT, Remacle C and Reusens B. Maternal low-
protein diet alters pancreatic islet mitochondrial function in a sex-specific 
manner in the adult rat. Am J Physiol Regul Integr Comp Physiol 297: R1516-
R1525, 2009. 
 39.  Theys N, Clippe A, Bouckenooghe T, Reusens B and Remacle C. Early low protein 
diet aggravates unbalance between antioxidant enzymes leading to islet 
dysfunction. PLoS ONE 4: e6110, 2009. 
 
 
141 
 
 40.  Simmons RA, Suponitsky-Kroyter I and Selak MA. Progressive accumulation of 
mitochondrial DNA mutations and decline in mitochondrial function lead to beta-
cell failure. J Biol Chem 280: 28785-28791, 2005. 
 41.  Peterside IE, Selak MA and Simmons RA. Impaired oxidative phosphorylation in 
hepatic mitochondria in growth-retarded rats. Am J Physiol Endocrinol Metab 
285: E1258-E1266, 2003. 
 42.  Selak MA, Storey BT, Peterside I and Simmons RA. Impaired oxidative 
phosphorylation in skeletal muscle of intrauterine growth-retarded rats. Am J 
Physiol Endocrinol Metab 285: E130-E137, 2003. 
 43.  Lenzen S, Drinkgern J and Tiedge M. Low antioxidant enzyme gene expression in 
pancreatic islets compared with various other mouse tissues. Free Radic Biol Med 
20: 463-466, 1996. 
 44.  Tiedge M, Lortz S, Drinkgern J and Lenzen S. Relation between antioxidant 
enzyme gene expression and antioxidative defense status of insulin-producing 
cells. Diabetes 46: 1733-1742, 1997. 
 45.  James AM and Murphy MP. How mitochondrial damage affects cell function. J 
Biomed Sci 9: 475-487, 2002. 
 46.  Yano M, Watanabe K, Yamamoto T, Ikeda K, Senokuchi T, Lu M, Kadomatsu T, 
Tsukano H, Ikawa M, Okabe M, Yamaoka S, Okazaki T, Umehara H, Gotoh T, 
Song WJ, Node K, Taguchi R, Yamagata K and Oike Y. Mitochondrial dysfunction 
and increased reactive oxygen species impair insulin secretion in sphingomyelin 
synthase 1-null mice. J Biol Chem 286: 3992-4002, 2011. 
 47.  Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. 
Diabetes 54: 1615-1625, 2005. 
 48.  Figeac F, Uzan B, Faro M, Chelali N, Portha B and Movassat J. Neonatal growth 
and regeneration of beta-cells are regulated by the Wnt/beta-catenin signaling in 
normal and diabetic rats. Am J Physiol Endocrinol Metab 298: E245-E256, 2010. 
 49.  Ohno T, Ishii C, Kato N, Ito Y, Shimizu M, Tomono S, Murata K and Kawazu S. 
Increased expression of a regenerating (reg) gene protein in neonatal rat 
pancreas treated with streptozotocin. Endocr J 42: 649-653, 1995. 
 
 
142 
 
 50.  Levine JL, Patel KJ, Zheng Q, Shuldiner AR and Zenilman ME. A recombinant rat 
regenerating protein is mitogenic to pancreatic derived cells. J Surg Res 89: 60-
65, 2000. 
 51.  Watanabe T, Yonemura Y, Yonekura H, Suzuki Y, Miyashita H, Sugiyama K, 
Moriizumi S, Unno M, Tanaka O, Kondo H and . Pancreatic beta-cell replication 
and amelioration of surgical diabetes by Reg protein. Proc Natl Acad Sci U S A 91: 
3589-3592, 1994. 
 52.  Huszarik K, Wright B, Keller C, Nikoopour E, Krougly O, Lee-Chan E, Qin HY, 
Cameron MJ, Gurr WK, Hill DJ, Sherwin RS, Kelvin DJ and Singh B. Adjuvant 
immunotherapy increases beta cell regenerative factor Reg2 in the pancreas of 
diabetic mice. J Immunol 185: 5120-5129, 2010. 
 53.  Rafaeloff R, Pittenger GL, Barlow SW, Qin XF, Yan B, Rosenberg L, Duguid WP 
and Vinik AI. Cloning and sequencing of the pancreatic islet neogenesis 
associated protein (INGAP) gene and its expression in islet neogenesis in 
hamsters. J Clin Invest 99: 2100-2109, 1997. 
 54.  Moon RT. Wnt/beta-catenin pathway. Sci STKE 2005: cm1, 2005. 
 55.  Tyers M and Jorgensen P. Proteolysis and the cell cycle: with this RING I do thee 
destroy. Curr Opin Genet Dev 10: 54-64, 2000. 
 56.  Tourrel C, Bailbe D, Meile MJ, Kergoat M and Portha B. Glucagon-like peptide-1 
and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn 
rats resulting in persistently improved glucose homeostasis at adult age. Diabetes 
50: 1562-1570, 2001. 
  
 
 
143 
 
CHAPTER 4: 
General Discussion and Future Experiments 
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This thesis examined the effects of administration of maternal LP diet in a mouse 
model on endocrine pancreas development and long term glucose homeostasis in the 
offspring. The plasticity of neonatal LP offspring was challenged by depletion of β-cells 
with multiple low doses of STZ and the capacity to regenerate was monitored. This was 
contrasted with STZ treated C-fed offspring, in which the mechanism of β-cell 
regeneration and potential signalling genes involved were investigated.  
4.1. The LP Mouse Model 
Our objective to compare findings from maternal feeding LP diet in mice with those 
previously described in the rat (1-6) was accomplished. We observed a decreased body 
weight at d1 in LP-fed offspring compared to C diet, followed by rapid catch up growth 
and impaired glucose intolerance in females in adulthood. This is comparable to findings 
in the rat (5; 7; 8). However, in the mouse we observed a reduction in α- and β-cell mass 
in LP offspring only at d7, while in the rat model β-cell mass was already reduced at birth 
(1; 2; 6). The reduction in islet mass at d7 preceded a significant increase at d14 in the 
female LP offspring. With respect to the β-cell mass, this increase was attributed mainly 
to cell hypertrophy. Therefore there are some species differences regarding the growth 
trajectory of the β-cell mass between mouse and rat, but the long term metabolic 
outcome remains the same.  
Interestingly, gender differences were observed in LP-fed mouse offspring. Female 
offspring were glucose intolerant at 130 days of age, as was observed with LP rats (5). 
The impairment in female LP rats was likely due to a relative deficiency of β-cell mass 
(5). In contrast, female LP mice had no change in β-cell mass at this time, therefore 
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pancreatic insulin content and glucose-stimulated insulin secretion (GSIS) in isolated 
islets should be measured to determine if there is a functional deficit in the β-cell. The 
male LP mice did not demonstrate any changes in glucose tolerance or β-cell mass as 
adults. Estrogen levels were not examined in the current study, but alterations may 
account for the gender differences observed in LP offspring. Previous research in rats 
and mice has shown that estrogens regulate glucose metabolism and tolerance through 
increased β-cell insulin content, insulin gene expression, and insulin release (9-11). 
Therefore estrogen hormone therapy may be appropriate to restore glucose tolerance 
and β-cell function in female LP mice. In contrast, LP male rats were found to have 
reduced plasma testosterone levels, which was postulated to contribute to insulin 
resistance (5), but in the current studies these parameters were not measured and no 
apparent impact on glucose homeostasis was observed in male LP mice. However, 
previous studies have determined that in maternal LP rat plasma, levels of prolactin, 
leptin, estradiol and progesterone are all altered during gestation (12). These changes 
may differentially program fetal trajectory of β-cell growth and glucose homeostasis 
later in life. Further studies must be considered to determine whether these hormones 
have gender specific effects.  
Deficits in glucose tolerance may be the result of reduced islet vascularization 
and therefore poor nutrient sensing or insulin delivery to target tissues. Prior LP 
exposure was shown to decrease islet vasculature in rats at birth and in neonates 
(1; 13). Long term deficits in islet vascularity could potentially contribute to β-cell 
dysfunction and glucose intolerance. To address this possibility, vasculature in 
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mouse pancreatic sections could be stained for platelet endothelial cell adhesion 
marker - 1 (PECAM-1; CD31) in LP neonatal mice to determine if islet vascular loss 
plays a role in alterations in endocrine function and growth. 
The underlying cause of β-cell dysfunction may result from reduced expression of 
genes important for the maintenance of glucose homeostasis such as insulin, Glut2 and 
Gck. One of the main regulators of these genes is the transcription factor Pdx-1 (14-17). 
A loss of Pdx-1 expression may explain the observed glucose intolerance in LP-fed 
female offspring. Recently, Pdx-1 expression was found to be reduced at d14 and 3 
months of age in offspring of rats that had undergone a bilateral uterine artery ligation 
to induce IUGR (18). While the method of insult differs from the current study, nutrient 
deficiency still occurs and these IUGR rat offspring also developed impaired glucose 
tolerance (19). The authors proposed that epigenetic silencing of Pdx-1 expression was 
responsible for the phenotype. Specifically, isolated islets from fetal, neonatal and adult 
offspring were analyzed for alterations in epigenetic modifications at the Pdx-1 
promoter (20). Control islets were associated with histone modifications indicative of 
open chromatin favouring gene transcription, as well as a lack of DNA methylation of the 
Pdx-1 promoter region. In contrast, islets from rats born with IUGR had a progressive 
change in epigenetic markings in islet cells from fetal life until 6 months of age. Histone 
markers of inactive chromatin were increased along with an increase in DNA 
methylation of CpG islands in the Pdx-1 promoter. Progression of these modifications 
paralleled the progressive decrease in Pdx-1 expression as glucose homeostasis 
deteriorated in IUGR offspring. Based on our microarray analysis at day 30, female LP 
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mice have a significant reduction in Pdx-1 expression. Therefore, it is possible that a 
similar mechanism is responsible for the impaired glucose tolerance in the current study 
with LP-fed mice. 
Support has been emerging for the theory that reprogramming of mitochondrial 
function is a key adaptation enabling the fetus to survive in a limited energy 
environment (21-23). However, these alterations in mitochondrial function can have 
deleterious effects in a nutrient-enriched environment postnatally. Previous microarray 
studies in 3 month old LP rat offspring found that expression of cellular respiratory 
genes were downregulated (24). This is consistent with the current observations in LP 
mice, where 31 transcripts encoding for electron transport chain (ETC) enzyme subunits 
were significantly altered in the LP group at d30. Similar observations were also found in 
insulin target tissues, the liver and skeletal muscle, in microarray experiments conducted 
in LP-fed C57Bl/6 mice at birth (25). Genes related to the mitochondria and more 
specifically, oxidative phosphorylation, were the most over-represented genes altered in 
the liver and skeletal muscle. Furthermore, measurements of oxidative phosphorylation 
in the liver and skeletal muscle were reduced in IUGR rats induced by bilateral uterine 
artery ligation, demonstrating mitochondrial dysfunction and reduced ATP production 
(22; 23). Therefore, not only is the pancreas impacted by the fetal environment, but 
programming of the mitochondria is also observed in other organs involved in glucose 
homeostasis. Additionally, islets of IUGR rats were shown to have a gradual increase in 
ROS production, oxidative stress and impaired ATP production with age (21). 
Mitochondrial dysfunction resulted in impaired insulin secretion from isolated islets of 
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IUGR rats. Here we have shown a decreased expression of genes encoding enzymes 
involved in the mitochondrial transport chain and antioxidant enzymes, which are 
important for ATP production and reduction of ROS, respectively. Together these 
changes may result in decreased β-cell function and diminished insulin secretion leading 
to glucose intolerance at adult age in LP mice. Future studies should measure the rate of 
ATP production in isolated islets along with GSIS and the levels of ROS or markers of 
oxidative damage.  
The mechanism of poor fetal development and the risk for glucose intolerance 
requires further investigation. While amino acids are important for fetal and neonatal 
growth(26), these effects may be secondary to poor placental development and reduced 
amino acid transporters (27). This may result in fetal hypoxia and reduce fetal plasma 
amino acid levels, contributing to catabolism and reduced fetal growth. Future studies 
should examine whether hormone or amino acid therapy can rescue the effects of LP on 
placental development. As well, further analysis is required to determine the β-cell 
specific changes in mitochondrial function and protein synthesis and whether epigenetic 
changes are involved the pancreatic gene expression changes following LP. Lastly, an 
altered diet can influence the gut microbiota and may impact host defence and risk of 
metabolic disease (28; 29). Prebiotic administration to LP dams may be viable option for 
rescuing the effects of on fetal growth and adult metabolism.  
4.2. STZ-Induced Beta Cell Regeneration  
In addition to examining the effects of fetal exposure to LP on endocrine pancreas 
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development, we examined the capacity for β-cell regeneration in C and LP neonatal 
mice. Partial β-cell destruction using multiple low doses of STZ was used to induce a 
subsequent regeneration. Following 50-60% loss of β-cell mass, regeneration in both 
male and female offspring of C-fed dams was observed by d30. In contrast, the single 
dose STZ regimen in rats induces a 90% loss of β-cell volume followed by a recovery to 
only 40% of the control values by 3 weeks (30; 31). Additionally, the capacity for 
regeneration decreases with increasing age at administration of STZ (31). Therefore the 
timing and STZ regimen used influences the degree of regeneration, so it is important to 
select the appropriate model for the desired outcome. We used multiple low doses of 
STZ in neonates with the expectation of a robust response for regeneration.  
Despite regeneration of β-cell mass, male C+STZ mice remained hyperglycemic 
throughout the period of study, while female mice maintained euglycemia. However, 
recovery was not sustained as functional deficits developed at d42 marked by glucose 
intolerance in both genders. We postulated that β-cells that survived following STZ 
treatment may have become stressed by the increased metabolic demand and/or newly 
regenerated β-cells were not fully mature leading to glucose intolerance at d42. Electron 
microscopy could be performed on pancreatic sections at d42 to examine the 
ultrastructural changes of the β-cell. Insulin granule number and granule maturity could 
be determined to indicate insulin production and β-cell maturity, respectively, possibly 
explaining the glucose intolerance observed at d42. Wang et al. noted that β-cells had 
slightly uneven granulation in 6-20 week old STZ rats (31). Furthermore, 33% of male 
C+STZ mice became overtly diabetic between 60-80 days of age and were sacrificed 
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prior to d130. On the other hand, all female C+STZ mice survived to d130, but the β-cell 
mass was significantly decreased. Impaired function observed at d42 may have resulted 
in continued stress on the β-cell, leading to β-cell apoptosis and loss of β-cell mass by 
d130. Although β-cell regeneration does occur following multiple low doses of STZ, this 
is not sustained over the long term. This is consistent with previous studies in the STZ 
treated rat, where long term diabetes develops even with an initial regeneration of β-
cells, with males developing diabetes earlier (31; 32). If stimulation of endogenous β-cell 
regeneration is to be of therapeutic benefit, newly generated β-cells must be fully 
capable of tight glucose regulation and maintain long term survival.  
Previous research has also observed gender differences in response to STZ 
exposure. It was found that STZ had an increased cytotoxicity in male mice compared to 
females, leading to increased plasma glucose levels (33-35). Testosterone treatment in 
females was shown to increase plasma glucose levels while castration of male mice led 
to a reduction in glucose levels (33). On the other hand, estrogens appear to protect the 
β-cell from STZ induced apoptosis (35; 36) which is supported by increased plasma 
glucose levels following castration in female STZ treated mice (33). These findings are 
consistent with the current results demonstrating that male C+STZ mice were 
hyperglycemic throughout the study and became overtly diabetic between 60-80 days of 
age, while the females were relatively euglycemic. 
4.3. β-cell Regeneration in LP-Fed Offspring 
In contrast to C-fed offspring, STZ treatment in neonatal LP offspring resulted in a 
failure of β-cell regeneration. After an initial loss of ~50% of β-cell mass, both male and 
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female LP+STZ mice had values of β-cell mass that were significantly lower than sham 
injected LP mice at all time points measured. Changes in glucose homeostasis were 
similar in male and female LP+STZ mice compared to their respective counterparts. The 
survival in male LP+STZ mice was lower than in C+STZ mice at 33% versus 67%. These 
findings are consistent with a study in which rat dams were 50% calorie restricted (R) 
from day 15 of gestation until weaning and the offspring injected with a single dose of 
STZ (100 mg/kg) at birth (37). β-cell mass regenerated rapidly by day 7 in STZ treated 
rats of C-fed dams, however, the R+STZ rats showed poor regeneration out to day 21. 
The observed impairment in β-cell regeneration was attributed to reduced neogenesis, 
while β-cell proliferation was preserved. These results suggests two important findings: 
1) protein restricted offspring lack the ability to expand β-cell mass which is of concern 
under certain physiological conditions, such has pregnancy and obesity, where increased 
β-cell mass is necessary to meet the insulin demand and 2) fetal programming may 
affect key components of regeneration such as β-cell replication or precursor cell 
differentiation, thereby limiting the possibility for therapeutic stimulation of 
endogenous β-cell regeneration in diabetes.  
4.4. The Mechanism of β-Cell Regeneration 
The regeneration of β-cells may involve many components including β-cell 
replication and/or precursor cell differentiation, a complex milieu of inflammatory or 
growth factor stimuli, the extracellular matrix and supportive endothelial and bone 
marrow cells. Examining the source of new β-cells, it was determined that male C+STZ 
mice regenerate primarily through β-cell proliferation, while female C+STZ mice showed 
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an increase in neogenesis and precursor cell differentiation. Whether the sex hormones 
play a role in stimulation of β-cell proliferation or precursor cell differentiation remains 
to be determined. Alternatively, β-cell proliferation was found to be increased following 
short term in vivo glucose infusion in rats (38) and suggests that hyperglycemia in C+STZ 
male mice stimulated β-cell proliferation primary to precursor differentiation. One could 
argue that both proliferation and neogenesis occur in hyperglycemic environments 
depending on the model (30; 39-41) and therefore glucose levels are unlikely to be the 
cause of gender differences in the mechanism of regeneration.  
Regeneration of β-cells in female C+STZ mice involved neogenesis and precursor cell 
differentiation. A previous study used a lineage tracing model (RIP-CreER;Z/AP) to 
specifically tag the insulin expressing cells with human placental alkaline phosphatase 
(AP) (42). It was determined that following 70% partial pancreatectomy (Px), 
regenerated β-cells were labelled with AP and therefore originated from β-cell 
replication and not from stem/precursor cell differentiation (42). Lineage tracing has not 
been used in STZ models, except to exclude bone marrow derived cells as a direct source 
of insulin producing β-cells (43; 44). RIP-CreER;Z/AP transgenic mice have been 
established in our laboratory and will be useful in support of the current study on the 
origin of  β-cells in STZ induced regeneration. To support the findings that female C+STZ 
mice regenerate via neogenesis and precursor cell differentiation we would expect an 
increased percentage of β-cells expressing insulin but lacking AP following STZ. 
Attempts to characterize a pancreatic stem cell or β-cell precursor in the postnatal 
pancreas have proven more difficult. One possible source of precursor cells may be the 
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subpopulation of cells within the islets we observed that expressed PDX-1 but lacked 
insulin expression. During embryogenesis early pancreatic precursors are characterized 
by PDX-1+/insulin— expression (45). Recently, Szabat et al. identified a population of 
PDX-1+/insulinlow cells that convert to PDX-1+/insulin+ without cell division (46), 
suggesting a potential precursor population that could be stimulated to increase β-cell 
mass. Interestingly, in LP+STZ female mice there was a significantly higher proportion of 
PDX-1+/Insulin— cells within the islets. This may represent an increase in the 
somatostatin-producing δ-cell population since a subset of δ-cells in the normal 
pancreas express Pdx-1 (40). A previous study found that 2 days after STZ treatment 
there was a significant increase in the number of somatostatin+/PDX-1+ cells, which was 
followed by differentiation to somatostatin+/PDX-1+/Ins+ and an increase in the number 
of β-cells 5 days after STZ treatment (40). This leads to three potential explanations for 
the observed increase in PDX-1+/Insulin— cells within the islets of LP+STZ mice. First, a 
subset of δ-cells expressing PDX-1 represents a reserve pool of β-cell precursors that 
proliferate and differentiate following β-cell loss (40). Second, δ-cells in general are β-
cell precursors and can initiate PDX-1 expression and further differentiate into β-cells. 
Lastly, it is possible that the PDX-1+/Insulin— cells are not δ-cells and represent a 
precursor population early in the β-cell differentiation pathway as observed during 
pancreatic organogenesis. Further characterization of the PDX-1+/Insulin— population 
through immunohistochemical staining for somatostatin and markers of β-cell 
differentiation (early - NGN3, MAFB; late – MAFA, PAX6) will be important for use of 
these putative precursors in therapeutic treatment. Despite the presence of PDX-
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1+/Insulin— cells within the islets of LP+STZ mice, a concomitant increase in β-cell mass 
did not occur. This may suggest that prior exposure to a LP diet negatively impacts the 
differentiation of β-cell precursors during regeneration. These effects could result from a 
lack of differentiation signals or epigenetic changes to downstream transcription factors, 
NGN3andMAFA, restricting their expression. 
The bone marrow compartment is a source of adult stem cells such as endothelial 
progenitors (47; 48), mesenchymal cells which are capable of deriving bone, adipose and 
cartilage (49) and also cells that can reconstitute the hematopoietic system (50). While 
evidence has shown that bone marrow-derived cells do not differentiate into insulin-
producing β-cells (51; 52), there has been strong support for the involvement of bone 
marrow derived cells in β-cell regeneration (43; 53; 54). The original study found that 
transplantation of ckit+ bone marrow-derived cells into STZ treated mice resulted in 
improved glycemia, increased β-cell survival, insulin production, islet cell proliferation 
and differentiation of donor derived cells into CD31+ endothelial cells (43). More 
recently, endogenous bone marrow-derived cells were found to home to the injured 
pancreas following STZ treatment and contributed to intra-islet angiogenesis leading to 
β-cell regeneration (44). It is possible that LP fetal programming may alter the ability of 
endogenous bone marrow cells to migrate to the injured pancreas and/or differentiate 
into supportive vasculature leading to a failure of β-cell regeneration in LP+STZ mice. A 
study examining LP rats found attenuated colony formation, proliferation, and 
differentiation of bone marrow stromal cells in the offspring and that this may 
contribute to delayed skeletal maturity with a delay in osteoblast activity (55). Other 
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compartments of the bone marrow, such as the endothelial progenitors, may also be 
altered by the LP diet and therefore limit the ability to support β-cell regeneration. 
Endogenous bone marrow-derived stem cells can be tracked in vivo using a 
transgenic mouse line (Vav-iCre; R26R-eYFP) that marks all hematopoietic lineage cells 
with enhanced yellow fluorescent protein (YFP) (44). This transgenic mouse line could be 
used to determine the impact of fetal protein restriction on migration and 
differentiation of bone marrow-derived cells in the injured pancreas. Migration could be 
measured by cell counts of YFP+ cells within the STZ pancreas, with and without prior 
exposure to LP. Additionally, the number of YFP+/CD31+ cells would provide an 
indication of the differentiation capability of bone marrow-derived cells in LP+STZ mice. 
Alterations in either migration or differentiation may underlie the failure of regeneration 
in LP+STZ mice. Rescue experiments could be performed in which YFP+ hematopoietic 
cells from control donors can be transplanted into LP+STZ wild type recipients. β-cell 
mass would be measured to determine the outcome of regeneration. 
Bone marrow-derived cells and revascularization of the islets may provide a milieu 
of growth factors and stimuli for regeneration of β-cells, however, other sources of 
regenerative signals must also be considered. Recently one study suggested that β-cells 
undergoing apoptosis may release factors that stimulate proliferation in nearby β-cells 
(56). This was found to occur through the release of microparticles from apoptosing β-
cells, which stimulated increased expression of the PSP/reg (Reg1) and insulin genes and 
increased proliferation (56). This may suggest that following STZ treatment, β-cells 
undergoing apoptosis signal to nearby β-cells, stimulating proliferation in an attempt to 
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increase β-cell mass. Alternatively, an inflammatory signal following STZ damage may 
stimulate β-cell regeneration. While infiltrating leukocytes and overwhelming 
inflammation were not observed in the current study, previously both human and 
mouse islets were shown to increase interleukin-6 (IL-6) release in vitro in response to 
metabolic stresses such as elevated glucose (57). Increasing local IL-6 levels may have 
paracrine/autocrine effects related to β-cell regeneration. Interestingly, functional IL-6 
response elements have been identified in the Reg1 promoter (58; 59). Furthermore, 
Reg1 was found to be upregulated during β-cell regeneration (60; 61). These studies 
suggest that microparticles or inflammatory signals such as IL-6 may be key stimulators 
of regeneration acting through Reg1 to promote β-cell proliferation.  
We used microarray analysis to identify candidate genes and signalling pathways as 
putative regeneration signals. Members of the Reg family (Reg1, Reg3δ) and the Wnt 
signalling pathway (Ctnnb1), as well as their downstream target genes, cyclin D1 (Ccnd1) 
and Cdk4, were chosen as viable candidates. As described above, Reg1 has been 
suggested to play a role in β-cell regeneration (60; 61), as well as other Reg genes, such 
as INGAP (Reg3δ), Reg2, Reg3α (62-64). Signalling through β-catenin (CTNNB1) has also 
been demonstrated to increase β-cell mass (65; 66). While whole pancreas analysis by 
qPCR revealed differential expression of the candidate genes at d7, 14 and 30, islet 
specific expression of Reg3δ, Ctnnb1, Ccnd1 and Cdk4 was quite low or undetermined 
when sampled at d7. Islet specific expression of Reg1 mRNA was significantly increased 
in LP+STZ islets. β-cell regeneration however failed in LP+STZ islets suggesting that the 
islets attempted to stimulate regeneration through increased Reg1 expression. 
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However, western blot analysis indicated a reduced protein level for REG1 in LP+STZ 
islets may be the cause of failed β-cell regeneration. In contrast, the C-fed offspring 
increased REG1 protein levels following STZ treatment which could account for β-cell 
regeneration.  
Given the significant increase in Reg1 mRNA expression, it was expected that 
protein expression would also be elevated in LP+STZ islets. However, the reverse was 
found. One possible explanation is that the protein is short lived due to a post-
translational modification targeting REG1 for degradation. Ubiquitination is a post-
translational modification in which the small highly conserved protein ubiquitin is 
attached to substrate proteins via an enzymatic cascade, leading to a polyubiquitin 
chain, and then the substrate is quickly captured and degraded by the 26S proteasome 
(67). It is not known whether REG1 is susceptible to post-translational modifications, 
however these events could represent a general effect of prior LP-feeding or a 
regulatory mechanism to prevent high levels of growth factor expression, such as REG1. 
Ubiquitin ligases recognize specific phosphorylated forms of the substrate (68), 
therefore another consideration is the upregulation of protein kinases leading to 
differential phosphorylation of REG1 post-translationally, ubiquitination and subsequent 
proteasome degradation. The use of inhibitors of the proteasome, such as derivatives of 
calpain inhibitors (68; 69), would establish the involvement of the ubiquitin-proteasome 
pathway in Reg1 degradation. A second explanation for the low levels of REG1 in LP+STZ 
islets would be alterations in protein biosynthesis. Based on microarray data from 
pancreatic samples at d30, we observed a large number of genes, mostly 
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downregulated, in LP offspring, suggesting a reduced capacity for or a dysfunction of 
protein biosynthesis. In addition to protein formation, proper protein folding is required 
for structure and function. REG1 contains 6 cysteines residues, suggesting the presence 
of intramolecular disulfide bonds (70). Improper folding of REG1 could also lead to 
degradation. Lastly, the demand for signalling molecules to stimulate β-cell regeneration 
in LP+STZ mice would be elevated, as indicated by increased Reg1 mRNA levels, so 
potentially REG1 is secreted at an increased rate and therefore islet content of REG1 is 
reduced. To examine this possibility, isolated islets from all four groups can be cultured 
in the presence of IL-6 and dexamethasone (59) or gastrin (71) to stimulate Reg1 
expression, followed by measurements of REG1 secretion in the media and then 
compared to the islet content. 
In addition to looking at the microarray for candidate genes for β-cell regeneration, 
we also followed up with the islet hormones. In particular, proglucagon gene expression 
was found to be significantly upregulated with STZ treatment. However, pancreatic 
glucagon content was unchanged compared to the sham injected group. Since glucagon 
is a product of a prohormone, we considered the possibility of alternative processing 
leading to increased production of glucagon-like peptide-1 (GLP-1) and found an 
increased GLP-1 content in STZ treated offspring. In the intestinal L cell, proglucagon is 
processed by prohormone convertase (PC) 1/3 to GLP-1, GLP-2 and glicentin, while the 
α-cells primarily express PC2 and convert proglucagon into glucagon (72; 73). GLP-1 is 
released from the intestinal L cells in response to nutrient ingestion to stimulate 
glucose-dependent insulin secretion and inhibits gastric emptying and glucagon 
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secretion (74; 75). GLP-1 also increases pancreatic insulin content and mRNA expression 
of insulin, Glut2 and Gck (76; 77). Additionally, GLP-1 has been identified as a β-cell 
survival factor, as GLP-1 signalling has been demonstrated to decrease apoptosis in STZ 
treated mice and other models of diabetes (78-80).  
Interestingly, observations suggest that GLP-1 acts as a trophic factor for β-cells. 
Proliferation of β-cells has been shown both in vitro using the Ins1 cell line (81; 82) and 
in vivo (39; 83-85). Studies also suggest that GLP-1 or GLP-1 receptor (GLP-1R) agonists 
stimulate islet neogenesis in STZ treated or Px rats (39; 86). GLP-1R knockout mice had a 
reduced capacity for β-cell regeneration following Px, suggesting a role for endogenous 
GLP-1 in regeneration (87). Furthermore, STZ treated rats had an increase in GLP-1 
content 8 days after STZ treatment which may be associated with precursor cell 
differentiation and/or α-cell transdifferentiation (41). The potential of increasing local 
GLP-1 would be a great advantage for β-cell regeneration and this may result from 
alternative processing of the proglucagon hormone in α-cells as suggested previously 
(41).  
In the current study, the α-cell mass was unchanged in C+STZ mice, but proglucagon 
mRNA was highly expressed and with an increased ratio of GLP-1 to glucagon content, 
suggests a relative increased GLP-1 production following STZ. Therefore GLP-1 may play 
a role in β-cell regeneration in C+STZ mice. The α-cell mass was reduced with prior LP-
feeding, however the expression of the proglucagon gene was increased following STZ, 
indicating that on a per α-cell basis there was a further increase in proglucagon gene 
expression. Furthermore, the GLP-1/glucagon content ratio was increased, suggesting 
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that prohormone processing further increases the GLP-1 product. Considering GLP-1 
content was increased in LP+STZ mice but regeneration failed, there may be a defect in 
the downstream signalling cascade. Moreover, GLP-1 has been shown to initiate PDX-1 
expression in ducts, β-cells and undifferentiated precursors (83; 88-91). It is tempting to 
speculate that GLP-1 signalling may increase PDX-1 expression in intra-islet precursor 
cells, consistent with the increased presence of PDX-1+/insulin— cells in the LP+STZ 
pancreas. However, further differentiation of PDX-1+/insulin— cells into mature β-cells 
appears to be blocked given the reduced β-cell mass in LP+STZ mice.  
Future experiments should examine isolated islets from LP offspring to determine 
whether the defect in GLP-1 signalling occurs at the level of the receptor (measure 
mRNA and protein levels) or the downstream targets. GLP-1 signalling through the GLP-
1R has been demonstrated to involve PI3k, AKT, MAPK and PKCζ (92-94). Western blot 
analysis could be used to measure activation of downstream targets following GLP-1 
treatment of islets from all four groups. Additionally, insulin content, GSIS and 
proliferation can be measured following GLP-1 administration. 
4.5. Limitations and Further Consideration  
Immunohistological analysis of pancreatic tissues has long been the gold standard 
for quantifying changes in islet mass. However, histology is a static measurement and 
may not represent the true dynamics within the pancreas. Furthermore, antibody 
specificity and quality vary and make consistent staining and analysis difficult. The need 
for in vivo imaging of the β-cell has never been greater.  This would allow for real-time 
quantification of β-cell mass and would greatly benefit human studies. Currently the 
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only evidence that can be obtained from humans is post-mortem analysis. Imaging β-cell 
mass would allow for improved identification of β-cell loss and disease progression, as 
well as monitoring survival of islet transplants. Magnetic resonance imaging (MRI) of 
supraparamagnetic iron oxide labelled islets detected as few as 200 labelled islets 
transplanted under the rat kidney capsule (95). In a similar study, labelled human islets 
were transplanted into the portal vein of the mouse liver and the progressive loss of islet 
mass was detected in real time using MRI (96). Another study used positron emission 
tomography (PET) to image islets transplanted under the kidney capsule transfected 
with a thymidine kinase that allows for retention of the contrast agent [18F]FHBG (97). 
Islets had a strong PET signal within the kidney capsule and during peak response of a 
glucose tolerance test, the PET signal was directly correlated with the peak insulin 
response to glucose, showing that it was proportional to the insulin secretory capacity of 
transplanted islets (97).  
Another important consideration for immunohistochemical analysis of β-cell 
regeneration is the use of lineage tracing models. Many studies over the years have 
postulated the origin of new β-cells based on transcription factor and other marker gene 
expression, as well as co-localization of heterogeneous cell markers. For example, 
proliferation of α-cells and demonstration of co-localization of glucagon with PDX-1 or 
GLUT2 during β-cell regeneration shows strong evidence for α- to β-cell 
transdifferentiation (41). However, definitive evidence for this theory was demonstrated 
by Thorel et al. (98) using lineage tracing to label the α-cells, which resulted in 
regenerated β-cells also containing the label.  
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Ultimately therapeutic interventions must be applicable to humans. However, it is 
more feasible to use non-human primates and rodents for disease modelling. Careful 
reflection must be used when translating observations from animal models to humans. 
In humans, islet maturation is complete at birth, while in rodents this occurs by weaning 
(99). For proper comparisons to be made with humans, extension of the LP diet until 
weaning may be required. In adult humans there are approximately 0.05 replicating β-
cells per islet within typical histological sections (100), in contrast with mice at 1 year 
which have ~0.50 replicating β-cells per islet (101). The greater capacity for β-cell 
replication in mice is further evidenced by the tenfold increase in β-cell mass in response 
to insulin resistance in obesity (101), while in humans long term morbid obesity seems 
to result in only ~50% increase in β-cell mass (100). Nevertheless, it remains that 
humans are capable of β-cell proliferation, even in older individuals with long-standing 
type 1 diabetes (102), and neogenesis has also been suggested to occur (reviewed in 
(103)). However, observations of islet neogenesis are largely based on associations of 
single hormone positive cells within the ductal epithelium or small clusters that appear 
to be “budding” from ducts. Again, lineage tracing is required, which cannot be 
performed in humans, and in mice there is a lack of consensus for a true ductal marker 
(SOX9 (104), HNF1β (105), CA II (106)). 
While there is hope for endogenous β-cell regeneration, in the setting of type I 
diabetes there is a requirement for immune suppression to prevent attack on newly 
generated β-cells. In clinical trials, treatment with anti-CD3 antisera delayed progression 
of diabetes through immune suppression in recent onset individuals (107). Current 
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immunosuppressant therapies in patients receiving islet transplantation have produced 
many side effects (108). Additionally, immunosuppressive drugs may reduce β-cell 
function, graft survival and proliferation (109-111). Therefore, the best treatment for 
type 1 diabetes must combine a supply of functional β-cells sufficient to maintain proper 
glucose regulation with an immunosuppressant regime without toxic side effects to the 
individual or newly generated β-cells. Immune suppression is not required in type 2 
diabetes and therefore endogenous regeneration may be more readily applied to type 2 
diabetes to overcome the reduced β-cell function and mass. 
4.6. Concluding Remarks 
This study has established a mouse model for further study of mechanisms 
underlying nutritional insults, such as LP, during fetal development and the increased 
risk for impaired glucose tolerance in adulthood. This mouse model has the advantage of 
using transgenic mice in future studies, over the well established LP rat model. 
Additionally, results from the current study suggest that LP programming of 
mitochondrial function may increase the susceptibility to pancreatic cell dysfunction. 
Further consequences of the LP model include a reduced capacity for β-cell regeneration 
following STZ induced β-cell loss. The ability to stimulate β-cell regeneration is a complex 
prospect and based on the current study, may be dependent on the environmental 
influences during fetal development. Moreover, these findings implicate a limited ability 
to adapt to pathophysiological changes requiring increased β-cell mass such as in obesity 
and pregnancy. In contrast, C-fed offspring demonstrated a significant capacity for β-cell 
regeneration, which may involve β-cell replication or duct associated islet neogenesis 
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and suggests that GLP-1 and/or REG1 may act to stimulate β-cell growth in the multiple 
low dose STZ neonatal mouse model (Figure 4.1). Further studies are required to 
determine how GLP-1 signalling is affected in LP offspring and whether this deficit can be 
overcome to improve β-cell plasticity to prevent long term impairments in low birth 
weight offspring. In conclusion, this study has provided a model that sheds light onto the 
effects of LP exposure in utero on β-cell growth and development and the potential role 
of GLP-1 and Reg1 following β-cell injury.  
  
 
 
165 
 
 
Figure 4.1. Summary of β-cell plasticity in female offspring. 
Following multiple low dose STZ treatment of female offspring from C-fed and LP-
fed dams, β-cell mass was reduced on d7 to 51% and 45% in C+STZ and LP+STZ mice, 
respectively. (a) In C+STZ female offspring, protein levels from isolated islet for Reg1 and 
pancreatic GLP-1 content were significantly increased at d7. Duct associated islet 
neogenesis was increased at d7 and an islet progenitor population expressing Pdx+ but 
lacking insulin was observed at d7 and 14. We postulate that increased levels of Reg1  
(- -) and/or GLP-1 (—) may stimulate differentiation of ductal or islet progenitors leading 
to regeneration of β-cell mass by d30. (b) On d7 and d14 there was a sginficantly 
increased presence of islet progenitors but no increase in duct associated islet 
neogenesis. GLP-1 content was increased at d7, but protein levels for Reg1 were 
reduced. We hypothesize that in LP+STZ female mice, reduced progenitor cell 
differentiation occurs as a result of a lack of Reg1 (- -) protein levels and/or the 
downstream signalling pathway of GLP-1 (—) has been altered due to prior LP exposure, 
leading to a failure in β-cell regeneration. 
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Appendix 
Appendix 1.1. Animal protocol approval
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Appendix 2. Immunohistochemistry Control Experiments 
Appendix 2.1. Control staining for insulin and glucagon 
Immunohistochemical staining was performed as described in the methods section 
(Chapter 2.2) for insulin (a, b) and glucagon (c, d) with the omission of the primary 
antibody (a, c) or the secondary antibody (b, d) to demonstrate specificity of the 
reaction. Immunoadsorption with each primary antibody has been performed 
previously. Primary antibodies used were rabbit anti-insulin and mouse anti-glucagon. 
Magnification bar = 100 μm. 
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Appendix 2.2. Control staining for insulin, glucagon and PCNA 
Immunohistochemical staining was performed as described in the methods section 
(Chapter 2.2) for insulin (a, b), glucagon (c, d) and PCNA (e, f) with the omission of the 
primary antibody (a, c, e) or the secondary antibody (b, d, f) to demonstrate specificity 
of the reaction. Primary antibodies used were guinea pig anti-insulin, rabbit anti-
glucagon and mouse anti-PCNA. Magnification bar = 100 μm. 
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Appendix 2.3. Control stain for insulin and Pdx-1 
Immunofluorescent staining was performed as described in the methods section 
(Chapter 2.2). DAPI (a, c) nuclear stain was used to localize the islet. Omission of the 
primary antibody for insulin (b) and Pdx-1 (d) was performed to demonstrate the 
specificity of the reaction. Primary antibodies used were mouse anti-insulin and rabbit 
anti-Pdx-1. Magnification bar = 250 μm. 
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Appendix 3. Standard Curves 
Appendix 3.1. ELISA standard curve 
An ELISA was performed on serum samples to measure the insulin concentration at d7, 
14 and 30 as described in the methods section (Chapter 2.2). A representative standard 
curve from one experiment is shown here. Concentration on the x-axis is measured in 
ng/mL. 
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Appendix 3.2. BCA assay standard curve 
The protein concentration of cell lysates from whole pancreas tissue used in RIA 
experiments and lysates from isolated islets used in western blot analysis was quantified 
using a micro BCA assay kit as described in the methods section (Chapter 3.2). A 
representative standard curve from one experiment is shown here. Concentration on 
the x-axis is measured in μg/mL. 
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Appendix 3.3. RIA standard curve 
Radioimmunoassays (RIA) were performed on whole pancreas lysates to measure 
pancreatic content for insulin, glucagon and GLP-1 as described in the methods section 
(Chapter 3.2). A representative standard curve from one experiment is shown here, with 
radioactivity measured in counts per min on the y-axis. 
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Appendix 4.1. RNA integrity 
RNA samples extracted from whole pancreas tissue and isolated islets were sent to the 
London Regional Genomics Center for qualitative analysis using the Agilent 2100 
Bioanalyzer. Samples with an RNA Integrity Number (RIN) of at least 6 (a) were 
considered acceptable for use in microarray and real-time PCR experiments. Panel b is 
an example of a sample with a maximal RIN of 10 and the reference ladder is shown in 
panel c. Images show the electropherogram on the left with the fluorescence labelled on 
the y-axis and time on the x-axis. On the right is the gel-like image with 2 dark bands 
corresponding to the 18s and 28s ribosomal bands. Quality of RNA samples were also 
confirmed by spectophotometry. Samples were considered acceptable with an 
absorbance ratio for the 260/280 values of 1.7-2.2. 
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Appendix 5. Primer Validation  
Appendix 5.1. RT-PCR experiments indicating appropriate size of expected products 
RT-PCR was performed to confirm that each primer amplified the expected product at 
the expected base pair size. Insulin I (134 bp), insulin II (90 bp), glucagon (147 bp), beta 
catenin (117 bp), cyclin D1 (129 bp), Cdk4 (87 bp), Reg1 (103 bp), Reg3d (83 bp), 18s 
(145 bp), cyclophilin A (102 bp). A previously tested primer set targeting a gene 
encoding a cytoskeletal protein (known as 15/16) was used as a positive control (+Cnt; 
200 bp). A negative control (-Cnt) consisted of a PCR reaction containing all reagents, 
insulin I primers and ultra pure water substituted for cDNA. 
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Appendix 5.2. Primer efficiency curves 
Real-time RT-PCR was performed for each primer using a dilution series of input cDNA. 
The log of the input cDNA was plotted against the threshold cycle (Ct) and the equation 
for the line of best fit was determined. The slope of the curve indicates the efficiency of 
the primer, with 100% efficiency equal to -3.32. Primer efficiencies were: insulin I – 
111%, insulin II – 106%, glucagon – 98%, beta catenin – 102%, cyclin D1 – 76%, Cdk4 – 
98%, Reg1 – 104%, Reg3δ – 98%, 18s – 90%, cyclophilin A – 106%. All primers were 
determined to have a suitable efficiency for further experimental use. Primers evaluated 
included insulin I, insulin II, glucagon, β-catenin, cyclin D1, Cdk4, Reg1, Reg3δ, 18s and 
cyclophilin A.  
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Appendix 6.1. Specificity of Reg1 antibody in western blot analysis 
Western blot analysis was performed using protein lysates from cells of the rat 
insulinoma cell line, Ins1, freshly isolated islets and whole pancreas tissue. (a) 
Immunoblotting for beta actin (42 kDa) was observed in all 3 samples. (b) Reg1 (14 kDa) 
protein was expressed in islets and pancreas samples but not in the cell line Ins1, as 
expected, showing specificity of the Reg1 antibody. 
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Appendix 7. Microarray Data 
Appendix 7.1. Significantly altered genes in the C+STZ group compared to the C+sham 
group 
Differentially expressed genes between the four groups were selected based on a p-
value cut-off of 0.05 and a fold change of ≥1.5. Fold change represents the difference 
from the C+sham group. A 2-way ANOVA was performed with a Student Newman-Keuls 
post test. 
Gene Symbol Gene Title p-value 
Fold 
change 
Iapp islet amyloid polypeptide 0.002 -5.32 
G6pc2 glucose-6-phosphatase, catalytic, 2 0.001 -5.25 
Iapp islet amyloid polypeptide 0.005 -5.02 
Ins1 insulin I 0.001 -4.96 
Iapp islet amyloid polypeptide 0.004 -3.79 
Ins2 insulin II 0.002 -3.29 
Iapp islet amyloid polypeptide 0.003 -3.29 
Mat2a methionine adenosyltransferase II, alpha 0.029 -3.12 
Mat2a methionine adenosyltransferase II, alpha 0.036 -2.84 
Mat2a methionine adenosyltransferase II, alpha 0.029 -2.78 
Mat2a methionine adenosyltransferase II, alpha 0.032 -2.78 
Neat1 nuclear paraspeckle assembly transcript 1 (non-protein coding) 0.004 -2.33 
Sfi1 Sfi1 homolog, spindle assembly associated (yeast) 0.022 -2.11 
Scg2 secretogranin II 0.026 -2.02 
Tmem27 transmembrane protein 27 0.020 -2.00 
--- --- 0.001 -1.99 
Sfrs7 splicing factor, arginine/serine-rich 7 0.047 -1.99 
Tuba1b tubulin, alpha 1B 0.021 -1.91 
Slc2a2 solute carrier family 2 (facilitated glucose transporter), member 2 0.004 -1.91 
Mat2a methionine adenosyltransferase II, alpha 0.041 -1.88 
Nelf nasal embryonic LHRH factor 0.009 -1.84 
Pcsk2 proprotein convertase subtilisin/kexin type 2 0.015 -1.83 
Mat2a methionine adenosyltransferase II, alpha 0.023 -1.83 
Slc25a4 
solute carrier family 25 (mitochondrial carrier, adenine nucleotide 
translocator 0.020 -1.78 
Hexb hexosaminidase B 0.030 -1.76 
Hnrpdl heterogeneous nuclear ribonucleoprotein D-like 0.006 -1.75 
Ppic peptidylprolyl isomerase C 0.035 -1.72 
Ccnd1 cyclin D1 0.048 -1.72 
Socs3 suppressor of cytokine signaling 3 0.020 -1.71 
Chga chromogranin A 0.026 -1.70 
Tia1 cytotoxic granule-associated RNA binding protein 1 0.046 -1.69 
Pcsk2 proprotein convertase subtilisin/kexin type 2 0.005 -1.68 
Insm1 insulinoma-associated 1 0.008 -1.67 
Trp53bp1 transformation related protein 53 binding protein 1 0.036 -1.66 
Nxph2 neurexophilin 2 0.032 -1.66 
Ccdc34 coiled-coil domain containing 34 0.028 -1.66 
Hook1 hook homolog 1 (Drosophila) 0.009 -1.65 
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D0H4S114 DNA segment, human D4S114 0.024 -1.65 
Hells helicase, lymphoid specific 0.044 -1.64 
Pnn pinin 0.032 -1.64 
Tmem57 transmembrane protein 57 0.010 -1.63 
Dnaja1 DnaJ (Hsp40) homolog, subfamily A, member 1 0.041 -1.62 
Nfkbiz 
nuclear factor of kappa light polypeptide gene enhancer in B-cells 
inhibitor, ze 0.018 -1.61 
Ddx5 DEAD (Asp-Glu-Ala-Asp) box polypeptide 5 0.048 -1.61 
Luc7l2 LUC7-like 2 (S. cerevisiae) 0.026 -1.60 
Gm6159/Hnrnpr predicted gene 6159/heterogeneous nuclear ribonucleoprotein R 0.041 -1.59 
Shcbp1 Shc SH2-domain binding protein 1 0.026 -1.57 
Cdca8 cell division cycle associated 8 0.048 -1.56 
Pisd/Pisd-ps1/Pisd-ps3 
phosphatidylserine decarboxylase/phosphatidylserine decarboxylase, 
pseudogene 0.025 -1.56 
Sf3b1 splicing factor 3b, subunit 1 0.020 -1.56 
Papss2 3'-phosphoadenosine 5'-phosphosulfate synthase 2 0.001 -1.56 
Zfp799 zinc finger protein 799 0.010 -1.55 
LOC632664/Ptprg 
similar to protein tyrosine phosphatase, receptor type, G/protein 
tyrosine phosphatse 0.050 -1.54 
Sfpq 
splicing factor proline/glutamine rich (polypyrimidine tract binding 
protein associated 0.022 -1.54 
Tmem107 transmembrane protein 107 0.006 -1.53 
Rab11fip2 RAB11 family interacting protein 2 (class I) 0.038 -1.53 
5830433M19Rik RIKEN cDNA 5830433M19 gene 0.041 -1.53 
6720475J19Rik RIKEN cDNA 6720475J19 gene 0.012 -1.51 
BC088983 cDNA sequence BC088983 0.029 -1.51 
Pycard PYD and CARD domain containing 0.018 -1.50 
Actb actin, beta 0.008 1.52 
Tsc22d3 TSC22 domain family, member 3 0.049 1.53 
Gm7120 predicted gene 7120 0.022 1.54 
Ndufa6 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 6 (B14) 0.034 1.54 
Ndufc1 NADH dehydrogenase (ubiquinone) 1, subcomplex unknown, 1 0.028 1.55 
9130219A07Rik RIKEN cDNA 9130219A07 gene 0.028 1.56 
Myc myelocytomatosis oncogene 0.033 1.59 
Gm10094/Sap18 predicted gene 10094/Sin3-associated polypeptide 18 0.033 1.62 
Slc19a2 solute carrier family 19 (thiamine transporter), member 2 0.029 1.66 
Gm12844/Rhoa predicted gene 12844/ras homolog gene family, member A 0.042 1.69 
AI646023 expressed sequence AI646023 0.044 1.89 
Slc19a2 solute carrier family 19 (thiamine transporter), member 2 0.012 1.94 
Snd1 staphylococcal nuclease and tudor domain containing 1 0.035 2.20 
Sdf2l1 stromal cell-derived factor 2-like 1 0.044 2.27 
Pim3 proviral integration site 3 0.010 2.29 
--- --- 0.046 2.35 
1200015M12Rik/1200016E2
4Rik/A130040M12Rik/ 
E430024C06Rik 
RIKEN cDNA 1200015M12 gene/RIKEN cDNA 1200016E24 gene/RIKEN 
cDNA A130040 0.049 3.49 
1810009J06Rik/Gm2663 RIKEN cDNA 1810009J06 gene/predicted gene 2663 0.032 3.62 
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Appendix 7.2. Significantly altered genes in the LP+sham group compared to the 
C+sham group 
Differentially expressed genes between the four groups were selected based on a p-
value cut-off of 0.05 and a fold change of ≥1.5. Fold change represents the difference 
from the C+sham group. A 2-way ANOVA was performed with a Student Newman-Keuls 
post test. 
Gene Symbol Gene Title p-value 
Fold 
change 
Iapp islet amyloid polypeptide 0.007 -3.75 
G6pc2 glucose-6-phosphatase, catalytic, 2 0.001 -3.69 
Iapp islet amyloid polypeptide 0.006 -3.44 
Iapp islet amyloid polypeptide 0.005 -3.17 
Gcg glucagon 0.017 -2.97 
Iapp islet amyloid polypeptide 0.003 -2.95 
Mat2a methionine adenosyltransferase II, alpha 0.024 -2.93 
Mat2a methionine adenosyltransferase II, alpha 0.021 -2.90 
Mat2a methionine adenosyltransferase II, alpha 0.020 -2.72 
Mat2a methionine adenosyltransferase II, alpha 0.023 -2.70 
Tmem27 transmembrane protein 27 0.003 -2.50 
Hba-a1/Hba-a2 hemoglobin alpha, adult chain 1/hemoglobin alpha, adult chain 2 0.040 -2.45 
Ins1 insulin I 0.011 -2.43 
Mat2a methionine adenosyltransferase II, alpha 0.029 -2.40 
Hbb-b1/Hbb-b2 hemoglobin, beta adult major chain/hemoglobin, beta adult minor chain 0.013 -2.38 
Sfrs7 splicing factor, arginine/serine-rich 7 0.014 -2.29 
Tuba1b tubulin, alpha 1B 0.006 -2.16 
Ins2 insulin II 0.014 -2.12 
Tubb2a tubulin, beta 2A 0.017 -2.06 
Ddx17 DEAD (Asp-Glu-Ala-Asp) box polypeptide 17 0.026 -2.05 
Vim vimentin 0.025 -2.05 
Rpl13a/Zfp526 ribosomal protein L13A/zinc finger protein 526 0.003 -2.03 
Snhg1 small nucleolar RNA host gene (non-protein coding) 1 0.041 -2.00 
LOC100045999/Ran 
similar to RAN, member RAS oncogene family/RAN, member RAS 
oncogene family 0.020 -1.96 
LOC100045999/ 
LOC640204/Ran 
similar to RAN, member RAS oncogene family/similar to RAN, member 
RAS oncogene family 0.023 -1.95 
Gm10164/Gm10223/ 
Gm10268/Gm10362/ 
Gm4329/Gm6133/Hk1/ 
LOC100048040/Rpl17 
ribosomal protein L17 pseudogene/ribosomal protein L17 
pseudogene/predicted 0.003 -1.94 
--- --- 0.001 -1.92 
Ankrd10 ankyrin repeat domain 10 0.005 -1.91 
Vim vimentin 0.019 -1.90 
Sh3bgrl SH3-binding domain glutamic acid-rich protein like 0.006 -1.89 
--- --- 0.001 -1.86 
Rps18 ribosomal protein S18 0.009 -1.86 
Rpl13a ribosomal protein L13A 0.004 -1.85 
Rps12 ribosomal protein S12 0.006 -1.85 
1110067D22Rik RIKEN cDNA 1110067D22 gene 0.031 -1.84 
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Gm8203/H2afz predicted gene 8203/H2A histone family, member Z 0.009 -1.84 
D0H4S114 DNA segment, human D4S114 0.006 -1.84 
LOC100045999/Ran 
similar to RAN, member RAS oncogene family/RAN, member RAS 
oncogene family 0.033 -1.84 
Rpl9 Ribosomal protein L9 0.009 -1.83 
Nme2 non-metastatic cells 2, protein (NM23B) expressed in 0.006 -1.83 
Ndufb9 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 9 0.006 -1.83 
Mat2a methionine adenosyltransferase II, alpha 0.032 -1.83 
Marcks myristoylated alanine rich protein kinase C substrate 0.001 -1.82 
3300001P08Rik RIKEN cDNA 3300001P08 gene 0.004 -1.81 
LOC100045999/Ran 
similar to RAN, member RAS oncogene family/RAN, member RAS 
oncogene family 0.020 -1.81 
Sst somatostatin 0.017 -1.81 
Ppib peptidylprolyl isomerase B 0.025 -1.81 
Aplnr apelin receptor 0.010 -1.80 
Rpl34 ribosomal protein L34 0.013 -1.80 
Col3a1 collagen, type III, alpha 1 0.038 -1.80 
Tia1 cytotoxic granule-associated RNA binding protein 1 0.019 -1.80 
Gm9844/LOC100048142/ 
Tmsb10 predicted gene 9844/similar to thymosin, beta 10/thymosin, beta 10 0.010 -1.80 
Scg2 secretogranin II 0.036 -1.79 
Rpl22 ribosomal protein L22 0.004 -1.79 
Gm10241/Gm13430/ 
Gm13690/ LOC100046167/ 
Sumo2 
predicted gene 10241/ predicted gene 13430/ predicted gene 13690/ 
similar 0.007 -1.79 
Rps27l ribosomal protein S27-like 0.017 -1.79 
Sfi1 Sfi1 homolog, spindle assembly associated (yeast) 0.039 -1.79 
Gm1821/ Gm8441/ 
LOC218963/ Ubb 
predicted gene 1821/ predicted gene 8441/ ubiquitin pseudogene/ 
ubiquitin 0.005 -1.78 
Rps21 ribosomal protein S21 0.007 -1.77 
Hint1 histidine triad nucleotide binding protein 1 0.011 -1.77 
Mat2a methionine adenosyltransferase II, alpha 0.019 -1.77 
Gm10257/ Gm8524/ H3f3a/ 
H3f3c/ LOC100045490 
predicted gene 10257/ predicted gene 8524/ H3 histone, family 3A/ H3 
hi 0.004 -1.76 
H2afz H2A histone family, member Z 0.016 -1.76 
Rps21 ribosomal protein S21 0.007 -1.76 
Gm10164/ Gm10223/ 
Gm10294/ LOC100041933/ 
LOC100046300/ 
LOC100047874/ Rpl17 
ribosomal protein L17 pseudogene/ ribosomal protein L17 pseudogene/ 
predicted 0.006 -1.76 
Cpe/ LOC100046434 carboxypeptidase E/ similar to carboxypeptidase E 0.028 -1.76 
1810073G21Rik RIKEN cDNA 1810073G21 gene 0.039 -1.76 
Gm10117/ Gm7206/ 
Gm9822/ Rpl9 
ribosomal protein L9 pseudogene/ predicted gene 7206/ ribosomal 
protein L9 0.006 -1.76 
Rps21 ribosomal protein S21 0.019 -1.75 
Ndufb6 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 6 0.006 -1.75 
Polr3k polymerase (RNA) III (DNA directed) polypeptide K 0.049 -1.74 
Hax1 HCLS1 associated X-1 0.006 -1.74 
Sdpr serum deprivation response 0.002 -1.74 
Tmem204 transmembrane protein 204 0.003 -1.74 
Rnaset2a/ Rnaset2b ribonuclease T2A/ ribonuclease T2B 0.005 -1.74 
Rps27l ribosomal protein S27-like 0.015 -1.73 
Rpl22l1 ribosomal protein L22 like 1 0.011 -1.73 
Tuba1a tubulin, alpha 1A 0.011 -1.73 
Ddx5 DEAD (Asp-Glu-Ala-Asp) box polypeptide 5 0.016 -1.73 
Eif3i eukaryotic translation initiation factor 3, subunit I 0.006 -1.73 
Gm10164/ Gm10223/ 
Gm10294/ LOC100041933/ 
LOC100046300/ Rpl17 
ribosomal protein L17 pseudogene/ ribosomal protein L17 pseudogene/ 
predicted 0.010 -1.72 
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Gm15500/ Rpl5 predicted gene 15500/ ribosomal protein L5 0.007 -1.72 
Gm15365/ Tomm20 
predicted gene 15365/ translocase of outer mitochondrial membrane 
20 homolog  0.035 -1.72 
Rpl26 ribosomal protein L26 0.012 -1.72 
D030056L22Rik RIKEN cDNA D030056L22 gene 0.001 -1.72 
Chchd2/ LOC100045688 
coiled-coil-helix-coiled-coil-helix domain containing 2/ similar to coiled-
coil 0.010 -1.71 
Rps10 ribosomal protein S10 0.006 -1.71 
Chac2 ChaC, cation transport regulator homolog 2 (E. coli) 0.032 -1.71 
Rps21 ribosomal protein S21 0.009 -1.71 
Nfkbiz 
nuclear factor of kappa light polypeptide gene enhancer in B-cells 
inhibitor, ze 0.006 -1.71 
Sfpq 
splicing factor proline/glutamine rich (polypyrimidine tract binding 
protein associated) 0.005 -1.71 
Tra2b transformer 2 beta homolog (Drosophila) 0.033 -1.71 
--- --- 0.001 -1.71 
Trp53bp1 transformation related protein 53 binding protein 1 0.019 -1.71 
Rpl35 ribosomal protein L35 0.009 -1.71 
Ogt 
O-linked N-acetylglucosamine (GlcNAc) transferase (UDP-N-
acetylglucosamine:polyp 0.027 -1.70 
Slc2a2 solute carrier family 2 (facilitated glucose transporter), member 2 0.006 -1.70 
Ywhab 
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation 
protein, beta pol 0.040 -1.70 
Cox6a1 cytochrome c oxidase, subunit VI a, polypeptide 1 0.026 -1.70 
Cnn3/ LOC100047856 calponin 3, acidic/ similar to calponin 3, acidic 0.038 -1.70 
Prdx4 peroxiredoxin 4 0.013 -1.70 
Rpl13a ribosomal protein L13A 0.006 -1.69 
Gm10027/ Gm10260/ Rps18 
ribosomal protein S18 pseudogene/ predicted gene 10260/ ribosomal 
protein  0.019 -1.69 
Cav1 caveolin 1, caveolae protein 0.007 -1.69 
Gm6722/ H2afz predicted gene 6722/ H2A histone family, member Z 0.041 -1.69 
Dnpep aspartyl aminopeptidase 0.025 -1.69 
Atp5f1 
ATP synthase, H+ transporting, mitochondrial F0 complex, subunit b, 
isoform 1 0.010 -1.69 
Cox6b1 cytochrome c oxidase, subunit VIb polypeptide 1 0.006 -1.69 
Sepp1 selenoprotein P, plasma, 1 0.006 -1.69 
Rpl35 ribosomal protein L35 0.010 -1.69 
Rps11 ribosomal protein S11 0.008 -1.69 
Dbi diazepam binding inhibitor 0.011 -1.68 
Gm11263/ Gm13654/ 
Gm14138/ Gm6476/ 
Gm8779/ LOC100043734/ 
LOC236932/ LOC639593/ 
Rps6 
predicted gene 11263/ predicted gene 13654/ 40S ribosomal protein S6 
(Phos 0.033 -1.68 
Rps8 ribosomal protein S8 0.006 -1.68 
Rps24 ribosomal protein S24 0.008 -1.68 
Prss3 protease, serine, 3 0.005 -1.68 
Ppic peptidylprolyl isomerase C 0.026 -1.68 
--- --- 0.021 -1.68 
Atp5h ATP synthase, H+ transporting, mitochondrial F0 complex, subunit d 0.003 -1.68 
Gm2962/ Uqcrb predicted gene 2962/ ubiquinol-cytochrome c reductase binding protein 0.034 -1.68 
Morf4l1 mortality factor 4 like 1 0.005 -1.68 
Sdpr serum deprivation response 0.046 -1.68 
Gm6948/ Gm8942/ 
LOC677113/ Rps24 
ribosomal protein S24 pseudogene/ predicted gene 8942/ similar to 
ribosomal 0.016 -1.68 
--- --- 0.001 -1.68 
Gm15451/ Rpl10a ribosomal protein L10a pseudogene/ ribosomal protein L10A 0.010 -1.67 
Fam96a family with sequence similarity 96, member A 0.003 -1.67 
Rpl34 ribosomal protein L34 0.017 -1.67 
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Psma7 proteasome (prosome, macropain) subunit, alpha type 7 0.014 -1.67 
Rpl3 ribosomal protein L3 0.008 -1.67 
Ero1l/ Gm10191/ Gm13004/ 
Gm16382/ Gm7689/ 
Gm9401/ LOC638399/ 
LOC675018/ Rpl31 ERO1-like (S. cerevisiae)/ predicted gene 10191/ predicted gene 13004/  0.008 -1.67 
Rps5 ribosomal protein S5 0.012 -1.66 
Pcsk2 proprotein convertase subtilisin/kexin type 2 0.020 -1.66 
Rps14 ribosomal protein S14 0.007 -1.66 
Emp1 epithelial membrane protein 1 0.016 -1.66 
Ero1l/ Rpl31 ERO1-like (S. cerevisiae)/ ribosomal protein L31 0.009 -1.66 
Sec61b Sec61 beta subunit 0.013 -1.66 
Gm5805/ Rps14 predicted gene 5805/ ribosomal protein S14 0.008 -1.65 
Prdx1 peroxiredoxin 1 0.015 -1.65 
Ggh gamma-glutamyl hydrolase 0.025 -1.65 
Romo1 reactive oxygen species modulator 1 0.013 -1.65 
Oaz1 ornithine decarboxylase antizyme 1 0.021 -1.65 
Rpl13a ribosomal protein L13A 0.007 -1.65 
Pcsk2 proprotein convertase subtilisin/kexin type 2 0.003 -1.65 
Cald1 caldesmon 1 0.002 -1.65 
Rps3 ribosomal protein S3 0.009 -1.65 
Eif4g2 eukaryotic translation initiation factor 4, gamma 2 0.032 -1.64 
Btf3 basic transcription factor 3 0.016 -1.64 
Qdpr quinoid dihydropteridine reductase 0.010 -1.64 
Gm10071/ Gm12918/ 
Gm15710/ Gm5075/ 
Gm9026/ LOC674921/ Rpl13 
predicted gene 10071/ predicted gene 12918/ predicted gene 15710/ 
predicted 0.015 -1.64 
Gm11263/ Gm13654/ 
LOC100043734/ LOC236932/ 
Rps6 
predicted gene 11263/ predicted gene 13654/ similar to ribosomal 
protein S 0.011 -1.64 
Tmsb4x thymosin, beta 4, X chromosome 0.010 -1.64 
Macrod2 MACRO domain containing 2 0.004 -1.64 
Atp5k ATP synthase, H+ transporting, mitochondrial F1F0 complex, subunit e 0.020 -1.64 
Ndufb9 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 9 0.010 -1.64 
Eif5a eukaryotic translation initiation factor 5A 0.040 -1.64 
Gm9354/ LOC100042019/ 
Rps27a 
predicted gene 9354/ similar to fusion protein: ubiquitin (bases 
43_513); rib 0.006 -1.64 
Cox5a cytochrome c oxidase, subunit Va 0.012 -1.64 
Tsc22d1 TSC22 domain family, member 1 0.050 -1.64 
Gm10213/ Gm10247/ 
Gm10296/ Gm15434/ Ino80/ 
LOC100046034/ 
mCG_133520/ Rpl35a 
ribosomal protein L35a pseudogene/ predicted gene 10247/ ribosomal 
protein 0.011 -1.63 
Anxa2 annexin A2 0.019 -1.63 
--- --- 0.013 -1.63 
Gm10119/ Gm9000/ Rps3a predicted gene 10119/ predicted gene 9000/ ribosomal protein S3A 0.022 -1.63 
Tmem208 transmembrane protein 208 0.009 -1.63 
Rpl35 ribosomal protein L35 0.014 -1.63 
Dnpep aspartyl aminopeptidase 0.048 -1.63 
Tpm4 tropomyosin 4 0.010 -1.63 
Rps10 ribosomal protein S10 0.011 -1.62 
Rpl19 ribosomal protein L19 0.013 -1.62 
Rps24 ribosomal protein S24 0.014 -1.62 
Rpl15 ribosomal protein L15 0.012 -1.62 
Actb actin, beta 0.039 -1.62 
Rpsa ribosomal protein SA 0.008 -1.62 
Sec11c SEC11 homolog C (S. cerevisiae) 0.010 -1.62 
Gm10443/ LOC100044740/ 
Rps28 
predicted gene 10443/ similar to ribosomal protein S28/ ribosomal 
protein  0.008 -1.62 
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Hnrnpa2b1 heterogeneous nuclear ribonucleoprotein A2/B1 0.016 -1.62 
Rpl39 ribosomal protein L39 0.011 -1.62 
Myeov2 myeloma overexpressed 2 0.006 -1.62 
Hnrpdl heterogeneous nuclear ribonucleoprotein D-like 0.008 -1.62 
Eef1b2 eukaryotic translation elongation factor 1 beta 2 0.009 -1.62 
Gm13654/ Rps6 predicted gene 13654/ ribosomal protein S6 0.005 -1.62 
Nxph2 neurexophilin 2 0.026 -1.62 
Myadm myeloid-associated differentiation marker 0.001 -1.62 
Tsc22d1 TSC22 domain family, member 1 0.013 -1.61 
Prdx1 peroxiredoxin 1 0.018 -1.61 
Rps24 ribosomal protein S24 0.014 -1.61 
Prdx4 peroxiredoxin 4 0.020 -1.61 
Fabp4 fatty acid binding protein 4, adipocyte 0.024 -1.61 
EG436523/ Gm10334/ Prss1/ 
Prss3 
predicted gene, EG436523/ predicted gene 10334/ protease, serine, 1 
(trypsin) 0.003 -1.61 
Rpl7a ribosomal protein L7A 0.007 -1.61 
Tomm20 translocase of outer mitochondrial membrane 20 homolog (yeast) 0.049 -1.61 
Ndufb11 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 11 0.006 -1.61 
1110003E01Rik RIKEN cDNA 1110003E01 gene 0.014 -1.61 
Morf4l1 mortality factor 4 like 1 0.006 -1.61 
Rps4x ribosomal protein S4, X-linked 0.020 -1.61 
1810027O10Rik RIKEN cDNA 1810027O10 gene 0.010 -1.61 
Matr3 matrin 3 0.042 -1.61 
Cd34 CD34 antigen 0.023 -1.61 
Eif1 eukaryotic translation initiation factor 1 0.013 -1.61 
Gt(ROSA)26Sor gene trap ROSA 26, Philippe Soriano 0.015 -1.60 
Serf2 small EDRK-rich factor 2 0.006 -1.60 
Sep-07 septin 7 0.009 -1.60 
EG668525 Predicted gene, EG668525 0.009 -1.60 
Prdx1 peroxiredoxin 1 0.014 -1.60 
Gm13654/ Rps6 predicted gene 13654/ ribosomal protein S6 0.009 -1.60 
Col4a1 collagen, type IV, alpha 1 0.034 -1.60 
Vamp3 vesicle-associated membrane protein 3 0.000 -1.60 
Eif2s2 eukaryotic translation initiation factor 2, subunit 2 (beta) 0.049 -1.60 
Gng10 guanine nucleotide binding protein (G protein), gamma 10 0.042 -1.60 
Gm10443/ Rps28 predicted gene 10443/ ribosomal protein S28 0.013 -1.60 
Tomm20 translocase of outer mitochondrial membrane 20 homolog (yeast) 0.043 -1.60 
Gm10191/ Gm16382/ 
Gm7689/ LOC638399/ 
LOC675018/ Rpl31 
predicted gene 10191/ ribosomal protein L31 pseudogene/ predicted 
gene 768 0.011 -1.60 
Nfe2l2 nuclear factor, erythroid derived 2, like 2 0.004 -1.60 
Hnrnph1 heterogeneous nuclear ribonucleoprotein H1 0.025 -1.60 
Ppia peptidylprolyl isomerase A 0.043 -1.59 
Gm11793/ Hnrnpf predicted gene 11793/ heterogeneous nuclear ribonucleoprotein F 0.019 -1.59 
Rps8 ribosomal protein S8 0.016 -1.59 
Ndufab1 NADH dehydrogenase (ubiquinone) 1, alpha/beta subcomplex, 1 0.011 -1.59 
Lrpap1 low density lipoprotein receptor-related protein associated protein 1 0.037 -1.59 
Rps7 ribosomal protein S7 0.018 -1.59 
Igfbp4 insulin-like growth factor binding protein 4 0.010 -1.59 
Myeov2 myeloma overexpressed 2 0.030 -1.59 
Hexb hexosaminidase B 0.042 -1.59 
Rpl14 ribosomal protein L14 0.013 -1.59 
Atp5j2 
ATP synthase, H+ transporting, mitochondrial F0 complex, subunit f, 
isoform 2 0.029 -1.59 
Rpl14 ribosomal protein L14 0.020 -1.59 
Gm4076 predicted gene 4076 0.027 -1.59 
Gm10269/ Gm4342/ Rpl35 predicted gene 10269/ predicted gene 4342/ ribosomal protein L35 0.013 -1.59 
Cox6c cytochrome c oxidase, subunit VIc 0.002 -1.59 
Itm2b integral membrane protein 2B 0.011 -1.59 
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H47 histocompatibility 47 0.021 -1.58 
Reep5 receptor accessory protein 5 0.024 -1.58 
Tff2 trefoil factor 2 (spasmolytic protein 1) 0.007 -1.58 
Rpl10 ribosomal protein 10 0.006 -1.58 
Gm10027/ Gm10260/ Rps18 
ribosomal protein S18 pseudogene/ predicted gene 10260/ ribosomal 
protein  0.015 -1.58 
Zzz3 zinc finger, ZZ domain containing 3 0.010 -1.58 
Eif3i eukaryotic translation initiation factor 3, subunit I 0.013 -1.58 
Glrx3 glutaredoxin 3 0.008 -1.58 
Pisd/ Pisd-ps1/ Pisd-ps3 
phosphatidylserine decarboxylase/phosphatidylserine decarboxylase, 
pseudogene 0.014 -1.58 
Hnrpdl heterogeneous nuclear ribonucleoprotein D-like 0.006 -1.58 
Gm10079/ LOC100047501/ 
Rps16 
ribosomal protein S16 pseudogene/ ribosomal protein S16 pseudogene/ 
riboso 0.012 -1.58 
Kpna2 karyopherin (importin) alpha 2 0.037 -1.58 
--- --- 0.004 -1.57 
Serf2 small EDRK-rich factor 2 0.009 -1.57 
Gm10063/ Gm12334/ 
Gm5462/ Gm7567/ Gm9153/ 
LOC676277/ Rps12 
predicted gene 10063/ predicted gene 12334/ ribosomal protein S12 
pseudoge 0.009 -1.57 
Cox7a2 cytochrome c oxidase, subunit VIIa 2 0.020 -1.57 
Ptn pleiotrophin 0.023 -1.57 
--- --- 0.015 -1.57 
Tmem107 transmembrane protein 107 0.002 -1.57 
Rpl7 ribosomal protein L7 0.022 -1.57 
Ndufa1 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 1 0.019 -1.57 
Sfrs11 splicing factor, arginine/serine-rich 11 0.023 -1.57 
P4hb prolyl 4-hydroxylase, beta polypeptide 0.027 -1.57 
1810028F09Rik RIKEN cDNA 1810028F09 gene 0.049 -1.57 
--- --- 0.018 -1.57 
Arl1 ADP-ribosylation factor-like 1 0.013 -1.57 
H47 histocompatibility 47 0.010 -1.57 
9430020K01Rik RIKEN cDNA 9430020K01 gene 0.000 -1.56 
Gm13819/Gm2423/ Ywhaq 
predicted gene 13819/ predicted gene 2423/ tyrosine 3-
monooxygenase/trypto 0.010 -1.56 
--- --- 0.011 -1.56 
1110028C15Rik RIKEN cDNA 1110028C15 gene 0.015 -1.56 
Mrpl13 mitochondrial ribosomal protein L13 0.003 -1.56 
Akr1a4 aldo-keto reductase family 1, member A4 (aldehyde reductase) 0.042 -1.56 
Polr1d polymerase (RNA) I polypeptide D 0.003 -1.56 
Brp44 brain protein 44 0.020 -1.56 
Rpl21 ribosomal protein L21 0.021 -1.56 
Mgst1 microsomal glutathione S-transferase 1 0.018 -1.56 
Gm11793/Hnrnpf predicted gene 11793/heterogeneous nuclear ribonucleoprotein F 0.017 -1.56 
4933421E11Rik RIKEN cDNA 4933421E11 gene 0.010 -1.56 
Neat1 nuclear paraspeckle assembly transcript 1 (non-protein coding) 0.046 -1.56 
Xbp1 X-box binding protein 1 0.013 -1.56 
--- --- 0.019 -1.56 
Serpini2 serine (or cysteine) peptidase inhibitor, clade I, member 2 0.033 -1.56 
Epas1 endothelial PAS domain protein 1 0.046 -1.56 
Gm10443/Rps28 predicted gene 10443/ribosomal protein S28 0.017 -1.56 
LOC100046668/Rps23 
similar to yeast ribosomal protein S28 homologue/ribosomal protein 
S23 0.013 -1.55 
Psmb4 proteasome (prosome, macropain) subunit, beta type 4 0.013 -1.55 
Hnrnph1 Heterogeneous nuclear ribonucleoprotein H1 0.027 -1.55 
Gm12270/Gm15483/ 
Gm6573/Gm6834/ 
LOC100044992/Rps13 
predicted gene 12270/predicted gene 15483/ribosomal protein S13 
pseudogene 0.010 -1.55 
--- --- 0.001 -1.55 
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Gnb2l1 guanine nucleotide binding protein (G protein), beta polypeptide 2 like 1 0.029 -1.55 
Chfr checkpoint with forkhead and ring finger domains 0.010 -1.55 
Gm5963/Rps21 predicted gene 5963/ribosomal protein S21 0.031 -1.55 
Uba2 ubiquitin-like modifier activating enzyme 2 0.003 -1.55 
Rps27l ribosomal protein S27-like 0.029 -1.55 
Rpl14 ribosomal protein L14 0.015 -1.55 
S100a11 S100 calcium binding protein A11 (calgizzarin) 0.019 -1.55 
Gstp1 glutathione S-transferase, pi 1 0.018 -1.55 
Gm6573/Gm6834/ 
LOC100044992/Rps13 
ribosomal protein S13 pseudogene/predicted gene 6834/similar to 
ribosomal S13 0.024 -1.55 
Rpl18 ribosomal protein L18 0.022 -1.55 
Sypl synaptophysin-like protein 0.009 -1.55 
Rpl35 ribosomal protein L35 0.007 -1.55 
--- --- 0.026 -1.55 
Vamp3 vesicle-associated membrane protein 3 0.003 -1.55 
Pdia2 protein disulfide isomerase associated 2 0.016 -1.55 
Rps15a ribosomal protein S15A 0.045 -1.55 
Marcks myristoylated alanine rich protein kinase C substrate 0.011 -1.54 
Serf2 small EDRK-rich factor 2 0.010 -1.54 
Eef1g/LOC100047986 
eukaryotic translation elongation factor 1 gamma/similar to eukaryotic 
translation 0.048 -1.54 
--- --- 0.009 -1.54 
Krtcap2 keratinocyte associated protein 2 0.034 -1.54 
Prdx1 peroxiredoxin 1 0.035 -1.54 
Ythdc1 YTH domain containing 1 0.020 -1.54 
Fbxo22 F-box protein 22 0.016 -1.54 
Ndufb8 NADH dehydrogenase (ubiquinone) 1 beta subcomplex 8 0.014 -1.54 
Sparc secreted acidic cysteine rich glycoprotein 0.046 -1.54 
Rpl13 ribosomal protein L13 0.017 -1.54 
Gm13020/Gm7379/Rpl38 
ribosomal protein L38 pseudogene/ribosomal protein L38 
pseudogene/ribosomal 0.021 -1.54 
Cox4i1 cytochrome c oxidase subunit IV isoform 1 0.035 -1.54 
Atp6v0b ATPase, H+ transporting, lysosomal V0 subunit B 0.006 -1.54 
Rpl7 ribosomal protein L7 0.033 -1.54 
Rpl6 ribosomal protein L6 0.026 -1.54 
Gdi2 guanosine diphosphate (GDP) dissociation inhibitor 2 0.017 -1.54 
Atp5h ATP synthase, H+ transporting, mitochondrial F0 complex, subunit d 0.008 -1.54 
Gm3244/Ndufb4 
predicted gene 3244/NADH dehydrogenase (ubiquinone) 1 beta 
subcomplex 4 0.010 -1.54 
Dbi diazepam binding inhibitor 0.013 -1.53 
Gja1 gap junction protein, alpha 1 0.004 -1.53 
Dynlt3 dynein light chain Tctex-type 3 0.017 -1.53 
Rpl23a ribosomal protein L23a 0.021 -1.53 
Tmed10 transmembrane emp24-like trafficking protein 10 (yeast) 0.041 -1.53 
Ccdc72 coiled-coil domain containing 72 0.036 -1.53 
Gja1 gap junction protein, alpha 1 0.012 -1.53 
Ndufb11 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 11 0.014 -1.53 
Rgs5 regulator of G-protein signaling 5 0.010 -1.53 
Cnn3/LOC100047856 calponin 3, acidic/similar to calponin 3, acidic 0.018 -1.53 
Cst3 cystatin C 0.017 -1.53 
Mff mitochondrial fission factor 0.001 -1.53 
Rps10 ribosomal protein S10 0.022 -1.53 
Igf1 insulin-like growth factor 1 0.045 -1.53 
Rps20 ribosomal protein S20 0.015 -1.53 
--- --- 0.001 -1.52 
Acat1 acetyl-Coenzyme A acetyltransferase 1 0.024 -1.52 
Acat1 acetyl-Coenzyme A acetyltransferase 1 0.050 -1.52 
Gm11599/Gm11687/ 
Gm12091/Gm12366/ 
predicted gene 11599/predicted gene 11687/predicted gene 12091/40S 
R 0.030 -1.52 
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Gm12922/Gm14583/ 
Gm16408/Gm4968/ 
Gm5921/Gm6139/ 
Gm6266/Gm6359/ 
Gm6433/Gm7143/ 
Gm8225/Gm8235/ 
Gm8520/LOC100048354/ 
LOC634916/LOC639606/Rps2 
Ddx5 DEAD (Asp-Glu-Ala-Asp) box polypeptide 5 0.050 -1.52 
Rpl26 ribosomal protein L26 0.041 -1.52 
Insm1 insulinoma-associated 1 0.012 -1.52 
Psmd6 proteasome (prosome, macropain) 26S subunit, non-ATPase, 6 0.013 -1.52 
Aqp1 aquaporin 1 0.003 -1.52 
Gm6159/Hnrnpr predicted gene 6159/heterogeneous nuclear ribonucleoprotein R 0.041 -1.52 
--- --- 0.008 -1.52 
Nelf nasal embryonic LHRH factor 0.030 -1.52 
Gm13611/ LOC100048508/ 
Rpl36 predicted gene 13611/similar to Rpl36 protein/ribosomal protein L36 0.024 -1.52 
Prpf4b PRP4 pre-mRNA processing factor 4 homolog B (yeast) 0.001 -1.51 
Dnaja1 DnaJ (Hsp40) homolog, subfamily A, member 1 0.046 -1.51 
Naca nascent polypeptide-associated complex alpha polypeptide 0.025 -1.51 
Ndufs8 NADH dehydrogenase (ubiquinone) Fe-S protein 8 0.012 -1.51 
Gm11263/Gm12242/ 
Gm13654/Gm14138/ 
Gm16406/Gm4796/ 
Gm6476/Gm9143/ 
LOC100043734/ 
LOC236932/LOC623245/ 
LOC639593/Rps6 
predicted gene 11263/predicted gene 12242/predicted gene 13654/40S 
r 0.013 -1.51 
Wbp5 WW domain binding protein 5 0.037 -1.51 
Basp1/LOC100045716 
brain abundant, membrane attached signal protein 1/similar to 22 kDa 
neuronal 0.001 -1.51 
Jtb jumping translocation breakpoint 0.041 -1.51 
Rpl14 ribosomal protein L14 0.028 -1.51 
Ndufa13 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 13 0.012 -1.51 
Rpl36al ribosomal protein L36A-like 0.025 -1.51 
Sumo1 SMT3 suppressor of mif two 3 homolog 1 (yeast) 0.026 -1.51 
Yif1a Yip1 interacting factor homolog A (S. cerevisiae) 0.010 -1.50 
Rpl27 ribosomal protein L27 0.024 -1.50 
Gm1821/Ubb predicted gene 1821/ubiquitin B 0.027 -1.50 
--- --- 0.010 -1.50 
Gm6301/Rpl27 ribosomal protein L27 pseudogene/ribosomal protein L27 0.043 -1.50 
2810422J05Rik/Gm11808 
/Uba52 
RIKEN cDNA 2810422J05 gene/predicted gene 11808/ubiquitin A-52 
residue r 0.013 -1.50 
Rps17 ribosomal protein S17 0.044 -1.50 
Gm10045/Gm10155/ 
Gm10163/Gm10240/ 
Gm12411/Gm13653/ 
Gm14648/Gm16376/ 
Gm5495/LOC100042767/ 
LOC100047019/ 
LOC100047314/ 
LOC676590/Rpl21 
predicted gene 10045/predicted gene 10155/predicted gene 
10163/predicted 0.032 -1.50 
Atp5j ATP synthase, H+ transporting, mitochondrial F0 complex, subunit F 0.024 -1.50 
Rplp0 ribosomal protein, large, P0 0.043 -1.50 
Cxcr7 chemokine (C-X-C motif) receptor 7 0.017 -1.50 
--- --- 0.019 -1.50 
Marcks myristoylated alanine rich protein kinase C substrate 0.011 -1.50 
B230219D22Rik RIKEN cDNA B230219D22 gene 0.044 -1.50 
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Gtpbp2 GTP binding protein 2 0.002 -1.50 
Scrt2 scratch homolog 2, zinc finger protein (Drosophila) 0.021 1.50 
Zfand2a zinc finger, AN1-type domain 2A 0.020 1.51 
Ceacam1 carcinoembryonic antigen-related cell adhesion molecule 1 0.001 1.51 
Pcca propionyl-Coenzyme A carboxylase, alpha polypeptide 0.009 1.51 
Samhd1 SAM domain and HD domain, 1 0.014 1.53 
Ncam1 neural cell adhesion molecule 1 0.005 1.53 
Pttg1 pituitary tumor-transforming gene 1 0.009 1.53 
St3gal6 ST3 beta-galactoside alpha-2,3-sialyltransferase 6 0.004 1.54 
Gm2380 predicted gene 2380 0.029 1.54 
--- --- 0.034 1.54 
Gdap2 ganglioside-induced differentiation-associated-protein 2 0.026 1.55 
Rab6b RAB6B, member RAS oncogene family 0.001 1.56 
Rnasek ribonuclease, RNase K 0.003 1.57 
Itih4 inter alpha-trypsin inhibitor, heavy chain 4 0.017 1.58 
Tnrc6a trinucleotide repeat containing 6a 0.022 1.61 
--- --- 0.029 1.62 
Gm5620/Gm7172/ 
LOC100045728/Tuba1a 
/Tuba1c predicted gene 5620/predicted gene 7172/similar to tubulin, alpha 1/ 0.000 1.63 
Ddx5 DEAD (Asp-Glu-Ala-Asp) box polypeptide 5 0.008 1.63 
Stap2 signal transducing adaptor family member 2 0.002 1.65 
Hdac11 histone deacetylase 11 0.014 1.66 
Gss glutathione synthetase 0.003 1.75 
Fcgr2b Fc receptor, IgG, low affinity IIb 0.016 1.81 
Klra21 killer cell lectin-like receptor subfamily A, member 21 0.007 1.84 
Car7 carbonic anhydrase 7 0.010 1.86 
1110002E22Rik RIKEN cDNA 1110002E22 gene 0.013 1.89 
Slc5a9 solute carrier family 5 (sodium/glucose cotransporter), member 9 0.005 1.93 
Opa3 optic atrophy 3 (human) 0.003 1.94 
Ang2 angiogenin, ribonuclease A family, member 2 0.012 1.94 
Ptgr2 prostaglandin reductase 2 0.011 1.95 
Actr1a ARP1 actin-related protein 1 homolog A, centractin alpha (yeast) 0.010 2.02 
Hoxa5 homeo box A5 0.004 2.24 
Armc8 armadillo repeat containing 8 0.002 2.26 
Duxbl double homeobox B-like 0.002 2.43 
Vat1 vesicle amine transport protein 1 homolog (T californica) 0.002 2.50 
D13Ertd787e DNA segment, Chr 13, ERATO Doi 787, expressed 0.006 2.67 
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Appendix 7.3. Significantly altered genes in the LP+STZ group compared to the C+STZ 
group 
Differentially expressed genes between the four groups were selected based on a p-
value cut-off of 0.05 and a fold change of ≥1.5. Fold change represents the difference 
from the C+STZ group. A 2-way ANOVA was performed with a Student Newman-Keuls 
post test. 
Gene Symbol Gene Title p-value 
Fold 
change 
Sgk1 serum/glucocorticoid regulated kinase 1 0.039 -3.03 
D4Wsu53e DNA segment, Chr 4, Wayne State University 53, expressed 0.023 -2.63 
Pim3 proviral integration site 3 0.009 -2.33 
--- --- 0.012 -2.18 
Errfi1 ERBB receptor feedback inhibitor 1 0.037 -2.11 
Nupr1 nuclear protein 1 0.012 -2.05 
Rps27 ribosomal protein S27 0.016 -1.98 
Gm7285/ Rps7 predicted gene 7285/ ribosomal protein S7 0.027 -1.95 
Gm4076 predicted gene 4076 0.009 -1.93 
Dbi diazepam binding inhibitor 0.007 -1.92 
Mtm1 X-linked myotubular myopathy gene 1 0.002 -1.91 
Gm13611/ Gm4604/ 
LOC100048508/ Rpl36 
predicted gene 13611/ predicted gene 4604/ similar to Rpl36 protein/ 
ribosomal L36 0.006 -1.90 
Slc19a2 solute carrier family 19 (thiamine transporter), member 2 0.015 -1.90 
Gm4149/ Rpl37a predicted gene 4149/ ribosomal protein L37a 0.013 -1.90 
Dbi diazepam binding inhibitor 0.003 -1.89 
--- --- 0.024 -1.89 
Atp5j2 
ATP synthase, H+ transporting, mitochondrial F0 complex, subunit f, 
isoform 2 0.021 -1.88 
Fau/ Gm9843 
Finkel-Biskis-Reilly murine sarcoma virus (FBR-MuSV) ubiquitously 
expressed (fox) 0.028 -1.88 
Ndufc1 NADH dehydrogenase (ubiquinone) 1, subcomplex unknown, 1 0.006 -1.85 
Gm10269/ Gm4342/ Rpl35 predicted gene 10269/ predicted gene 4342/ ribosomal protein L35 0.005 -1.85 
Gm3244/ Ndufb4 
predicted gene 3244/ NADH dehydrogenase (ubiquinone) 1 beta 
subcomplex 4 0.008 -1.85 
Rps9 ribosomal protein S9 0.008 -1.85 
Gm13611/ LOC100048508/ 
Rpl36 predicted gene 13611/ similar to Rpl36 protein/ ribosomal protein L36 0.007 -1.85 
Rplp2 ribosomal protein, large P2 0.010 -1.85 
Ndufa7 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 7 (B14.5a) 0.007 -1.84 
Dbi diazepam binding inhibitor 0.017 -1.84 
Cox7a2 cytochrome c oxidase, subunit VIIa 2 0.009 -1.84 
Gm13611/ Gm4604/ 
LOC100048508/ Rpl36 
predicted gene 13611/ predicted gene 4604/ similar to Rpl36 protein/ 
ribosomal protein L36 0.013 -1.83 
Gm10079/ Rps16 ribosomal protein S16 pseudogene/ ribosomal protein S16 0.011 -1.83 
Nupr1 nuclear protein 1 0.011 -1.82 
Ndufb2 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 2 0.003 -1.81 
--- --- 0.001 -1.81 
Ube2d3 ubiquitin-conjugating enzyme E2D 3 (UBC4/5 homolog, yeast) 0.047 -1.81 
Ndufa6 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 6 (B14) 0.009 -1.80 
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Gm3362/ Rpl23a predicted gene 3362/ ribosomal protein L23a 0.011 -1.80 
Uqcr ubiquinol-cytochrome c reductase (6.4kD) subunit 0.010 -1.80 
Cox6b1 cytochrome c oxidase, subunit VIb polypeptide 1 0.007 -1.79 
Rpl35 ribosomal protein L35 0.010 -1.79 
Rps17 ribosomal protein S17 0.019 -1.78 
Atp5l ATP synthase, H+ transporting, mitochondrial F0 complex, subunit g 0.007 -1.78 
Klk1b5 kallikrein 1-related peptidase b5 0.046 -1.78 
Atp5j ATP synthase, H+ transporting, mitochondrial F0 complex, subunit F 0.009 -1.78 
Rpl35 ribosomal protein L35 0.011 -1.78 
Atp5j2 
ATP synthase, H+ transporting, mitochondrial F0 complex, subunit f, 
isoform 2 0.019 -1.77 
Gm14303/ Rps29 predicted gene 14303/ ribosomal protein S29 0.012 -1.77 
Rpl34 ribosomal protein L34 0.018 -1.77 
Ndufa4 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4 0.038 -1.77 
Tmed11 transmembrane emp24 protein transport domain containing 0.046 -1.76 
Ccnl2 cyclin L2 0.038 -1.76 
Uqcrq ubiquinol-cytochrome c reductase, complex III subunit VII 0.011 -1.75 
Rpl35 ribosomal protein L35 0.013 -1.75 
Rps21 ribosomal protein S21 0.014 -1.75 
Rpl26 ribosomal protein L26 0.017 -1.75 
Rpl23a ribosomal protein L23a 0.010 -1.75 
Uqcrh ubiquinol-cytochrome c reductase hinge protein 0.004 -1.74 
Rpl32 ribosomal protein L32 0.014 -1.74 
Rpl12 ribosomal protein L12 0.014 -1.74 
Sepw1 selenoprotein W, muscle 1 0.010 -1.74 
Gm10213/ Gm10247/ 
Gm10296/ Gm15434/ Ino80/ 
LOC100046034/ 
mCG_133520/ Rpl35a 
ribosomal protein L35a pseudogene/ predicted gene 10247/ ribosomal 
protein 0.011 -1.74 
--- --- 0.002 -1.74 
Rps7 ribosomal protein S7 0.027 -1.74 
Gm11353/ Gm14289/ 
Gm15501/ Gm6998/ 
LOC100042180/ 
LOC100048094/ Rps8 
predicted gene 11353/ ribosomal protein S8 (Rps8) pseudogene/ 
predicted gene 0.021 -1.74 
Rps15 ribosomal protein S15 0.011 -1.74 
LOC100046223/ Rps15 similar to insulinoma protein (rig)/ ribosomal protein S15 0.008 -1.73 
Rpl37a ribosomal protein L37a 0.024 -1.73 
Rps10 ribosomal protein S10 0.013 -1.73 
Rpl9 Ribosomal protein L9 0.023 -1.73 
Ssr4 signal sequence receptor, delta 0.014 -1.73 
Hist1h2bc/ Hist1h2be/ 
Hist1h2bl/ Hist1h2bm/ 
Hist1h2bp/ LOC100046213/ 
LOC665622/ RP23-38E20.1 histone cluster 1, H2bc/ histone cluster 1, H2be/ histone cluster 1, H2bl  0.041 -1.73 
Atp5e 
ATP synthase, H+ transporting, mitochondrial F1 complex, epsilon 
subunit 0.007 -1.73 
Gm10709/ Gm12447/ 
Gm12704/ Gm13841/ 
Gm5561/ Gm6344/ Gm8088/ 
Rpl29 
predicted gene 10709/ predicted gene 12447/ predicted gene 12704/ 
predicted 0.017 -1.73 
Dad1 defender against cell death 1 0.025 -1.72 
Rpl34 ribosomal protein L34 0.029 -1.72 
Dbi diazepam binding inhibitor 0.016 -1.72 
Edf1 endothelial differentiation-related factor 1 0.032 -1.72 
Hist1h2bc histone cluster 1, H2bc 0.016 -1.72 
Bsg basigin 0.045 -1.72 
Rps11 ribosomal protein S11 0.011 -1.71 
Itm2b integral membrane protein 2B 0.017 -1.71 
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Gm6948/ Gm8942/ 
LOC677113/ Rps24 
ribosomal protein S24 pseudogene/ predicted gene 8942/ similar to 
ribosomal 0.022 -1.71 
Ndufb6 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 6 0.011 -1.71 
Cox6c cytochrome c oxidase, subunit VIc 0.004 -1.71 
Gm6301/ Rpl27 ribosomal protein L27 pseudogene/ ribosomal protein L27 0.023 -1.71 
Gm6573/ Gm6834/ 
LOC100044992/ Rps13 
ribosomal protein S13 pseudogene/ predicted gene 6834/ similar to 
ribosomal 0.016 -1.71 
Rabac1 Rab acceptor 1 (prenylated) 0.010 -1.70 
Rpl23 ribosomal protein L23 0.018 -1.70 
Atp5k ATP synthase, H+ transporting, mitochondrial F1F0 complex, subunit e 0.014 -1.70 
Gm10027/ Gm10260/ Rps18 
ribosomal protein S18 pseudogene/ predicted gene 10260/ ribosomal 
protein  0.030 -1.70 
Atp5k ATP synthase, H+ transporting, mitochondrial F1F0 complex, subunit e 0.015 -1.70 
--- --- 0.005 -1.70 
Gm10709/ Gm12508/ 
Gm13841/ Gm5561/ 
Gm6344/ Rpl29 
predicted gene 10709/ predicted gene 12508/ predicted gene 13841/ 
predicted 0.023 -1.70 
Txn1 thioredoxin 1 0.018 -1.69 
Rpl22 ribosomal protein L22 0.010 -1.69 
Reep5 receptor accessory protein 5 0.022 -1.69 
Eif4a2 eukaryotic translation initiation factor 4A2 0.042 -1.69 
Cox6a1/ Gm7795 cytochrome c oxidase, subunit VI a, polypeptide 1/ predicted gene 7795 0.012 -1.69 
Cox6c cytochrome c oxidase, subunit VIc 0.002 -1.69 
Rpl14 ribosomal protein L14 0.016 -1.69 
LOC100046668/ Rps23 
similar to yeast ribosomal protein S28 homologue/ ribosomal protein 
S23 0.010 -1.69 
Gm10027/ Gm10260/ Rps18 
ribosomal protein S18 pseudogene/ predicted gene 10260/ ribosomal 
protein  0.014 -1.69 
Ndufb11 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 11 0.007 -1.68 
Rps17 ribosomal protein S17 0.028 -1.68 
Tmed6 transmembrane emp24 protein transport domain containing 6 0.010 -1.68 
Rps19 ribosomal protein S19 0.009 -1.68 
Atp5o/ LOC100047429 
ATP synthase, H+ transporting, mitochondrial F1 complex, O subunit/ 
similar to 0.018 -1.68 
Gm3244/ Ndufb4 
predicted gene 3244/ NADH dehydrogenase (ubiquinone) 1 beta 
subcomplex 4 0.007 -1.68 
Gm12967/ Gm4468/ Rpl37 predicted gene 12967/ predicted gene 4468/ ribosomal protein L37 0.031 -1.68 
Ndufa1 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 1 0.016 -1.68 
Gm10051/ Gm15435/ Rpl28 
predicted gene 10051/ ribosomal protein L28 pseudogene/ ribosomal 
protein  0.016 -1.68 
Eif3k eukaryotic translation initiation factor 3, subunit K 0.014 -1.68 
Atp2c2 ATPase, Ca++ transporting, type 2C, member 2 0.001 -1.67 
2810422J05Rik/ Gm11808/ 
Uba52 
RIKEN cDNA 2810422J05 gene/ predicted gene 11808/ ubiquitin A-52 
residue r 0.015 -1.67 
Rps24 ribosomal protein S24 0.017 -1.67 
Hist1h2ad/ Hist1h2an/ 
Hist2h2aa1/ Hist2h2aa2/ 
Hist2h2ac/ Hist2h3c1 
histone cluster 1, H2ad/ histone cluster 1, H2an/ histone cluster 2, 
H2aa1 0.005 -1.67 
Rpl14 ribosomal protein L14 0.020 -1.67 
Gpx1 glutathione peroxidase 1 0.011 -1.67 
Naca nascent polypeptide-associated complex alpha polypeptide 0.026 -1.67 
Rps27l ribosomal protein S27-like 0.024 -1.67 
Rps25 ribosomal protein S25 0.013 -1.67 
Gm10164/ Gm10223/ 
Gm10294/ LOC100041933/ 
LOC100046300/ Rpl17 
ribosomal protein L17 pseudogene/ ribosomal protein L17 pseudogene/ 
predicted 0.021 -1.67 
--- --- 0.006 -1.67 
2010107H07Rik RIKEN cDNA 2010107H07 gene 0.014 -1.67 
Ndufb2 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 2 0.003 -1.67 
 
 
205 
 
Rpl41 ribosomal protein L41 0.005 -1.67 
Snrpd3 small nuclear ribonucleoprotein D3 0.020 -1.67 
Gm14303/ Rps29 predicted gene 14303/ ribosomal protein S29 0.023 -1.67 
Ndufv2 NADH dehydrogenase (ubiquinone) flavoprotein 2 0.014 -1.66 
Atp5h ATP synthase, H+ transporting, mitochondrial F0 complex, subunit d 0.007 -1.66 
Rpl18a ribosomal protein L18A 0.016 -1.66 
Ftl1 ferritin light chain 1 0.022 -1.66 
Reep5 receptor accessory protein 5 0.006 -1.66 
Ndufa3 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 3 0.013 -1.66 
Eif5a eukaryotic translation initiation factor 5A 0.038 -1.66 
Rpl19 ribosomal protein L19 0.018 -1.66 
Rpl15 ribosomal protein L15 0.017 -1.66 
Gm2614/ Rps17 predicted gene 2614/ ribosomal protein S17 0.020 -1.66 
Rps17 ribosomal protein S17 0.030 -1.66 
Rpl14 ribosomal protein L14 0.014 -1.66 
Pfdn5 prefoldin 5 0.010 -1.66 
Rpl11 ribosomal protein L11 0.019 -1.65 
Gm10164/ Gm10223/ 
Gm10268/ Gm10362/ 
Gm4329/ Gm6133/ Hk1/ 
LOC100048040/ Rpl17 
ribosomal protein L17 pseudogene/ ribosomal protein L17 pseudogene/ 
predic 0.020 -1.65 
Map1lc3b microtubule-associated protein 1 light chain 3 beta 0.006 -1.65 
Gm10071/ Gm12918/ 
Gm15710/ Rpl13 
predicted gene 10071/ predicted gene 12918/ predicted gene 15710/ 
ribos 0.025 -1.65 
Oaz1 ornithine decarboxylase antizyme 1 0.032 -1.65 
Rpl35 ribosomal protein L35 0.006 -1.65 
Cst3 cystatin C 0.013 -1.65 
Rpl13a/ Zfp526 ribosomal protein L13A/ zinc finger protein 526 0.026 -1.65 
Slc19a2 solute carrier family 19 (thiamine transporter), member 2 0.031 -1.65 
--- --- 0.013 -1.65 
Rps3 ribosomal protein S3 0.015 -1.65 
2310016E02Rik RIKEN cDNA 2310016E02 gene 0.010 -1.65 
Myc myelocytomatosis oncogene 0.025 -1.65 
Ndufs8 NADH dehydrogenase (ubiquinone) Fe-S protein 8 0.008 -1.65 
Ndufs8 NADH dehydrogenase (ubiquinone) Fe-S protein 8 0.041 -1.65 
Ndufa3 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 3 0.009 -1.64 
Rps24 ribosomal protein S24 0.019 -1.64 
Krtcap2 keratinocyte associated protein 2 0.030 -1.64 
Psmb10 proteasome (prosome, macropain) subunit, beta type 10 0.005 -1.64 
Gm11425/ Gm4957/ 
Gm5962/ Gm6285/ Gm6336/ 
Gm7117/ LOC546695/ 
LOC630855/ LOC639477/ 
Rpl12 
predicted gene 11425/ ribosomal protein L12 pseudogene/ predicted 
gene 596 0.011 -1.64 
Gm10709/ Gm13841/ 
Gm5561/ Gm6344/ Rpl29 
predicted gene 10709/ predicted gene 13841/ predicted gene 5561/ 
predic 0.025 -1.64 
Rpl13a ribosomal protein L13A 0.017 -1.64 
Qdpr quinoid dihydropteridine reductase 0.037 -1.64 
Gm10709/ Gm13841/ 
Gm3550/ Gm6344/ Rpl29 
predicted gene 10709/ predicted gene 13841/ predicted gene 3550/ 
predic 0.030 -1.64 
Rps10 ribosomal protein S10 0.017 -1.64 
Rps18 ribosomal protein S18 0.038 -1.64 
Ggh gamma-glutamyl hydrolase 0.040 -1.64 
Ndufs8 NADH dehydrogenase (ubiquinone) Fe-S protein 8 0.008 -1.64 
Gm10117/ Gm7206/ 
Gm9822/ Rpl9 
ribosomal protein L9 pseudogene/ predicted gene 7206/ ribosomal 
protein L9 0.017 -1.64 
--- --- 0.027 -1.64 
1110002B05Rik RIKEN cDNA 1110002B05 gene 0.009 -1.64 
Stk24 serine/threonine kinase 24 (STE20 homolog, yeast) 0.044 -1.64 
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Tbca tubulin cofactor A 0.021 -1.64 
Gm10335/ Rpl23a predicted gene 10335/ ribosomal protein L23a 0.013 -1.64 
Ndufa13 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 13 0.009 -1.64 
Sec61b Sec61 beta subunit 0.024 -1.64 
Gal galanin 0.012 -1.64 
Gm10045/ Gm10155/ 
Gm10163/ Gm10240/ 
Gm12411/ Gm13653/ 
Gm14648/ Gm16376/ 
Gm5495/ LOC100042767/ 
LOC100047019/ 
LOC100047314/ LOC676590/ 
Rpl21 
predicted gene 10045/ predicted gene 10155/ predicted gene 10163/ 
predicted 0.023 -1.64 
Cox7a2 cytochrome c oxidase, subunit VIIa 2 0.019 -1.63 
Sec61g SEC61, gamma subunit 0.039 -1.63 
LOC100048449/ Rpl18 similar to ribosomal protein L18/ ribosomal protein L18 0.032 -1.63 
Eif3i eukaryotic translation initiation factor 3, subunit I 0.016 -1.63 
Rpl37 ribosomal protein L37 0.034 -1.63 
Fabp4 fatty acid binding protein 4, adipocyte 0.018 -1.63 
Hnrnpa1 heterogeneous nuclear ribonucleoprotein A1 0.035 -1.63 
Rps10 ribosomal protein S10 0.019 -1.63 
Ifitm2 interferon induced transmembrane protein 2 0.038 -1.63 
Erp27 endoplasmic reticulum protein 27 0.009 -1.63 
Prss3 protease, serine, 3 0.011 -1.63 
Rpl22l1 ribosomal protein L22 like 1 0.030 -1.63 
Gm9385/ Rpl24 predicted gene 9385/ ribosomal protein L24 0.017 -1.63 
Gm13020/ Gm7379/ Rpl38 
ribosomal protein L38 pseudogene/ ribosomal protein L38 pseudogene/ 
riboso 0.020 -1.63 
Gm10164/ Gm10223/ 
Gm10294/ LOC100041933/ 
LOC100046300/ 
LOC100047874/ Rpl17 
ribosomal protein L17 pseudogene/ ribosomal protein L17 pseudogene/ 
predicted 0.021 -1.63 
Rps21 ribosomal protein S21 0.024 -1.62 
Rpl21 ribosomal protein L21 0.024 -1.62 
Rps14 ribosomal protein S14 0.014 -1.62 
Rps5 ribosomal protein S5 0.025 -1.62 
--- --- 0.028 -1.62 
Ndufa11 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 11 0.014 -1.62 
Rpl14 ribosomal protein L14 0.017 -1.62 
Gm15451/ Rpl10a ribosomal protein L10a pseudogene/ ribosomal protein L10A 0.022 -1.62 
--- --- 0.024 -1.62 
1810005K13Rik RIKEN cDNA 1810005K13 gene 0.029 -1.62 
Gstm2 glutathione S-transferase, mu 2 0.022 -1.62 
Cox4i1 cytochrome c oxidase subunit IV isoform 1 0.035 -1.62 
--- --- 0.007 -1.62 
Rpsa ribosomal protein SA 0.014 -1.62 
Ufm1 ubiquitin-fold modifier 1 0.049 -1.61 
Rps8 ribosomal protein S8 0.015 -1.61 
Rps24 ribosomal protein S24 0.020 -1.61 
Rps26 ribosomal protein S26 0.032 -1.61 
Chchd10 coiled-coil-helix-coiled-coil-helix domain containing 10 0.007 -1.61 
Gm10335/ Gm3940/ 
Gm5384/ Gm7413/ Gm8158/ 
LOC100042058/ Rpl23a 
predicted gene 10335/ predicted gene 3940/ predicted gene 5384/ 
predicted 0.024 -1.61 
Akr1a4 aldo-keto reductase family 1, member A4 (aldehyde reductase) 0.050 -1.61 
Atp5k ATP synthase, H+ transporting, mitochondrial F1F0 complex, subunit e 0.037 -1.61 
Rps15a ribosomal protein S15A 0.049 -1.61 
Rps8 ribosomal protein S8 0.024 -1.61 
Fabp4 fatty acid binding protein 4, adipocyte 0.038 -1.61 
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Gm10119/ Gm9000/ Rps3a predicted gene 10119/ predicted gene 9000/ ribosomal protein S3A 0.039 -1.61 
Eif1 eukaryotic translation initiation factor 1 0.026 -1.61 
1810046J19Rik RIKEN cDNA 1810046J19 gene 0.012 -1.61 
Gm13654/ Rps6 predicted gene 13654/ ribosomal protein S6 0.014 -1.61 
Rpl39 ribosomal protein L39 0.019 -1.61 
Rpl7 ribosomal protein L7 0.035 -1.61 
--- --- 0.046 -1.60 
Rpl27a ribosomal protein L27A 0.018 -1.60 
Rplp1 ribosomal protein, large, P1 0.019 -1.60 
Cstb cystatin B 0.011 -1.60 
Mettl7a1 methyltransferase like 7A1 0.031 -1.60 
Spint2 serine protease inhibitor, Kunitz type 2 0.047 -1.60 
Ero1l/ Gm10191/ Gm13004/ 
Gm16382/ Gm7689/ 
Gm9401/ LOC638399/ 
LOC675018/ Rpl31 ERO1-like (S. cerevisiae)/ predicted gene 10191/ predicted gene 13004/  0.019 -1.60 
Qdpr quinoid dihydropteridine reductase 0.021 -1.60 
Gm10191/ Gm16382/ 
Gm7689/ LOC638399/ 
LOC675018/ Rpl31 
predicted gene 10191/ ribosomal protein L31 pseudogene/ predicted 
gene 768 0.017 -1.60 
Jtb jumping translocation breakpoint 0.039 -1.60 
Lgals1 lectin, galactose binding, soluble 1 0.015 -1.60 
Gm2614/ Gm5215/ Gm7780/ 
LOC674335/ Rps17 
predicted gene 2614/ predicted gene 5215/ predicted gene 7780/ 
hypothetical 0.023 -1.60 
Tmed3 transmembrane emp24 domain containing 3 0.027 -1.60 
Rplp0 ribosomal protein, large, P0 0.039 -1.60 
Rpl18 ribosomal protein L18 0.027 -1.60 
Ndufb6 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 6 0.024 -1.60 
Rpl13a ribosomal protein L13A 0.010 -1.59 
Hint1 histidine triad nucleotide binding protein 1 0.042 -1.59 
Rpl7a ribosomal protein L7A 0.013 -1.59 
Atp5f1 
ATP synthase, H+ transporting, mitochondrial F0 complex, subunit b, 
isoform 1 0.027 -1.59 
--- --- 0.042 -1.59 
Rpl7 ribosomal protein L7 0.030 -1.59 
Tmem208 transmembrane protein 208 0.018 -1.59 
Eef1d 
eukaryotic translation elongation factor 1 delta (guanine nucleotide 
exchange protein) 0.014 -1.59 
--- --- 0.002 -1.59 
Ero1l/ Rpl31 ERO1-like (S. cerevisiae)/ ribosomal protein L31 0.022 -1.59 
Btbd3 BTB (POZ) domain containing 3 0.043 -1.59 
Eif3h eukaryotic translation initiation factor 3, subunit H 0.014 -1.59 
Pfdn5 prefoldin 5 0.002 -1.59 
Rps7 ribosomal protein S7 0.030 -1.59 
Ndufb9 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 9 0.031 -1.59 
Romo1 reactive oxygen species modulator 1 0.030 -1.59 
Eef1b2 eukaryotic translation elongation factor 1 beta 2 0.018 -1.58 
Gnb2l1 guanine nucleotide binding protein (G protein), beta polypeptide 2 like 1 0.038 -1.58 
Rhoa ras homolog gene family, member A 0.028 -1.58 
Nme2 non-metastatic cells 2, protein (NM23B) expressed in 0.033 -1.58 
Ndufv3 NADH dehydrogenase (ubiquinone) flavoprotein 3 0.012 -1.58 
2810422J05Rik/ Gm11808/ 
Uba52 
RIKEN cDNA 2810422J05 gene/ predicted gene 11808/ ubiquitin A-52 
residue r 0.013 -1.58 
Chchd2/ LOC100045688/ 
Scand3 
coiled-coil-helix-coiled-coil-helix domain containing 2/ similar to coiled-
coil 0.032 -1.58 
5730427N09Rik RIKEN cDNA 5730427N09 gene 0.003 -1.58 
Rpl36al ribosomal protein L36A-like 0.025 -1.58 
Gm10443/ Rps28 predicted gene 10443/ ribosomal protein S28 0.023 -1.58 
Gm10063/ Gm12334/ predicted gene 10063/ predicted gene 12334/ ribosomal protein S12 0.015 -1.58 
 
 
208 
 
Gm5462/ Gm7567/ Gm9153/ 
LOC676277/ Rps12 
pseudogene 
Gabarapl1 gamma-aminobutyric acid (GABA) A receptor-associated protein-like 1 0.010 -1.58 
Rpl18 ribosomal protein L18 0.013 -1.58 
Prdx4 peroxiredoxin 4 0.038 -1.58 
Gm10079/ LOC100047501/ 
Rps16 
ribosomal protein S16 pseudogene/ ribosomal protein S16 pseudogene/ 
ribosomal 0.019 -1.58 
Lcmt1 leucine carboxyl methyltransferase 1 0.012 -1.58 
Mrpl52 mitochondrial ribosomal protein L52 0.024 -1.58 
Atp5g1/ Gm10039 
ATP synthase, H+ transporting, mitochondrial F0 complex, subunit c 
(subunit 9),  0.049 -1.58 
LOC100047839/ Tomm6 
hypothetical protein LOC100047839/ translocase of outer mitochondrial 
membrane 0.037 -1.58 
Ndufb11 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 11 0.013 -1.57 
Rpl13 ribosomal protein L13 0.022 -1.57 
Rps10 ribosomal protein S10 0.022 -1.57 
Ube2b ubiquitin-conjugating enzyme E2B, RAD6 homology (S. cerevisiae) 0.043 -1.57 
Serf2 small EDRK-rich factor 2 0.015 -1.57 
Gng5 guanine nucleotide binding protein (G protein), gamma 5 0.031 -1.57 
Higd2a HIG1 domain family, member 2A 0.002 -1.57 
Ftl1/ Ftl2/ Gm10116 
ferritin light chain 1/ ferritin light chain 2/ ferritin light chain 1 
pseudogene 0.039 -1.57 
--- --- 0.005 -1.57 
LOC100044627/ Rpl23 similar to HL23 ribosomal protein/ ribosomal protein L23 0.021 -1.57 
Atp5g3 
ATP synthase, H+ transporting, mitochondrial F0 complex, subunit c 
(subunit 9),  0.036 -1.57 
Hbxip hepatitis B virus x interacting protein 0.028 -1.57 
Cox5b cytochrome c oxidase, subunit Vb 0.013 -1.56 
Gm11263/ Gm13654/ 
LOC100043734/ LOC236932/ 
Rps6 
predicted gene 11263/ predicted gene 13654/ similar to ribosomal 
protein S 0.027 -1.56 
Naca nascent polypeptide-associated complex alpha polypeptide 0.029 -1.56 
Kdelr1 
KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention 
receptor 1 0.020 -1.56 
Rpl23 ribosomal protein L23 0.030 -1.56 
Atp5d ATP synthase, H+ transporting, mitochondrial F1 complex, delta subunit 0.015 -1.56 
Ndufb9 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 9 0.025 -1.56 
Rpl13a ribosomal protein L13A 0.021 -1.56 
Cox6b1 cytochrome c oxidase, subunit VIb polypeptide 1 0.005 -1.56 
Hnrpdl heterogeneous nuclear ribonucleoprotein D-like 0.012 -1.56 
Ndufc1 NADH dehydrogenase (ubiquinone) 1, subcomplex unknown, 1 0.024 -1.56 
H2afj H2A histone family, member J 0.003 -1.56 
Gm10443/ Rps28 predicted gene 10443/ ribosomal protein S28 0.026 -1.56 
Nid1 nidogen 1 0.017 -1.56 
Ndufa7 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 7 (B14.5a) 0.006 -1.56 
--- --- 0.011 -1.56 
Gm10071/ Gm12918/ 
Gm15710/ Gm5075/ 
Gm9026/ LOC674921/ Rpl13 
predicted gene 10071/ predicted gene 12918/ predicted gene 15710/ 
predicted 0.037 -1.56 
Ndufb5 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 5 0.040 -1.56 
Gm10241/ Gm13430/ 
Gm13690/ LOC100046167/ 
Sumo2 
predicted gene 10241/ predicted gene 13430/ predicted gene 13690/ 
similar 0.038 -1.56 
Gm15500/ Rpl5 predicted gene 15500/ ribosomal protein L5 0.028 -1.56 
Btf3 basic transcription factor 3 0.007 -1.56 
Gnmt glycine N-methyltransferase 0.043 -1.56 
Myeov2 myeloma overexpressed 2 0.015 -1.56 
Atp5g2 
ATP synthase, H+ transporting, mitochondrial F0 complex, subunit c 
(subunit 9),  0.007 -1.55 
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Gm9786/ Oaz1 
ornithine decarboxylase antizyme 1 pseudogene/ ornithine 
decarboxylase antizy 0.024 -1.55 
Gm3379/ Gm4892/ Gm7476/ 
Rpl10 
predicted gene 3379/ ribosomal protein 10 pseudogene/ 60S ribosomal 
protein 0.035 -1.55 
Gm13654/ Rps6 predicted gene 13654/ ribosomal protein S6 0.013 -1.55 
--- --- 0.033 -1.55 
1110003E01Rik RIKEN cDNA 1110003E01 gene 0.031 -1.55 
Gm5805/ Rps14 predicted gene 5805/ ribosomal protein S14 0.025 -1.55 
Gabarap gamma-aminobutyric acid receptor associated protein 0.025 -1.55 
Ptpla 
protein tyrosine phosphatase-like (proline instead of catalytic arginine), 
member 0.028 -1.55 
Rpl6 ribosomal protein L6 0.038 -1.55 
Rala v-ral simian leukemia viral oncogene homolog A (ras related) 0.019 -1.55 
Hamp2 hepcidin antimicrobial peptide 2 0.004 -1.55 
Cox5b cytochrome c oxidase, subunit Vb 0.011 -1.55 
Ndufa7 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 7 (B14.5a) 0.018 -1.55 
Gm14303/ Rps29 predicted gene 14303/ ribosomal protein S29 0.015 -1.55 
Cml1 camello-like 1 0.010 -1.55 
Fkbp2 FK506 binding protein 2 0.045 -1.54 
Mrps28 mitochondrial ribosomal protein S28 0.017 -1.54 
1110003E01Rik RIKEN cDNA 1110003E01 gene 0.024 -1.54 
Gm11970/ Gm12936/ 
Gm6525/ Gm8001/ Gm8697/ 
Rpl36a 
predicted gene 11970/ predicted gene 12936/ predicted gene 6525/ 
predicted 0.026 -1.54 
Gm10080/ Gm5526/ 
Gm8894/ Myl6 
predicted gene 10080/ predicted gene 5526/ predicted gene 8894/ 
myosin, 0.007 -1.54 
Gcat glycine C-acetyltransferase (2-amino-3-ketobutyrate-coenzyme A ligase) 0.024 -1.54 
Bag1 BCL2-associated athanogene 1 0.043 -1.54 
Rpl27 ribosomal protein L27 0.022 -1.54 
Ccdc56 coiled-coil domain containing 56 0.015 -1.54 
Ube2d1 ubiquitin-conjugating enzyme E2D 1, UBC4/5 homolog (yeast) 0.014 -1.54 
Creg1 cellular repressor of E1A-stimulated genes 1 0.004 -1.54 
Tff2 trefoil factor 2 (spasmolytic protein 1) 0.017 -1.54 
Rgs5 regulator of G-protein signaling 5 0.016 -1.54 
--- --- 0.033 -1.54 
Zfand6 zinc finger, AN1-type domain 6 0.029 -1.54 
Gabarapl2 gamma-aminobutyric acid (GABA) A receptor-associated protein-like 2 0.037 -1.54 
Gm6573/ LOC100044992/ 
Rps13 
ribosomal protein S13 pseudogene/ similar to ribosomal protein S13/ 
ribosomal 0.024 -1.53 
Mid1ip1 Mid1 interacting protein 1 (gastrulation specific G12-like (zebrafish)) 0.026 -1.53 
Rps12 ribosomal protein S12 0.043 -1.53 
Gm9354/ LOC100042019/ 
Rps27a 
predicted gene 9354/ similar to fusion protein: ubiquitin (bases 43_513); 
rib 0.021 -1.53 
Fth1 ferritin heavy chain 1 0.028 -1.53 
Gm11599/ Gm11687/ 
Gm12091/ Gm12366/ 
Gm12922/ Gm14583/ 
Gm16408/ Gm4968/ 
Gm5921/ Gm6139/ Gm6266/ 
Gm6359/ Gm6433/ Gm7143/ 
Gm8225/ Gm8235/ Gm8520/ 
LOC100048354/ LOC634916/ 
LOC639606/ Rps2 
predicted gene 11599/ predicted gene 11687/ predicted gene 12091/ 
40S R 0.043 -1.53 
Rps21 ribosomal protein S21 0.039 -1.53 
Mt1 metallothionein 1 0.010 -1.53 
Sec62 SEC62 homolog (S. cerevisiae) 0.036 -1.53 
Gm12270/ Gm15483/ 
Gm6573/ Gm6834/ 
LOC100044992/ Rps13 
predicted gene 12270/ predicted gene 15483/ ribosomal protein S13 
pseudogene 0.020 -1.53 
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EG436523/ Gm10334/ Prss1/ 
Prss3 
predicted gene, EG436523/ predicted gene 10334/ protease, serine, 1 
(tryps 0.010 -1.53 
--- --- 0.001 -1.53 
Serf2 small EDRK-rich factor 2 0.018 -1.53 
Ndufab1 NADH dehydrogenase (ubiquinone) 1, alpha/beta subcomplex, 1 0.025 -1.53 
Sod1 superoxide dismutase 1, soluble 0.024 -1.53 
LOC100046344/ Nme1 
similar to Nucleoside diphosphate kinase A (NDK A) (NDP kinase A) 
(Tumor metastasis) 0.050 -1.53 
Rpl8 ribosomal protein L8 0.030 -1.53 
Atp6v1f ATPase, H+ transporting, lysosomal V1 subunit F 0.019 -1.53 
Dynlt1/ Dynlt1-ps1/ 
LOC100040563 
dynein light chain Tctex-type 1/ dynein light chain Tctex-type 1, 
pseudogene  0.010 -1.53 
Cox5b cytochrome c oxidase, subunit Vb 0.007 -1.53 
Cops6 
COP9 (constitutive photomorphogenic) homolog, subunit 6 (Arabidopsis 
thaliana) 0.037 -1.53 
Chchd3 coiled-coil-helix-coiled-coil-helix domain containing 3 0.036 -1.53 
Rpl30 ribosomal protein L30 0.049 -1.53 
Eif3i eukaryotic translation initiation factor 3, subunit I 0.029 -1.53 
Rpl27 ribosomal protein L27 0.034 -1.52 
--- --- 0.014 -1.52 
Rpl7 ribosomal protein L7 0.036 -1.52 
1810026B05Rik RIKEN cDNA 1810026B05 gene 0.007 -1.52 
Prelid1 PRELI domain containing 1 0.044 -1.52 
Atp5h ATP synthase, H+ transporting, mitochondrial F0 complex, subunit d 0.014 -1.52 
Gm10257/ Gm8524/ H3f3a/ 
H3f3c/ LOC100045490 
predicted gene 10257/ predicted gene 8524/ H3 histone, family 3A/ H3 
hi 0.030 -1.52 
1810010K12Rik RIKEN cDNA 1810010K12 gene 0.038 -1.52 
Creg1 cellular repressor of E1A-stimulated genes 1 0.026 -1.52 
Serf2 small EDRK-rich factor 2 0.019 -1.52 
Lamp2 lysosomal-associated membrane protein 2 0.014 -1.52 
Spink3 serine peptidase inhibitor, Kazal type 3 0.014 -1.52 
Ndufa2 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 2 0.018 -1.52 
Cox8a cytochrome c oxidase, subunit VIIIa 0.023 -1.52 
Ndufs5 NADH dehydrogenase (ubiquinone) Fe-S protein 5 0.044 -1.51 
--- --- 0.034 -1.51 
H47 histocompatibility 47 0.049 -1.51 
Sepx1 selenoprotein X 1 0.013 -1.51 
H2-D1 histocompatibility 2, D region locus 1 0.043 -1.51 
Lamp1 lysosomal-associated membrane protein 1 0.020 -1.51 
Tm2d2 TM2 domain containing 2 0.021 -1.51 
Eif1 eukaryotic translation initiation factor 1 0.037 -1.51 
Tecr trans-2,3-enoyl-CoA reductase 0.027 -1.51 
Mff mitochondrial fission factor 0.002 -1.51 
Cox5b cytochrome c oxidase, subunit Vb 0.009 -1.51 
--- --- 0.017 -1.51 
Fam96a family with sequence similarity 96, member A 0.015 -1.51 
Hsbp1 heat shock factor binding protein 1 0.023 -1.51 
Rpl13a ribosomal protein L13A 0.031 -1.51 
Ndufv2 NADH dehydrogenase (ubiquinone) flavoprotein 2 0.022 -1.51 
Sec11c SEC11 homolog C (S. cerevisiae) 0.031 -1.51 
Rps20 ribosomal protein S20 0.032 -1.51 
1810027O10Rik RIKEN cDNA 1810027O10 gene 0.031 -1.51 
Mrps24 mitochondrial ribosomal protein S24 0.008 -1.51 
Eif5 eukaryotic translation initiation factor 5 0.049 -1.51 
Acat1 acetyl-Coenzyme A acetyltransferase 1 0.041 -1.51 
Atp6v0b ATPase, H+ transporting, lysosomal V0 subunit B 0.013 -1.50 
Rpl10 ribosomal protein 10 0.019 -1.50 
Tceb2 transcription elongation factor B (SIII), polypeptide 2 0.025 -1.50 
--- --- 0.026 -1.50 
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Gm10443/ LOC100044740/ 
Rps28 
predicted gene 10443/ similar to ribosomal protein S28/ ribosomal 
protein  0.027 -1.50 
H47 histocompatibility 47 0.024 -1.50 
Rap1b RAS related protein 1b 0.013 -1.50 
Ddost dolichyl-di-phosphooligosaccharide-protein glycotransferase 0.045 -1.50 
Mdh1 malate dehydrogenase 1, NAD (soluble) 0.041 -1.50 
RP23-195K8.6 hypothetical protein LOC622404 0.001 -1.50 
Lat2 Linker for activation of T cells family, member 2 0.023 1.51 
Txn1 thioredoxin 1 0.042 1.53 
Kcnh3 potassium voltage-gated channel, subfamily H (eag-related), member 3 0.038 1.57 
Dpp6 dipeptidylpeptidase 6 0.015 1.59 
Klra21 killer cell lectin-like receptor subfamily A, member 21 0.034 1.61 
Gss glutathione synthetase 0.010 1.63 
Mgea5 meningioma expressed antigen 5 (hyaluronidase) 0.001 1.64 
N6amt2 N-6 adenine-specific DNA methyltransferase 2 (putative) 0.015 1.65 
Hoxa5 homeo box A5 0.044 1.70 
Duxbl double homeobox B-like 0.035 1.74 
Armc8 armadillo repeat containing 8 0.018 1.75 
Ptgr2 prostaglandin reductase 2 0.033 1.78 
Pvr poliovirus receptor 0.018 1.91 
Opa3 optic atrophy 3 (human) 0.005 1.96 
D13Ertd787e DNA segment, Chr 13, ERATO Doi 787, expressed 0.040 2.05 
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Appendix 7.4. Significantly altered genes in the LP+STZ group compared to the 
LP+sham group 
Differentially expressed genes between the four groups were selected based on a p-
value cut-off of 0.05 and a fold change of ≥1.5. Fold change represents the difference 
from the LP+sham group. A 2-way ANOVA was performed with a Student Newman-Keuls 
post test. 
Gene Symbol Gene Title p-value 
Fold 
change 
Clk1 CDC-like kinase 1 0.014 -1.72 
Neat1 
nuclear paraspeckle assembly transcript 1 
(non-protein coding) 0.023 -1.70 
Rab24 RAB24, member RAS oncogene family 0.019 -1.67 
Nupr1 nuclear protein 1 0.031 -1.67 
Mettl7a1 methyltransferase like 7A1 0.027 -1.54 
Ankrd24 ankyrin repeat domain 24 0.046 -1.52 
1810005K13Rik RIKEN cDNA 1810005K13 gene 0.033 -1.51 
Nupr1 nuclear protein 1 0.035 -1.51 
1810010K12Rik RIKEN cDNA 1810010K12 gene 0.028 -1.50 
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